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Aims: Ischaemic postconditioning (IPostC) is a powerful protective mechanism that activates 
prosurvival intrinsic signalling cascades to limit reperfusion injury but the exact signalling 
pathway involved in this cardioprotective effect still remains unclear. 
In ischaemic preconditioning, a powerful prosurvival path, known as the Survivor Activating 
Factor Enhancement (SAFE) pathway, has recently been discovered to protect against 
reperfusion injury. The SAFE pathway involves the activation of the cytokine, tumour necrosis 
factor alpha (TNFα) and the signal transducer and activator of transcription-3 (STAT-3) during 
ischaemic preconditioning. The aim of this thesis was to investigate whether ischaemic and 
pharmacological postconditioning can protect via activation of the SAFE pathway. In addition, 
we explored the influence of obesity and diabetes in the successful effect of ischaemic 
postconditioning, as these two pathologies are often associated with patients with myocardial 
infarction. 
Methods: Isolated Langendorff perfused mouse hearts from TNF knockout (TNF
-/-
), TNF 




), and cardiomyocyte-specific STAT-3 
knockouts (STAT-3
-/-
) and their respective wild types were subjected to a global ischaemia and 
were postconditioned with either short periods of ischaemia, TNFα (0.5 ng/ml), adenosine (100 
μM), bradykinin (100 nM) or the specific delta opioid agonist, D-Ala2‟, D-Leu5‟-enkephalin 
acetate salt (DADLE) (100 nM). Infarct size was measured using triphenyltetrazolium chloride 
staining technique and computerized planimetry. Western blot analysis of nuclear, cytosolic or 
mitochondrial proteins was performed to evaluate activation of STAT-3, Akt and extracellular 
signal-regulated kinase 1/2 (Erk1/2), during reperfusion.  
To explore the influence of obesity and diabetes on IPostC-induced cardioprotection, TNF-WT 
and TNF
-/- 
animals were fed with a high carbohydrate diet for 11 weeks to induce obesity. 
Diabetes was induced by administration of a single intraperitoneal injection of streptozotocin 
(180mg/kg).  
Results:  IPostC or pharmacological postconditioning with bradykinin or DADLE reduced 
infarct size in TNF-WT, TNFR1
-/- 







 mice. Adenosine reduced infarct size in TNF-WT, TNF
-/-
, and STAT-3-WT but failed 
to protect STAT-3
-/-
 mice. TNFα-postconditioning mimicked IPostC in TNF-WT and STAT-3-
xxvi 
 




 hearts. Both IPostC and TNF-PostC increased phosphorylated 
STAT-3 in the nucleus, while Akt and Erk1/2 were only activated after an IPostC stimulus. 
Similarly, bradykinin and DADLE increased phosphorylated STAT-3 in the mitochondria.  
IPostC protected hearts against ischaemia-reperfusion in obese or diabetic WT mice. 
Surprisingly, the protective effect of IPostC was partially restored in TNF
-/-
  obese mice but the 
infarct-sparing effect was absent in diabetic TNF
-/-
 mice.  
Conclusion: In this thesis we have delineated a novel prosurvival pathway activated in IPostC to 
limit ischaemia-reperfusion injury. This pathway, known as the SAFE pathway, requires 
activation of TNFα and activates STAT-3 via TNFR2. Pharmacological postconditioning with 
bradykinin and opioids mimics IPostC via the SAFE pathway. Although adenosine does not 
require TNFα in pharmacological postconditioning, STAT-3 is still required, thus confirming the 
existence of multiple protective pathways in the heart to protect against reperfusion injury. In 
our experimental conditions, obesity and diabetes do not influence the outcome of ischaemic 
postconditioning but TNFα appears to play a deleterious role in obesity.  
The existence of multiple alternate pathways in IPostC and pharmacological postconditioning at 
the time of reperfusion may have potential therapeutic application against ischaemia-reperfusion 
injury. Furthermore, we show that the protective effect of ischaemic postconditioning is 
maintained in a modestly obese and diabetic mouse model suggesting that, relative to the 





























Transporting blood throughout the body to each organ and tissue, throughout our lives, requires 
an efficient and healthy heart. As we grow older, the heart becomes progressively less efficient 
in maintaining a healthy circulatory system. However, even as our age increases, the heart, as is 
the case with any muscle, benefits from a healthy lifestyle, coupled with regular age-appropriate 
exercise. An individual who lives such a lifestyle could expect to live to be a “ripe old age”. 
Unfortunately, with the modern world‟s fast pace of living and working, people are exposed to a 
number of risk factors which promote cardiovascular diseases resulting in a shortened lifespan as 
well as being a burden on the social system of a country. Risk factors such as hypertension, 
diabetes, elevated cholesterol levels, just to mention a few, all contribute eventually to a 
narrowing of the arteries, compromising the circulatory system. The flow of blood and therefore, 
the oxygen supply and essential nutrients, to the muscle cells of the heart, is decreased resulting 
in a “heart attack” or myocardial infarction.  
The heart is a resilient organ and possesses intrinsic survival mechanisms in an attempt to protect 
itself. Recently, the heart has been shown to possess a remarkable ability to adapt to conditions 
of stress and this has been one of the focal points of intense research over the past 15 years in the 
hope that the underlying mechanisms may be harnessed for therapeutic development.  
In this thesis we propose to explore the activation of a major intrinsic cytokine, tumour necrosis 
factor alpha (TNFα), as a possible tool to protect the heart against stressful conditions observed 
during myocardial infarction. This study will be performed in healthy animals or in 
obese/diabetic animals, two pathologies often triggering myocardial infarction. 
 
1. Ischaemic Heart Disease 
Ischaemic heart disease is characterized by a reduced blood supply (ischaemia) to the heart 
muscle, usually due to coronary artery disease (atherosclerosis of the coronary arteries). 
In the adult human body there are 96,600 kilometers of arteries, veins and capillaries 
pulsating at 100,000 rhythmic, muscular heart beats per day. These arteries, veins and 
capillaries, together with the heart, make up the cardiovascular system. Ischaemic heart 
disease affects individuals in their prime of life, reducing their life expectancy and their 
contribution towards the economy of a country substantially and is thus perceived as a 
growing global burden. Ischaemic events can occur as a consequence of either a thrombosis 
(blood clot) or narrowing and hardening of the arteries as a result of plaque accumulation. 
Atherosclerotic plaques within coronary arteries cause rapid occlusion in coronary artery 
disease resulting in the heart suffering a loss of blood flow and oxygen supply with 
subsequent death of the cardiomyocytes, the muscle cells of the heart. During occlusion of 
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the artery or arteries supplying the myocardium, the demand for oxygen may exceed the 
supply and myocardial ischaemia develops. Rupture of a plaque may result in a secondary 
thrombus formation in a coronary artery. If left untreated, this form of coronary artery 
disease culminates in an acute reduction of blood supply to the myocardium and is 
characterized by the rapid development of myocardial necrosis (Jennings, 1991). 
The number one cause of death worldwide is cardiovascular disease (CVD), with more people 
dying annually from coronary artery disease than from any other cause (WHO, 2009). Low and 
middle income countries seem to be more affected than developed countries with 82% of 
cardiovascular related deaths occurring in the lesser developed countries and almost equally in 
men and women. By 2030, it is predicted that almost 23.6 million people will die from coronary 
artery disease – mainly from ischaemic heart disease and stroke (WHO, 2009) and the leading 
cause of death in the industrialized world is already ischaemic heart disease. Ischaemic heart 
disease is projected to become the major worldwide cause of death and disability by 2020 – only 
a decade away!! (WHO, 1996).  
 “As long as Africa remains impoverished, a major rise in coronary artery disease is unlikely” – this was 
the general perception about ischaemic heart disease in Africa in 1997 as expressed by Walker et 
al (Walker, 1998). However, in 2006, the World Bank reported that Africa was making 
economic progress. Unfortunately, along with economic improvements, there is a rise in chronic 
diseases of lifestyle such as ischaemic heart disease, a consequence of epidemiological 
transition. Ischaemic heart disease is rapidly becoming a leading cause of death in sub-Saharan 
Africa and in 2008 it was ranked as the 8
th
 leading cause of death in men and women of this 
region (Menash, 2008). The progression of ischaemic heart disease in the ranking is attributed 
largely to lifestyle and behavioural changes associated with urbanization of the region (Menash, 
2008). Ischaemic heart disease is responsible for the greatest number of cardiovascular fatalities 
in males and the second largest number of cardiovascular related deaths in females, in South 
Africa, (Figure 1). More alarmingly, a report issued by the South African Medical Research 
Council in 2005, states that ischaemic heart disease was the leading cause of death in the total 
population of the Western Cape (one of the provinces of South Africa) in a single year 




1.1 Major risk factors for ischaemic heart disease 
The major cardiovascular risk factors are as follows: 
 
1.1.1 Atherosclerosis and dyslipidaemia  
One of the main causes of coronary artery disease is atherosclerosis (Hansson, 2005). 
Atherosclerosis is an inflammatory disease in which the inflammatory system interacts with 
metabolic risk factors, triggering atherosclerotic plaques in the arterial tree. Myocardial 
infarction occurs when the atheromatous process prevents blood flow through the coronary 
artery and disruption of the plaque is considered dangerous as it releases harmful thrombotic 
material from the centre of the plaque into the circulation (Hansson, 2005). Dyslipidaemia is 
one of the causes of atherosclerosis, with low density lipoprotein cholesterol (LDL) 
contributing to the formation of plaques. Endothelial disruption and erosion also plays a role 




Fig 1: Ischaemic heart disease. Estimated to be the greatest cause of CVD mortality in 2000.  
(adapted from Norman, 2000) 
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The cholesterol that accumulates in atheromatous lesions is derived primarily from plasma low 
density lipoprotein (LDL), which accounts for 60-75% of plasma cholesterol, giving LDL a 
powerful and direct relationship with coronary heart disease (Nestruck and Davignon, 1986). 
Oxidative stress and smoking are just two of the many factors which can contribute to damage of 
the endothelium. Consequently, excess production of oxidised LDL-cholesterol (oxLDL) occurs 
in the bloodstream. In an attempt to reduce the amount of oxLDL cholesterol to normal levels, 
macrophages engulf the oxLDL and in doing so become “foam cells”, (Figure 3). However, if 
there is too much oxLDL-cholesterol present, the macrophages accumulate against the vessel 
wall in what will become an atherosclerotic plaque. Eventually this wall of plaque may either 
block the vessel completely or it may rupture, resulting in the release of pro-coagulant factors 
and the formation of a thrombosis (Libby, 2002). Both of these events inhibit the flow of blood 






Fig 2: Plaque build up in coronary artery. Loss of blood flow and oxygen supply will eventually 






High density lipoprotein (HDL) cholesterol, also known as the „good‟ cholesterol, helps to clear 
excess LDL-cholesterol from the blood back to the liver (a process known as “reverse 
cholesterol transport”, thereby reducing the risk of atherosclerosis. Many studies have shown 
that there is an increased risk of ischaemic heart disease in individuals with low levels of HDL 
(Assmann et al., 1996; Curb et al., 2004; Gordon et al., 1989; Gordon et al., 1977; Sharrett et al., 
2001; Turner et al., 1998). However, there is also a direct relationship between increased HDL-
cholesterol and decreasing cardiovascular risk with epidemiological data indicating that for 
every increase of 0.03 mM/L of HDL-cholesterol, the risk for cardiovascular events decreases by 
2-3% (Gordon et al., 1989). 
Fig 3: Formation of atherosclerotic plaque. Damaged endothelium favours the infiltration and 
oxidation of excess LDL-cholesterol. The oxidisised LDL-cholesterol (ox-LDL) is taken up by the 
macrophages in an attempt to keep plama cholesterol homeostasis. However, in the presence of 
excess ox-LDL the macrophages accumulate against the vessel wall and form an atherosclerotic 








Obesity has been defined by the World Health Organisation as a disease in which excess body 
fat has accumulated to such an extent that health may be adversely affected (WHO, 2000).  
An imbalance between energy intake and expenditure results in excess energy being stored in fat 
cells which enlarge or increase in number, and this may eventually result in overweight and 
obesity. A healthy lifestyle does not necessarily mean a healthy heart if one carries excess 
weight, especially around the abdomen. Obesity is increasing, worldwide, at an alarming rate, 
and just 5 years ago, there was an estimated 1.3 billion people overweight or obese (WHO, 
2005). Data from 14 years ago already revealed that this global trend towards overweight and 
obesity was being followed by South Africa with an disturbing number of citizens becoming 
overweight (South Africa Demographic Health Survey, 1996). Increasing rates of childhood and 
adolescent obesity are also a cause of great concern as once children have become overweight or 
obese, interventions to reverse these conditions are rarely successful (Pinhas-Hamiel and Zeitler, 
2000). Current definitions designate overweight in adults as those having a body mass index 
Fig 4: Typical progression of coronary atherosclerosis.  At first, the atheroscletotic plaque tends to 
stay external to the lumen, which allows the coronary artery diameter to be maintained. As the plaque 
encroaches into the lumen, the diameter of the artery decreases until eventually the flow of blood  is 





between 25.0 and 30.0 kg/m
2 
and obesity as a BMI of greater than 30.0 kg/m
2 
(Poirier et al., 
2006).  Distribution of body fat, or adipose tissue, appears to play a significant role in 
determining the presence or absence of metabolic dysfunctions that predispose to chronic 
diseases (Poirier, 2003). The skinfold test is another means of defining obesity by determining a 
person‟s body composition and body fat percentage. Metabolic syndrome, which consists of a 
cluster of diabetogenic and atherogenic abnormalities, correlates closely with CVDs and 
diabetes. Much has been written about the metabolic syndrome with some cardiologists 
favouring its existence and others questioning it. It appears that of all the parameters suggested 
to define metabolic syndrome, the one of most importance is that of the waist-circumference 
measurement (Alberti et al., 2005; Opie, 2006). A common finding in the obese state is a low-
grade systemic inflammation with increased circulating levels of a number of cytokines, amongst 
which is tumour necrosis factor alpha (TNFα) (Bullo et al., 2003; Roytblat et al., 2000; Yudkin 
et al., 1999). Anti-inflammatory therapies targeting TNFα activity have indicated that blocking 
TNFα may interrupt the inflammatory cascade that occurs with abdominal obesity (Bernstein et 
al., 2006). 
A large number of clinical problems are associated with being obese and these can be subdivided 
into two groups: those that are associated with excess adipose tissue and those that are linked to 
the metabolic effects of the increased adiposity (Bray, 2004). The diseases associated with the 
latter group include coronary heart disease, hypertension, type 2 diabetes mellitus and certain 
kinds of cancer (Garfinkel, 1985; Jooste et al., 1988; Lew, 1985; Manson et al., 1995; Pi-Sunyer, 
1990; Pi-Sunyer, 1991; Steyn et al., 1990). Accumulation of abdominal fat increases the 
probability of cardiovascular disease and mortality (Donahue et al., 1987; Ducimetiere et al., 
1986; Lapidus et al., 1984; Larsson et al., 1984). The metabolic effects of obesity result from the 
increased release of free fatty acids (FFA) and the production of adipokines which are secreted 
by several factors, including the cytokines TNFα and interleukin-6 (IL-6), hormones such as 
leptin and adiponectin and other adipokines such as resistin and angiotensinogen. These factors 
can impair insulin signalling and alter glucose homeostasis as well as lipid metabolism (Arner, 
2003; Nieto-Vazquez et al., 2008).  Obesity is therefore, now being considered as a chronic state 
of low-intensity inflammation, with one of the major health consequences being the increased 








Type 1 diabetes: the pancreatic beta cells of the body fail to produce insulin as the body’s 
immune system has attacked and destroyed them. At present, this type of diabetes requires the 
afflicted person to inject insulin. 
Type 2 diabetes: results from insulin resistance, a condition in which cells fail to use insulin 
properly and is sometimes combined with an absolute insulin deficiency. At first, the pancreas 
produces more insulin to compensate, but eventually it loses the ability to secrete insulin in 
response to meals. Being overweight and lack of exercise increase the risk of developing this 
type of diabetes. 
Diabetes and its associated complications have become a worldwide health problem. The 
prevalence of diabetes is rising, reaching epidemic proportions in some population groups. Type 
2 diabetes is responsible for much of the increased occurrence of diabetes but there is also 
evidence that the incidence of type 1 diabetes is on the increase, although to a lesser extent than 
type 2 diabetes (Podar et al., 2001). In addition, impaired glucose tolerance is on the increase 
with about 197 million individuals worldwide having this disorder, predominantly as a result of 
obesity and the associated metabolic syndrome (Hossain, 2007). Abnormalities in both the action 
and secretion of insulin are responsible for the pathogenesis of diabetes. Insulin resistance is 
defined as the diminished ability of the cell to respond to the action of insulin with a subsequent 




increase in lipolysis, release of glycerol and free fatty acids (FFA) into the circulation, ultimately 






The development of insulin resistance has been linked to both genetic and environmental factors, 
with obesity being an important contributor. Most studies thus far have focussed on type 2 
diabetes. However, type 1 diabetes also has serious cardiovascular consequences which occur in 
a much younger age group (Orchard et al., 2006).  The powerful effect of the duration of type 1 
diabetes should be taken into consideration when regarding cardiovascular risk associated with 
this type of diabetes. In the intervening years between diagnosis and the patient‟s 3
rd
 decade, 20 
years or more have passed and a considerable amount of damage to the cardiovasculature may 
have occurred. The development of type 1 diabetes is shown in Figure 7: 
Fig 6: Schematic representing the different steps in the development of type 1 and type 2 diabetes, 
(adapted from Nieto-Vasquez, 2008). 
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Both type 1 and type 2 diabetic individuals are prone to developing ischaemic heart disease, 
including acute myocardial infarction and subsequent complications (Aguilar et al., 2004; 
Ramani et al., 1996; Stevens et al., 2004; Zairis et al., 2004). More than 50% of deaths in 
diabetic patients have been attributed to ischaemic heart disease (Kannel and McGee, 1979) and 
the mortality rate from acute myocardial infarction is almost doubled in diabetic individuals 
compared to non-diabetics (Abbott et al., 1988). Although it is well established that the long-
term outcome of diabetic patients with ischaemic heart disease is worsened, studies have been 
contradictory as to whether the diabetic heart responds well or not to treatment in the event of an 
ischaemic episode. For instance, hearts from streptozotocin-induced diabetic rats were more 
resistant initially to ischaemia/reperfusion, but over a period of 8 weeks, this effect was reversed 
(Tosaki et al., 1996). This initial positive response to ischaemia-reperfusion was also seen in a 
type 2 diabetes model with an in vivo study (Liu et al., 1993). Indeed, in an alloxan-induced 
diabetic rabbit model, a decrease in infarct size was observed 8 weeks after the alloxan injection, 
compared to controls (Hadour et al., 1998).  
The majority of clinical studies have however, demonstrated a worse outcome from acute 
myocardial infarction in patients who are already compromised by diabetes (Osario, 2010).  
 
Fig 7: Development of type 1 diabetes: As production of insulin by the pancreatic cells is impaired, 






1.1.4 High blood pressure (hypertension) 
 
Hypertension has been defined as when the arterial blood pressure rises above 140 mmHg for 
systolic pressure and 90 mmHg for diastolic pressure (Kaplan et al., 2010).  
Elevated arterial blood pressure is the most common cause of enlargement of the left ventricle of 
the heart (Diamond et al., 2005; Ferdinandy, 2007; Massie and Shah, 1997; Prisant, 2005). 
Experimental evidence suggests that the hypertrophied myocardium is more susceptible to 
ischaemia-reperfusion damage than a normotensive heart (Attarian et al., 1981). However, no 
difference in infarct size between hypertensive and normotensive animals was demonstrated 
either in vivo in a rat heart infarct model (Ebrahim et al., 2007) or in vitro in a rat model of 
coronary occlusion (Speechly-Dick et al., 1994).  
 
2.0 Reperfusion and reperfusion injury  
Reperfusion is defined as the restoration of blood flow to an organ or tissue that has had its 
blood supply cut off. Reperfusion injury refers to the damage done to the organ or tissue caused 
when blood supply returns to the tissue after a period of ischaemia. 
In the event of an acute myocardial infarction, rapid restoration of the blood flow to the 
ischaemic area is one of the best ways to salvage the heart. Provided that reperfusion occurs 
shortly after coronary artery occlusion, it is effective in reducing the infarct size thus limiting the 
damage inflicted by the myocardial infarct (Maroko et al., 1971). Despite the undoubted benefit 
of reperfusion of blood to the ischaemic tissue, reperfusion itself is not risk free. A cascade of 
adverse reactions can occur during reperfusion, (see review (Yellon and Downey, 2003)) which 
paradoxically results in an exacerbation of tissue injury known as “reperfusion injury”. 
Restoration of the blood flow in the clinical setting involves either thrombolytic agents or 
cardiac catheterization (angioplasty), in which a stent is inserted into the occluded vessel 
followed by gentle inflation of a balloon to rupture the plaque or clot which is causing the 
blockage.  
The destructive role played by reperfusion has been the subject of much debate amongst 
clinicians and scientists (Ferrari and Hearse, 1997; Kloner, 1993; Ovize, 1997; Przyklenk, 1997; 
Yellon, 1992). 
There is little doubt that unremitting ischaemia causes cell death but until recently, the 
predominant view was that if ischaemia itself was the culprit in cell death as a result of 
adenosine triphosphate (ATP) depletion and its numerous consequences, then reperfusion was 
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essential to restore ATP synthesis, thereby rescuing the uninjured cells or those which were 
reversibly injured.  
Others, however, held the view that the death of cells irreversibly injured by ischaemia was 
merely accelerated by the restoration of blood flow. Yet another point of view was that 
reperfusion injury was caused by the sudden influx of blood releasing reactive oxygen species 
and other harmful substances. Agreement has, however, been reached that 4 forms of reperfusion 
injury exist (Ovize, 1997):  
i)     myocardial stunning,  
ii)    reperfusion arrythmias, 
iii)   vascular reperfusion injury and  
iv)   lethal reperfusion injury 
Lethal reperfusion injury is a term used to describe myocardial cell death caused by reperfusion, 

























Fig 8: Lethal reperfusion injury. During ischaemia some of the cardiomyocytes are irreversibly 
injured (dark grey), whilst even more damage is done during the reperfusion period (light grey), 




2.1 Mechanisms resulting in reperfusion injury 
Reperfusion injury is associated with all the signs of necrotic cell death, such as release of 
intracellular proteins and major morphological changes which include swelling of the 
mitochondria. Studies over the past 10 years have revealed that mitochondria play a critical part 
in determining the fate of the cell after cellular stresses, (see review Kroemer et al., 2007). One 
of the critical components of mitochondrial response to stress is the activation of the 
mitochondrial permeability transition pore (mPTP) (Bernardi et al., 2006; Halestrap and 
Brenner, 2003). The mPTP is a non-specific, multimeric pore structure that bridges the outer and 
inner mitochondrial membranes. The true composition of the pore remains uncertain and is the 
subject of much debate. Cyclophilin-D is the only known component of the mPTP and is 
inhibited by cyclosporine-A (Crompton et al., 1988; Gomez et al., 2009). The inner 
mitochondrial membrane is impermeable to solutes while it remains closed under normal 
physiological conditions. During conditions of cell stress, with high matrix calcium ion 
accumulation, accompanied by depletion of adenine nucleotide, elevated inorganic phosphate 
and oxidative stress, the mPTP opens in the inner mitochondrial membrane, releasing 
cytochrome C and promoting cell death. These are exactly the conditions which occur during 
reperfusion after a period of ischaemia (Javadov et al., 2003). The mechanisms determining 
whether the pore opens or not during ischaemia-reperfusion have been extensively studied over 
the last 20 years with most investigators now being of the opinion that it is the conditions during 
early reperfusion which trigger the opening of the pore and that if the pore remains closed during 
these first early moments of reperfusion this will protect against cell death (Crompton et al., 
1987; Di Lisa and Bernardi, 2006; Di Lisa et al., 2001; Duchen et al., 1993; Halestrap et al., 
2004; Halestrap et al., 1998; Lemasters et al., 1997) 
Griffiths et al, demonstrated that if the pore remains closed at the onset of reperfusion, a distinct 
reduction in infarct size is observed in experimental ischaemia-reperfusion (Griffiths and 
Halestrap, 1993). The past 5 years have seen the proposal of mPTP inhibition as being the 
ultimate cardioprotective target, with mounting evidence that it may be a crucial point of 
convergence for many of the cardioprotective signalling pathways. If this proves to be the case, 
administration of cyclosporine-A, a known mPTP antagonist, will be a simple and practical 
procedure, which could be delivered in the ambulance en route to the hospital and reduce the 
subsequent reperfusion injury which occurs with percutaneous coronary intervention (PCI) or 
with administration of a thrombolytic agent (Gomez et al., 2009). 
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In summary, this necrotic cell death, which has been termed “lethal reperfusion injury”, is a 
major obstacle to reperfusion therapy without which the ischaemic tissue cannot be salvaged. In 
addition, it has been suggested that the greater the degree of the initial ischaemic insult, the more 
severe the reperfusion injury will be and that if the ischaemic insult lasts long enough, no 
recovery is possible (Vinten-Johansen et al., 2005). Reperfusion has thus been dubbed as a 
“double edged sword” and a reassessment of reperfusion injury and its mechanisms is clearly 
needed to maximise the benefits of reperfusion and limit infarct size. 
3.0 Conditioning the heart to limit reperfusion injury 
3.1 Ischaemic preconditioning  
Ischaemic preconditioning is defined as brief periods of ischaemia followed by reperfusion 
which occur prior to the prolonged ischaemic insult.  
While investigating adenosine triphosphate (ATP) levels in a canine model of the failing heart, 
Murry and Jennings serendipitously discovered a biological mechanism which harnessed the 
intrinsic ability of the heart to protect itself (Murry et al., 1986).  By applying four brief episodes 
of alternating reperfusion and occlusion prior to the infarct-inducing episode of myocardial 
ischaemia, Murry was able to demonstrate an astonishing reduction of 75% in the infarct size of 
canine hearts (Murry et al., 1986). This type of cardioprotection became known as “ischaemic 
preconditioning” (IPC) and a flurry of activity followed with the reproducibility of IPC being 
proved in multiple experimental settings using various animal models (Kuzuya et al., 1993; 
Marber et al., 1993; Murry et al., 1986; Przyklenk et al., 1993). 
Further studies revealed the existence of two “windows” of protection in IPC. The first window, 
termed as “classic preconditioning” occurs immediately after initiating IPC and lasts for up to 3 
hours. The second window of protection, known as SWOP or delayed preconditioning, occurs 24 
to 72 hours after the initial application of IPC and is thought to protect the heart to a lesser extent 
than classical IPC, (see review (Yellon and Downey, 2003)).  
 
3.1.1 Mechanisms of IPC: 
Following the discovery of IPC, intensive research to delineate the mechanism involved has 
been undertaken but the exact signalling pathway still remains unclear. The major signalling 
pathways which have been implicated in IPC are illustrated in the following schematic, (Figure 




3.1.2 Gi-protein coupled receptors (GPCR)  
G-proteins are situated within the lipid bilayer of cells and they can move freely, thus allowing a 
large number of G-proteins to be activated by a single occupied receptor complex (Lubert, 
1988). Gi-protein coupled receptors constitute a large and diverse family of proteins, the 
primary function of which is to transduce extracellular stimuli into intracellular signals. 
Two types of G-proteins have been identified: the G stimulatory protein (Gs), which is cholera 
toxin sensitive, and the G-inhibitory protein (Gi) which is pertussis toxin sensitive. However, 
controversy surrounds the role of the Gi protein in cardioprotection. Thornton et al, used an in 
vivo rabbit model and Miura et al, used a canine model to investigate the involvement of the Gi-
proteins in the protective effects of IPC. Both groups found that IPC-induced cardioprotection 
was conferred via the Gi-proteins (Miura et al., 1997; Thornton et al., 1993). In contrast, Liu and 
Fig 9: Diagram depicting suggested prosurvival signalling pathways involved in classic 
ischaemic preconditioning. IPC invokes the activation of signal transduction cascades by 
autocoid triggers and kinases. ROS targets the mKATP and the mPTP. Abbreviations as defined 
in text, (adapted from Ovize, et al, 2010). 
17 
 
Downey were unable to demonstrate a role of the Gi-proteins in IPC-induced protection in an 
open chest rat model of myocardial infarction (Liu and Downey, 1993). 
G-coupled protein receptors activated by adenosine, bradykinin, and the opioid receptors will be 
further discussed under “Cardioprotective agents and ischaemic postconditioning” in Section E. 
 
3.1.3 The RISK pathway  
A powerful cardioprotective signalling pathway termed as the “Reperfusion Injury Salvage 
Kinase (RISK) pathway” consists of a group of prosurvival protein kinases, including 
phosphotidylinositol 3-kinase (PI3-kinase)/Akt and extracellular signal-regulated kinases, 
p44/p42 (Erk1/2) (Hausenloy and Yellon, 2004). 
  
i) Phosphotidylinositol 3-kinase/Akt  
The PI3-kinase/Akt signalling cascade is activated by the stimulation of a wide range of 
receptors, including those of growth factors and G-protein coupled receptors (Cross et al., 2000).  
In the setting of ischaemia-reperfusion, signalling through PI3-kinase has been demonstrated to 
confer protection against ischaemia-reperfusion injury by inhibiting apoptosis in cardiomyocytes 
subjected to hypoxia via the activation of Akt (Matsui et al., 1999).  
In 2002 Mocanu et al, first demonstrated a link between ischaemic preconditioning, PI3-kinase 
/Akt and infarct limitation in the isolated perfused rat heart by individual infusion of the 
inhibitors, wortmannin and LY294002, during the preconditioning protocol (Mocanu et al., 
2002).  
 
ii) Extracellular signal-regulated kinase  
The role of Erk1/2 has been extensively studied in the setting of cardioprotection. Erk 1 (p44) 
was not activated by global ischaemia in a perfused rat heart model but ischaemia-reperfusion 
increased the phosphorylation and kinase activity of both Erk1 and Erk2 (p42) in the nuclear 
fraction (Mizukami and Yoshida, 1997).  In an in vivo rat model of ischaemia-reperfusion, 
activation of Erk1 was not triggered by ischaemia alone but was activated by 5 – 30 minutes of 
reperfusion (Omura et al., 1999).  
Hausenloy and colleagues demonstrated that IPC resulted in the activation of both PI3-
kinase/Akt and the Erk1/2 signal cascades at the time of reperfusion (Hausenloy et al., 2004b). 
They reported that inhibition of PI3-kinase at the time of reperfusion resulted in the activation of 
Erk1/2 which, in turn, activated p70-ribosomal s6 kinase (p70s6K). However, when Erk1/2 was 
inhibited, the PI3-kinase/Akt pathway was activated but p70s6K remained inactive, therefore 
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suggesting a cross talk between the kinases (Hausenloy et al., 2004b). During the 
preconditioning stimulus, Erk1/2 was phosphorylated and activated in the isolated rat heart and 
this was associated with a decrease in infarct size (Fryer et al., 2001). In contrast, Mocanu et al, 
found that infusion of PD98059, the Erk1/2 inhibitor, during the IPC stimulus of the isolated rat 
heart, did not block the protection afforded by preconditioning, therefore suggesting that Erk1/2 
was not involved in the PI3-kinase–induced reduction in infarct size during IPC (Mocanu et al., 
2002).  
By 2007, the downstream targets of the RISK pathway included other cardioprotective kinases 
such as protein kinase C (PKC), protein kinase G (PKG), p70-ribosomal s6 kinase (p70s6K) and 
glycogen synthase kinase-3 beta (GSK-3β) (Hausenloy and Yellon, 2007b) (Figure 10). 
 
3.1.4 Protein Kinase C  
The first kinase to be examined in detail in ischaemia-reperfusion was PKC. Of the 11 isoforms 
of protein kinase C, PKC alpha (α), PKC delta (δ) and PKC epsilon (ε) have been implicated in 
IPC in the rat heart (Yoshida K et al., 1997), while PKCε and PKC gamma (γ) have been 
implicated in IPC in the rabbit heart and mouse heart (Gray et al., 2004; Ping et al., 1997). 
Enhanced membrane PKC activity in myocardial ischaemia was first demonstrated by Prasad et 
al, in 1992, using a protein kinase activity assay of the cytosol and membrane fractions of hearts 
which had been subjected to ischaemia or ischaemia-reperfusion (Prasad and Jones, 1992). 
Wei et al, demonstrated in an in vivo rat ischaemia-reperfusion model, that when PKCβ 
inhibitors were administered for a period of 2 weeks prior to experimentation, protection was 
conferred against cardiac microvascular ischaemia-reperfusion injury, thus implicating the β 
isoform of PKC in cardioprotection (Wei et al., 2010).  
Activation and subsequent translocation of PKC has been reported as necessary for the 
protective effects of IPC (Ping et al., 1997). Administration of inhibitors of PKC prior to and/or 
during IPC abolished the cardioprotective effect of IPC in most animal models (Pain et al., 2000; 
Yellon and Downey, 2003). Furthermore, IPC could be mimicked by administration of a PKC 
agonist prior to an I/R insult (Speechly-Dick et al., 1994). Other studies in which agonists of 
PKC were used in isolated rat hearts and in cell culture (cardiomyocytes) supported these 
findings (Gray et al., 1997). It has been suggested that the PI3-kinase/Akt pathway, nitric oxide 
(NO), the mitochondrial potassium-sensitive adenosine triphosphate channel (mKATP) channel 
and ROS are upstream of PKC activation in the preconditioned heart (Baines et al., 1997; Ping et 
al., 1999a; Tong et al., 2000; Wang., 1999). Hausenloy et al, however, speculated that PKC may 
contribute to the cardioprotective effect of IPC by the phosphorylation of PI3-kinase/Akt at the 
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time of reperfusion (Hausenloy et al., 2004b). Downstream targets of PKC include p38 mitogen 
activated protein kinase (p38 MAPK), c-Jun-NH2-terminal kinases (JNK), and extracellular 
signal-regulated kinase 1/2 (Erk1/2) (Maulik et al., 1996; Ping, et al., 1999b; Ping, et al., 1999c). 
 
 
3.1.5 Mitogen activated protein kinases and c-jun-NH2-terminal kinases  
Activation of the mitogen activated protein kinases (MAPK), p38 and c-Jun-NH2-terminal 
kinases (JNK) to confer protection at the time of reperfusion gave conflicting results, with some 
studies reporting cardioprotective roles of these kinases at the time of myocardial reperfusion (da 
Silva et al., 2004) and others suggesting a detrimental role (Sun et al., 2006). A study conducted 
in a conscious rabbit model demonstrated that IPC stimulation increased the activity of JNK and 
p38 MAPK (Ping et al., 1997). This increase, together with the protective effect of IPC, was 
abrogated by PKC inhibition (Ping et al., 1999d). Earlier studies in rabbit and rat hearts had 
reported an increased activation of p38MAPK following an IPC stimulus and also during the 
index ischaemia in isolated rat and rabbit hearts (Maulik et al., 1996; Maulik et al., 1998; 
Nakano et al., 2000; Weinbrenner et al., 1997). In contrast, an in vivo study in pigs  
demonstrated that the activation of p38 MAPK was unaltered (Behrends et al., 2000) and a later 
Fig 10: Hypothetical scheme outlining two phases of kinase cascade activation in response to IPC. 
During IPC, mitochondrial reactive oxygen species are released and PKC is activated. These events 
reactivate the PI3-kinase/Akt/p70S6K and Erk1/2/p70S6K cascades which comprise the reperfusion 
injury salvage kinase (RISK) pathway, at reperfusion. The RISK pathway mediates cellular survival 
through several possible mechanisms, which may include inhibition of mitochondrial permeability 




study reported that in the in vivo canine heart, the activation of p38 MAPK was actually 
decreased (Sanada et al., 2002). Therefore, the exact role of p38MAPK in IPC still needs to be 
clarified. 
 
3.1.6 Nitric oxide - cyclic guanosine monophosphate - protein kinase G signalling cascade  
Many studies, in different animal models, have reported that inhibition of nitric oxide (NO) is 
deleterious in ischaemia-reperfusion (Gonon et al., 2000; Maulik et al., 1995; Ockaili et al., 
1999; Rakhit et al., 2000; Xi and Kukreja, 2000). In these studies, different nitric oxide agonists 
were administered before initiation of ischaemia. The protection afforded by the activation of 
nitric oxide was abrogated when antagonists were administered during the ischaemic period and 
continued for the first few minutes of reperfusion. A study done in the isolated rat heart 
demonstrated a reduction in infarct size when the vasodilator, adrenomedullin, was given during 
early reperfusion and this effect was lost if nitric oxide synthase (NOS) was inhibited (Hamid 
and Baxter, 2005). Similar results were observed in the mouse heart, after administration of 
adrenomedullin prior to reperfusion (Hamid et al., 2007).  
Evidence for the generation of NO and peroxynitrite during ischaemia-reperfusion has been 
provided by numerous studies (Csonka et al., 1999; Wang and Zweier, 1996; Weselcouch et al., 
1995; Yasmin et al., 1997), but no increase in tissue NO could be demonstrated during the 
preconditioning protocol itself (Csonka et al., 1999). In 2000 Lochner et al, using an isolated rat 
heart model, demonstrated a role for NO and cyclic guanosine monophosphate (cGMP) as a 
trigger in classic preconditioning (Lochner et al., 2000).  
NO generation results in the activation of soluble guanyl cyclase and an accumulation of cyclic 
guanosine monophosphate (cGMP), with subsequent activation of protein kinase G, a cGMP-
dependent protein kinase (Hausenloy and Yellon, 2006). PKG is considered to be an important 
mediator of cardioprotection in IPC, (see review (Burley et al., 2007)). Activation of PI3-
kinase/Akt phosphorylates endothelial nitric oxide synthase (eNOS), producing NO (Cohen et 
al., 2000; Critz et al., 2005; Oldenburg et al., 2002) which has been implicated in the protection 
of endothelial cells (Dimmeler et al., 1999). NO, in turn, has been shown to protect by inhibiting 
the opening of the mPTP (Balakirev et al., 1997). 
 
3.1.7 Reactive oxygen species  
Free radicals are molecules or atoms with unpaired electrons in their outer shell. Free radicals 
that originate from oxygen are called reactive oxygen species (ROS) and are highly reactive. 
21 
 
ROS are produced by several enzymes and biochemical processes in the body. In the 
cardiovascular system the main sources of ROS are: a) Nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase, (b) the enzyme, xanthine oxidoreductase, (c) nitric oxide synthase 
(NOS) and, (d) the mitochondrial cytochromes (Donzelli et al., 2006; Grisham et al., 1999; 
Mason et al., 2000; Wink and Mitchell, 1998). However, in the myocardium itself, the 
mitochondria appear to be the main source of ROS production (Di Lisa et al., 2007).  
Production of ROS during ischaemia has been shown in isolated cardiomyocytes and in isolated 
hearts (Becker et al., 1999; Kevin et al., 2003). A recent in vivo model of endothelial ischaemia-
reperfusion injury in the arm demonstrated for the first time, in humans, that endothelial function 
after I/R injury is affected by ROS production (Loukogeorgakis et al., 2010).  At the onset of 
reperfusion, a sudden burst of ROS occurs, which has been shown to contribute to myocardial 
injury and cardiomyocyte death (see review(Hausenloy, 2009)).  
In an isolated rat heart model IPC reduced the excessive amount of ROS production at the onset 
of reperfusion, suggesting a deleterious role for the excess ROS in the early stages of reperfusion 
(Crestanello et al., 1996).  In contrast, a study by Baines et al, suggested that ROS may also play 
a critical role in the signal transduction pathway underlying IPC. This group demonstrated that 
the antioxidant, N-2-mercaptopropionylglycine (MPG), blocked the infarct-sparing effect of IPC 
in  both  in vitro and in vivo rabbit heart experiments, therefore suggesting that the presence of 
ROS was necessary for protection (Baines et al., 1997). In fact, a moderate release of ROS 
following the preconditioning stimulus leads to a decrease of ROS production at the onset of 
reperfusion (see review (Hausenloy, 2009)). 
 
3.1.8 The JAK-STAT pathway 
The Janus Kinases (JAKs) are a family of tyrosine kinases associated with membrane receptors. 
Ligands such as TNFα, interleukin 6 (IL-6) or growth factors activate the membrane receptors 
enabling the transphosphorylation and activation of two adjacent juxtaposed JAKs which can 
then subsequently activate the signal transducer and activator of transcription-3 (STAT-3) during 
ischaemia-reperfusion (see review (Lecour, 2009a)). STAT-3 is then phosphorylated at the 
tyrosine level, enabling it to form homodimers or heterodimers that subsequently translocate to 





The first study to implicate STAT-3 after acute myocardial infarction was performed in 2001 by 
Negoro and colleagues. In this experiment, the activation and increased phosphorylation of 
STAT-3 was observed for up to 24 hours after ligation of the left coronary artery in rats (Negoro 
et al., 2001) and the inhibitor of the JAK/STAT pathway, AG490, suppressed the 
phosphorylation of STAT-3 with a resulting increase in the number of apoptotic cells, 
implicating STAT-3 as a protective agent in ischaemia (Negoro et al., 2001). 
Using an in vivo left coronary artery ligation model in mice, Bolli‟s group was the first to 
demonstrate the phosphorylation and translocation of STAT-3 to the nucleus in the delayed 
phase of ischaemic preconditioning (Xuan et al., 2001). In early ischaemic preconditioning, 
JAK2 and STAT-3 are activated following the IPC stimulus in isolated working rat hearts and 
this effect was almost completely abrogated with the inhibitor of JAK2, AG490 (Hattori et al., 
2001). Furthermore, cardiac-specific STAT-3 knockout mice cannot be protected with an 
ischaemic preconditioning stimulus (Smith et al., 2004).  
Confirmation of the role of STAT-3 in ischaemic preconditioning has also been shown with 
pharmacological protective agents such as cardiotrophin-1 (Brar et al., 2001), erythropoietin 
The JAK-STAT pathway  
Fig 11: The JAK-STAT-3 signalling pathway. JAK2 is activated in response to a stimulus. 
Activated JAK 2 recruits STAT-3 from the cytoplasm and phosphorylates STAT-3 on a tyrosine 
residue. This phosphorylation allows STAT-3 to form homodimers and translocate to the nucleus 
where it upregulates transcription. STAT-3 is further phosphorylated on a serine residue to improve 





(Nishihara et al., 2006; Rafiee et al., 2005) or cannabinoid agonists (Montecucco et al., 2009). 
Preconditioning mimetics such as TNFα (Suleman et al., 2008) and opioids (Gross et al., 2006; 
Gross et al., 2007) also activate STAT-3 during the trigger phase of preconditioning.  
Several downstream effectors of the JAK/STAT pathway have been identified, including growth 
factors such as vascular endothelial growth factor (VEGF), pro survival proteins, proteins 
involved in cell proliferation such as Bcl-2, Bcl-xl, Mcl-1, Fas, cyclin D1, E1, p21 and other 
transcription factors (Amit-Vazina et al., 2005; Ikezoe et al., 2004; Liu et al., 2006; Marques et 
al., 2007; Torbenson et al., 2002; Zhang et al., 2007). In the context of ischaemic 
preconditioning, STAT-3 increases the anti-apoptotic gene, Bcl-2 and reduces the pro-apoptotic 
gene Bax (Hattori et al., 2001). Also, STAT-3 has been implicated in the mediation of 
preconditioning protection via the phosphorylation and therefore, the inactivation, of the pro-
apoptotic factor Bad (Lecour et al., 2005b). Other possible targets of STAT-3 may be 
mitochondrial connexion 43, an important component of the signal transduction cascade of IPC-
induced protection (Ozog et al., 2004; Schulz et al., 2007), Akt and GSK3-β (Gross et al., 2006; 
Juhaszova et al., 2004).  
 
3.1.9 The SAFE pathway 
An alternative and, possibly parallel, signalling pathway to the RISK path has recently been 
implicated in IPC. Lecour et al, have named this pathway the Survivor Activating Factor 
Enhancement (SAFE) pathway, (Figure 22) which includes the cytokine, tumour necrosis factor 
alpha (TNFα) and the transcription factor STAT-3 as triggers and mediators (Lecour, 2009a). 
This pathway will be discussed in further detail in the section 4.8 and in Section D. 
 
3.1.10   Receptors for Advanced Glycation End Products (RAGE) 
 Advanced glycation end products (AGEs) are formed by the nonenzymatic glycation and 
oxidation of proteins and lipids. The signal transduction receptor for AGEs is known as RAGE. 
A range of signal transduction cascades is activated by RAGE, including the MAPKs, PI3-
kinase/Akt, JAK-STAT, NFκB, GSK-3β and production of ROS via NADPH oxidase (Aleshin 
et al., 2008; Bierhaus et al., 2001; Huang et al., 2001; Kim et al., 2008; Marsche and others, 
2007; Shang et al., ; Wautier et al., 2001).  
Multiple cell types express RAGE, including cardiomyocytes and ischaemia-reperfusion is a 
potent generator of AGEs. In a study using ischaemic rat hearts, expression of RAGE was 
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significantly upregulated and pretreatment of the rats, 3 days prior to experimentation, with 
soluble RAGE (which acts as a decoy to bind the ligands of the receptor thus blocking it) 
reduced ischaemic injury and improved functional recovery of the myocardium (Bucciarelli et 
al., 2006). Moreover, the same group demonstrated that isolated and perfused hearts from RAGE 
null mice subjected to ischaemia-reperfusion were strikingly protected against I/R damage 
(Bucciarelli et al., 2006). RAGE can also modulate hypoxia/reoxygenation injury in adult 
murine cardiomyocytes via JNK and GSK-3β signalling pathways (Shang et al.). High-Mobility 
Group Box-1 (HMGB-1), a nuclear factor released by necrotic cells, signals via RAGE. When 
mice were preconditioned with HMGB-1 in an ischaemia-reperfusion model, TNFα levels were 
decreased and lipopolysaccharide (LPS) tolerance was induced, suggesting that the RAGE 
receptor was  involved in ischaemic preconditioning (Aneja et al., 2008). 
3.1.11  Proteinase activated receptor-2  
Proteinase activated receptors (PAR-2) are a recently described, novel family of seven 
transmembrane G-protein coupled receptors which are activated by protease cleavage (Cirino 
et al., 2000; Nystedt et al., 1994)  
PAR-2 is expressed in vascular tissue and highly vascularized organs (Bohm et al., 1996; 
Nystedt et al., 1994; Nystedt et al., 1995; D'Andrea et al., 1998). The first evidence that PAR-2 
was expressed in the heart and that it also contributes in the reduction of myocardial ischaemia-
reperfusion injury was provided by Napoli et al, (Napoli et al., 2000). In Napoli‟s seminal study, 
an agonist of PAR-2 was added to the perfusate of the isolated heart 15 minutes into the 
stabilisation period and continued for 5 minutes into reperfusion. This study demonstrated that 
activation of PAR-2 resulted in an improved functional response associated to an improvement 
of metabolic parameters of the heart during experimental ischemia-reperfusion injury. Napoli 
and colleagues subsequently used an isolated perfused rat heart model to demonstrate that 
enhanced activation of PAR-2 during the IPC stimulus, with a PAR-2 activating peptide, 
improved the protective effect of ischaemic preconditioning (Napoli, 2002). A study conducted 
in rat neonatal ventricular cardiomyocytes, demonstrated that  in the heart, PAR-2 stimulated 
p38 MAPK and  ERK1/2, elevated calcium concentration and also activated JNK and Akt (Sabri 
et al., 2000). PAR-2 has also been implicated in vessel relaxation via the NO pathway (Cheung 
et al., 1998; Cicala et al., 1999; Emilsson et al., 1997)  and  endothelin-1 (Magazine et al., 1996) 





In addition, activation of PAR-2 significantly reduced the infarct size 24 hours after 
administration in a mouse model of acute myocardial ischaemia (Lim et al., 2007). The 
cardioprotective effect of PAR-2 agonists has been linked to PKC and Erk1/2 activation 
(Blackheart et al., 1996), increased TNFα levels in cardiac tissue (Bopassa et al., 2006a) and 
manganese superoxide dismutase activity (Camerer et al., 2000).  
 
3.1.12   Glycogen synthase kinase-3 beta  
GSK-3β is a serine/threonine kinase that was originally identified as an enzyme that 
phosphorylates and downregulates glycogen synthase, the rate limiting enzyme of glycogen 
metabolism (Rylatt et al., 1980). Subsequently, it has been shown that the role and importance of 
GSK-3β extends far beyond intermediary metabolism but the nomenclature remains in use. 
Phosphorylation of GSK-3β results in its inactivation which has been reported to be 
antiapoptotic. Inhibition of GSK-3β plays an important role in the mediation of cardioprotection 
via phosphorylation by proteins such as the tyrosine kinases, Akt, PKC and activation of the 
mitochondrial ATP-sensitive potassium channel (mKATP) and the mPTP (Juhaszova et al., 2004).  
A study using a pressure overload hypertrophic rabbit heart model subjected to ischaemia-
reperfusion, demonstrated that contractile function after ischaemia in hypertrophied hearts 
treated with a GSK-3β inhibitor was better preserved and that tolerance to ischaemia-reperfusion 
injury in the hypertrophied myocardium was improved in the presence of the inhibitor (Barillas 
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Fig 13: Scheme showing various kinases that phosphorylate and inacivate GSK-3β. In the 
absence of upstream kinases, unphosphorylated GSK-3β is active, phosphorylating and 
deactivating downstream targets such as glycogen synthase, or phosphorylating transcription 
factors and targeting them for degradation. GS = glycogen synthase; RSK = p90 ribosomal S6 
kinase; ILK = integrin-linked kinase; WNT = homologues of Wingless; P = phosphorylation, 
(Murphy, 2004). 
to a regional ischaemia-reperfusion insult at two different perfusion pressures showed an 
improved infarct size (Mozaffari et al, 2008). 
Numerous studies have implicated inhibition of GSK-3β in the cardioprotective effects of IPC 
(Gross et al., 2004; Gross et al., 2006; Juhaszova et al., 2004; Tong et al., 2002). In one of these 
studies, evidence implicating the involvement of GSK-3β in the protective effect of IPC was 
provided with the use of two inhibitors of GSK-3β, lithium and SB216763, administered during 
the IPC protocol in an isolated rat heart model of ischaemia-reperfusion (Tong et al., 2002).  
From this study it was reported that phosphorylation and inactivation of GSK-3β occurred 
during IPC which would be consistent with a role for GSK-3β in preconditioning. In addition, 
this group linked PI3-kinase to the cardioprotective effect of phosphorylation of GSK-3β (Tong 
et al., 2002). In 2004, Juhaszova et al, suggested the inhibition of GSK-3β as a “master 
signalling switch” which leads to the convergence of the various prosurvival pathways to the 








3.1.13 Role of the mitochondria, the mitochondrial ATP-sensitive potassium channel and 
the mitochondrial permeability transition pore in IPC 
Mitochondria are spherical or rod shaped organelles found within the cytoplasm of eukaryotic 
cells and often referred to as the “powerhouse of the cell” since they act as the site for the 
production of adenosine triphosphate (ATP) which is vital as an energy source for several 
cellular processes.  
Many prosurvival signalling cascades appear to converge to the mitochondria and given that the 
mitochondria are the “powerhouse” of the cell, this is no surprise. It is still a matter of debate as 
to how the prosurvival signals actually terminate at the mitochondria.  
 
i) Mitochondrial Adenosine Triphosphate-sensitive potassium channel  
Two potassium adenosine triphosphate-sensitive potassium channel subtypes coexist in the 
myocardium. One is located in the sarcolemmal membrane (sarcKATP) and the other in the inner 
mitochondrial membrane (mKATP). These channels allow coupling of membrane potential to 
cellular metabolic status and can be pharmacologically modulated by potassium channel 
openers and inhibitors.  
Pharmacological agents which open the mKATP channel protect the ischaemic myocardium by 
direct protection of cardiac myocytes (Weselcouch et al., 1995). A study using an isolated canine 
gracilis muscle model demonstrated that when a mKATP opener was administered by direct 
infusion into the artery supplying the muscle, the infarct size was significantly reduced, therefore 
suggesting that mKATP activation is an important protective mechanism in this tissue 
(Weselcouch et al., 1995). 
Garlid‟s group perfused isolated rat hearts with diazoxide, a potent opener of the putative mKATP 
channel, prior to ischaemia, demonstrating that opening of the channel was cardioprotective 
(Garlid et al., 1997). In addition, pharmacological activation of both PKC and MAPK which 
induce cardioprotection can be blocked with 5HD, a mKATP channel inhibitor, thus indicating 
that the channel may be downstream to these preconditioning mediators (Hopper et al., 2000; 
Yue et al., 2002). Other studies have demonstrated that PKC activates both the sarcKATP and the 
mKATP channels (Hu et al., 1996; Sato T et al., 1998) but the actual role of these channels in IPC 
is controversial (Hanley P J., 2005). It should be noted that the mKATP channel has never been 
cloned and that much of the evidence obtained which has implicated the mKATP channel as 
playing a critical role in IPC was obtained using pharmacological inhibitors (Garlid et al., 1997; 




ii) Mitochondrial permeability transition pore  
The mPTP is a large non-selective ion channel in the inner mitochondrial membrane. 
Mitochondrial permeability transition is an increase in the permeability of the mitochondrial 
membranes to molecules of less than 1500 Daltons in molecular weight. Mitochondrial 
permeability transition results from opening of mitochondrial permeability transition pores. 
Under normal physiological conditions the mitochondrial inner membrane is impermeable to 
most molecules. During stressful conditions,  such as ischaemia-reperfusion, the mPTP opens, 
allowing the transfer of molecules to the inner mitochondria (Hausenloy et al., 2004a) causing 
swelling and rupture of the outer mitochondrial membrane (Halestrap et al., 2004). Irreversible 
opening of this channel in response to the sudden return of flow of blood at reperfusion is 
considered to be responsible for cardiomyocyte death by uncoupling oxidative phosphorylation 
(Hausenloy, 2009).  
Transient opening and closure of the mitochondrial permeability transition pore (mPTP) at the 
time of reperfusion has emerged as an important target for cardioprotection in IPC. In 2002, 
Hausenloy et al used an isolated rat heart model of IPC to demonstrate that an infusion of 
cyclosporine-A (CsA) at reperfusion, inhibited the opening of the mPTP, mimicking IPC-
induced protection (Hausenloy et al., 2002). Subsequent studies have also implicated the closure 
of the pore at reperfusion in the protective effect of preconditioning (Hausenloy et al., 2004a; 
Javadov et al., 2003). Although the mechanism for this effect still needs to be elucidated, it may 
involve certain components of the RISK pathway such as Akt, Erk1/2 or GSK-3β (Abdallah et 
al., 2006; Bopassa et al., 2006b).  
3.1.14 Applications of ischaemic preconditioning 
A robust and reproducible protection is exerted by the phenomenon of IPC and this has been 
demonstrated in the heart of every animal species tested thus far e.g. rabbits, dogs, ferrets, pigs, 
guinea pigs, sheep, mice, chicken and man (see review (Lawson and Downey, 1993)). However, 
these experimental results, done mainly in healthy, young animals may not be reproducible in 
humans as comorbidities, such as diabetes, obesity and left ventricular hypertrophy often 
accompany ischaemic heart disease in humans and these may influence the outcome of IPC 
(Moolman et al., 1997; Tsang et al., 2005).  Moreover, the need to intervene before the index 
ischaemic event limits the clinical application of IPC as an acute myocardial infarction (AMI) 
cannot yet be predicted. The application of IPC in the clinical arena is, therefore, limited to 
scenarios in which the index ischaemia can be reliably predicted, such as in patients undergoing 
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surgery with extracorpal circulation. Yellon et al, were the first to report that IPC induced by 
intermittent cross-clamping of the aorta in coronary artery bypass graft surgery preserved the 
patient‟s ATP levels during the subsequent global ischaemic period (Yellon et al., 1993). Brief 
episodes of ischaemia are experienced by many patients prior to an acute myocardial infarction 
and it is theoretically possible that this pre-infarct angina may precondition the heart. Hence, it 
has been demonstrated that the presence of angina before AMI is associated with a smaller 
infarct size (Kloner et al., 1995). The discovery of “remote ischaemic preconditioning” in which 
either an upper limb or the leg can be used to apply IPC (usually by repeated, intermittent blood 
pressure cuff inflations and deflations) has revived the interest in IPC. This non-invasive remote 
form of IPC, known as RIPC, has been used successfully in children undergoing corrective heart 
surgery (Cheung et al., 2006), patients undergoing coronary artery bypass grafts (Hausenloy et 
al., 2007; Venugopal et al., 2009) and in elective percutaneous coronary interventions (Hoole et 
al., 2009). 
3.2 Ischaemic postconditioning  
Ischaemic postconditioning has been defined as a series of brief mechanical interruptions of 
reperfusion applied at the onset of reperfusion (Zhao et al., 2003).  
Ischaemic postconditioning (IPostC) was first proposed in 2003 by Vinten-Johansen‟s group as 
an attempt to offer an intervention which could be applied at the time of myocardial reperfusion 
to protect patients diagnosed with an acute myocardial infarction, (Figure 14). 
  
As in IPC, many experiments have demonstrated that IPostC reduces infarct size in hearts of 
several different animal species such as: rabbit, mice, rats dogs, and pigs (Bopassa et al., 2006b; 
Darling et al., 2005; Heusch et al., 2006; Iliodromitis et al., 2006; Tsang et al., 2004; Yang et al., 
2005; Zhao et al., 2003). The degree to which the heart is protected by ischaemic 
IPOSTC 
Cardioprotection 
 Reperfusion  – – BUT  - 
Alternating episodes of reperfusion and ischaemia 
Ischaemic insult 
Reperfusion period 
Fig 14: Schematic representation of ischaemic postconditioning. IPostC is initiated at the onset of 




postconditioning appears to be similar or slightly less than that obtained by ischaemic 
preconditioning (Fantinelli and Mosca, 2007; Halkos et al., 2004; Kin et al., 2004; Zhao et al., 
2003) but the effect of IPostC is not enhanced by IPC (Halkos et al., 2004). As the clinical 
application of IPC was limited, the IPostC phenomenon has opened a novel era of research to 
limit reperfusion injury. 
In their seminal paper, Zhao and colleagues, demonstrated that interruption of myocardial 
reperfusion with 3 x 30 second episodes of myocardial ischaemia and reperfusion in a canine 
model, resulted in a dramatic reduction in myocardial infarct size, comparable to that seen with 
IPC (Zhao et al., 2003). Thus, ischaemic postconditioning (IPostC) evolved as a method to 
reduce reperfusion injury. The protective effect of IPostC is clearly demonstrated in figure 15 
which shows a section from a mouse heart subjected to IPostC compared to a heart which 
received no intervention. 
 
 
3.2.1 Mechanisms of IPostC: A remarkable assortment of molecular mechanisms, similar to 
those implicated in IPC, has been demonstrated to contribute to the protective effects of IPostC. 




Fig 15: Ischaemic postconditioning reduces infarct size.  A: heart subjected to ischaemia-reperfusion with 
no intervention. B: heart postconditioned with alternating cycles of reperfusion and ischaemia. Red area = 

























Fig 16: Hypothetical scheme outlining a few major signalling mechanisms common to IPC and 




A number of signalling pathways which have been recruited by IPostC have been identified. 
These can be divided into the following: 
 
3.2.2  Gi-protein coupled receptors  
The human genome has been estimated to have an extremely large number of GPCRs and based 
on their sequences as well as on their known or suspected functions, there are estimated to be 
five or six major classes of GPCRs (Kroeze et al., 2003). Depending on the type of G protein to 
which a receptor is coupled, a variety of downstream signalling pathways can be activated 
(Marinissen and Gutkind, 2001; Neves et al., 2002). 
The role of adenosine, bradykinin and opioids receptors will be discussed in section 3.3 related 
to pharmacological pre- and postconditioning. 
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3.2.3  The RISK pathway 
In an isolated perfused rat heart, inhibition of PI3-kinase at reperfusion with wortmannin or 
LY290042 abolished the protective effect of IPostC (Tsang et al., 2004). Similarly, addition of 
PD98059, an inhibitor of Erk1/2 at the onset of reperfusion suggested that the protective benefits 
of IPostC were dependent on the activation of Erk1/2 (Yang et al., 2004b). Subsequent studies in 
both healthy and diseased animals as well as human atrial muscles have confirmed the role for 
Akt and Erk1/2 in IPostC (Feng et al., 2006; Sivaraman et al., 2007; Zhu et al., 2006). Potential 
distal signalling elements of the RISK pathway are suggested to be PKG, PKCε and GSK-3β 
(Burley and Baxter, 2009; Gomez et al., 2008) as already described in section 3.1.4.  
However, a few recent experimental studies conducted in swine and rabbit models have failed to 
show components of the RISK pathway as mediators of IPostC-induced protection, therefore 
suggesting the existence of alternative pathways (Darling et al., 2005; Skyschally et al., 2009). 
  
3.2.4 The JAK-STAT pathway  
Phosphorylation of STAT-3 was first implicated in the cardioprotective effect of IPostC in 2006 
by Lecour‟s group (Suleman et al., 2006). In isolated hearts, the protective effect of IPostC was 
abolished in the presence of the JAK2 inhibitor, AG490, and western blot analysis after 15 
minutes of reperfusion revealed that IPostC decreased the phosphorylation of STAT-3 in the 
cytosol, therefore suggesting activation and translocation of STAT-3 to the nucleus after IPostC. 
The role of STAT-3 in IPostC was confirmed by Boengler et al in an in vivo STAT-3 knockout 
mouse model (Boengler et al., 2008). However, the evidence of interaction between the 
JAK/STAT pathway and the PI3-kinase pathway at the onset of reperfusion and during IPostC is 
inconclusive (Goodman et al., 2008) and the mechanism responsible for the activation of the 
JAK/STAT pathway in IPostC is unknown.  
3.2.5  Nitric oxide-cGMP-PKG signalling cascade  
The protective effects of IPostC have been demonstrated to be sensitive to pharmacological 
inhibition of the NO-cGMP-PKG pathway (Penna et al., 2006a; Yang et al., 2005). It is believed 
that, in response to IPostC, activated PKG opens the mKATP channel through PKCε (Costa et al., 
2005) which is presumably activated via the Akt component of the RISK pathway and eNOS 





3.2.6 ROS signalling 
IPostC reduced the amount of harmful ROS generation at the onset of myocardial reperfusion 
(Zhao et al., 2003). ROS signalling in the first moments of reperfusion, however, appears 
necessary for the protective effect of IPostC (Penna et al., 2006b) as inhibitors of ROS given at 
the onset of reperfusion, abolished the protective effect of IPostC. At present, the role of ROS 
signalling during IPostC still remains unclear. 
3.2.7 Receptor for advanced glycation end products 
A current literature search revealed no articles on RAGE and IPostC but the receptors for 
advanced glycation end products have been involved in protection during ischaemia-reperfusion 
and seem to be implicated in IPC (Aneja et al., 2008; Bucciarelli et al., 2006). Therefore, it is 
appropriate to suggest that RAGE may play a role in IPostC. 
3.2.8 Proteinase Activated Receptor-2 
Ischaemia-reperfusion injury and angioplasty balloon catheter injury are reported to increase the 
expression of PAR-2 (Damiano et al., 1999; Napoli et al., 2000) and PAR-2 activation has been 
shown to be protective in other tissues, including brain, airways and myocardium undergoing 
ischaemia or lipopolysaccharide challenge (Jin et al., 2005; Morello et al., 2005; Napoli et al., 
2000). 
Although never studied in IPostC, Vinten-Johansen‟s group demonstrated firstly, that PAR-2 is 
present in the left ventricular tissue of rat heart, in neonatal rat cardiomyocytes and in H9C2 rat 
cardiac-derived cells and secondly, that a PAR-2 agonist administered 5 minutes before 
reperfusion in the isolated rat heart, salvaged the myocardium via an Erk1/2 pathway (Jiang et 
al., 2007). These data suggested that IPostC may protect via activation of PAR-2. 
3.2.9 Glycogen synthase kinase-3 beta (GSK-3β) 
Inactivation of GSK-3β is a well-established downstream target of the RISK pathway. As in 
IPC, inhibition of GSK-3β is believed to play an important role in IPostC, although experimental 
results have been somewhat contradictory.  In an isolated rat heart model, Gross et al, first 
implicated inhibition of GSK-3β at the onset of reperfusion (Gross et al., 2004). Gomez et al, 
reported that inhibition of GSK-3β by postconditioning was required in transgenic mice to 
prevent the opening of the mPTP during reperfusion (Gomez et al., 2008). In contrast, Nishino et 
al, also using transgenic mice, found that inactivation of GSK-3β was not required to confer 
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protection in either IPC or IPostC (Nishino et al., 2008). Skyschally and colleagues 
postconditioned pigs in the presence of inhibitors of the RISK pathway and found that protection 
was still induced in the pigs although blockade of the RISK pathway resulted in a reduced GSK-
3β phosphorylation and p70s6K (Skyschally et al., 2009).  
However, as previously mentioned, GSK-3β could possibly be the central point where a number 
of protective signalling cascades converge and its cellular location close to the mPTP may be of 
significance in transferring prosurvival signals (Juhaszova et al., 2009).  
3.2.10 Mitochondrial involvement in IPostC 
Many of the signalling pathways transmitting the cardioprotective signal of IPostC appear to 
converge to the mitochondria. The heart is a rich source of mitochondria with approximately 
40% of total cardiomyocyte volume consisting of mitochondria (Barth et al., 1992). Thus, 
mitochondria are both targets and sources of injury during cardiac ischaemia and reperfusion 
with both the putative mKATP channel and the mPTP being implicated as possible end effectors 
of the protective pathway (Gross and Gross, 2006; Gross et al., 2004; Hausenloy et al., 2002).  
i) Mitochondrial potassium ATP channels  
Pharmacological inhibition of the mKATP at the onset of reperfusion abrogated IPostC-induced 
protection (Donato et al., 2007; Yang et al., 2004b) but no direct studies have shown that IPostC 
can actually open this channel during reperfusion. A recent study by Garlid‟s group suggested 
that IPostC generates a signalosome which conveys the signal from the G-protein coupled 
receptors to the opening of the mKATP leading to the inhibition of the opening of the mPTP 
(Quinlan et al., 2008). 
 
ii) Mitochondrial permeability transition pore 
 Several studies suggest a critical role of the mPTP in IPostC. Isolated rabbit heart mitochondria 
subjected to a standard IPostC protocol, are more resistant to calcium-induced opening of the 
mPTP, therefore suggesting that IPostC inhibits mPTP opening at reperfusion (Argaud et al., 
2005).  Bopassa et al, subsequently reported that inhibition of PI3-kinase/Akt with wortmannin 
or LY294002 at the onset of reperfusion abolishes the inhibitory effect on the pore‟s opening of 
IPostC, implicating IPostC in the mediation of pore inhibition via the activation of PIK-
kinase/Akt (Bopassa et al., 2006a). Also, mice lacking cyclophilin-D, the only known 




3.2.11 Clinical application of ischaemic postconditioning 
Within 2 years following its initial description, IPostC proved to be effective in clinical studies. 
Several sequences of inflation/deflation of the angioplasty balloon applied after opening of the 
infarcted vessel, reduced infarct size, improved coronary blood flow and improved myocardial 
reperfusion in patients with acute myocardial infarction (Laskey, 2005; Ma et al., 2006; Staat et 
al., 2005; Yang et al., 2007). However, the application of IPostC in these studies was strictly 
restricted to patients undergoing primary percutaneous intervention (PCI) as the protocol was 
invasive.  
Therefore, it is important to delineate the signalling pathways which are responsible for the 
cardioprotective effect of IPostC. Knowledge of these signalling cascades may pave the way for 
manipulation of pharmacological targets to achieve the same end result as IPostC. Cyclosporine-
A, which prevents the opening of the mPTP at reperfusion has already been used in the clinical 
setting with a promising outcome. An important “proof of concept” study, provided evidence in 
humans that inhibition of the mPTP at reperfusion in patients with acute myocardial infarction is 
associated with reduction in infarct size (Piot et al., 2008).  
  
3.3 Pharmacological pre- and postconditioning – the next step in limiting infarct size 
Given the invasive nature of ischaemic pre and postconditioning and its limited use to elective 
PCI patients or patients undergoing cardiac surgery, pharmacological agents mimicking the 
protective effects of IPostC were sought and found. Included amongst the protective 
pharmacological agents were: adenosine, bradykinin and opioids. 
  
3.3.1 Adenosine 
 Adenosine is a nucleoside composed of a molecule of adenine attached to a ribose sugar molecule 
moiety. It is a purine nucleoside endogenously expressed in the body and modulates many biological 
processes after binding to one of the adenosine receptors.  
Increased release of adenosine has been reported during ischaemia and early reperfusion 
(Schrader et al., 1977). Adenosine, infused directly into the left descending coronary artery in a 
canine model reduced the deleterious effects of ischaemia by decreasing infarct size. This 
protective effect was attributed to the vasodilatory effects of adenosine (Engler, 1987; Olafsson 
et al., 1987; Takeo et al., 1988). Adenosine is one of three autacoids released by ischaemic 





3.3.2 Adenosine receptors  
There are 4 adenosine receptor subtypes, A1, A2A, A2B and A3 with all of the receptors being 
expressed in different cell types of the heart and blood vessels. Cardioprotection has been 
attributed mainly to the A1 and A3 receptors, (Black et al., 2002; Reichelt et al., 2005) with the 
A3 receptor appearing to share a few similarities with the A1 receptor, both having been 
associated with different kinase systems such as PKC, MAPK‟s, PI-3 kinase and Akt (Dana et 
al., 2000; Headrick et al., 2003; Mubagwa and Flameng, 2001). However, evidence also exists 
showing that the A2A receptor is associated with cardioprotection (Norton et al., 1992; Xu et al., 
2001). Adenosine and adenosine receptor agonists are the most widely studied cardioprotective 
ligands, but as yet, there is no definite agreement as to which receptor subtype contributes to 
cardioprotection during ischaemia or reperfusion phases. 
 
3.3.3 Preconditioning with adenosine  
The cardioprotective effect of IPC has been successfully mimicked by adenosine administration 
in various animal models tested, and in human atrial trabeculae (Cleveland et al., 1997; Liu et 
al., 1994; Liu et al., 1991). In a seminal study using in vivo rabbit hearts, Liu et al, infused two 
different non-selective adenosine antagonists directly before the IPC protocol was applied and 
each successfully blocked the IPC-induced protection (Liu et al., 1991). This data suggested that 
adenosine released during preconditioning stimulates the A1 receptor. A few years later Liu et al, 
using a selective A1 receptor antagonist and a selective A3 receptor agonist, provided evidence 
demonstrating that the protection of IPC was not exclusively mediated by the A1 receptor in 
heart but could also involve the A3 receptor (Liu et al., 1994). 
 
3.3.4 Postconditioning with adenosine 
Downey‟s research group was the first to implicate adenosine in IPostC (Yang et al., 2005). In 
an isolated perfused rabbit heart, the presence of a non-selective A1 receptor antagonist, an 
inhibitor of the PI3-kinase signalling cascade, wortmannin, and an inhibitor of guanyl cyclase 
abolished the infarct-sparing effect of IPostC and their data suggest that postconditioning-
induced protection requires the adenosine A1 receptor to activate PI3-kinase and guanyl cyclase 
(Yang et al., 2005). Similarly, Kin and colleagues used an isolated perfused mouse heart model 
to demonstrate that IPostC reduces the level of adenosine released during reperfusion (Kin et al., 
2005a). This same group confirmed their data in an open chest rat model of myocardial 
infarction using A1, A2, or A3 receptor antagonists, administered 5 minutes before reperfusion in 
the presence or absence of IPostC. Interestingly, IPostC in the rat protected the heart, reduced 
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the adenosine washout at 2 minutes of reperfusion and reduced infarct size and this effect was 
not abolished by the A1 receptor antagonist. However, the A2 and A3 receptor antagonists did 
abrogate the protective effect of IPost, therefore suggesting that IPostC involved endogenous 
activation in the heart of the A2 or A3 receptor but not the A1 receptor subtype (Kin et al., 
2005a).  
 
3.3.5 Proposed mechanisms in adenosine-induced cardioprotection 
Contrary to the proposal by Cohen et al, suggesting that adenosine-induced protection was not 
dependent on opening of the mKATP (see review (Cohen and Downey, 2008)),  intracoronary 
infusion with adenosine and dipyridamole (a drug which inhibits thrombus formation and also 
causes vasodilation) before occlusion in a canine model of IPC produced a significant reduction 
in infarct size which was abolished by pretreatment with glybenclamide, an ATP-dependent 
potassium channel antagonist. This suggested that activation of the A1 receptors in the heart 
produces myocardial preconditioning via the opening of the KATP channels (Auchampach and 
Gross, 1993). The mechanism of protection may, therefore, be dependent on whether adenosine 
acts as a trigger or mediator of IPC.  
PKCε has also been implicated as a mediator in adenosine‟s preconditioning signalling pathway 
(Cohen and Downey, 2008). Cohen et al, hypothesized that in postconditioning, adenosine 
activates PKCε which subsequently activates the A2B receptor, Erk1/2, Akt and p70s6K, 
therefore inhibiting GSK-3β and preventing the opening of the mPTP (Cohen and Downey, 
2008). PI3-kinase and guanyl cyclase are involved in adenosine-induced postconditioning (Yang 
et al., 2005) and other investigators have also implicated the components of the RISK pathway 
in adenosine-induced cardioprotection (Kis et al., 2006; Park et al., 2006a; Yang et al., 2004a). 
 
3.3.6 Clinical application of Adenosine 
The ability of adenosine to limit reperfusion injury has been tested in two clinical trials 
involving patients with AMI. In the AMISTAD-I trial, patients undergoing fibrinolysis were 
randomised to receive either adenosine (70μg/kg/min for 3 hours) or a normal saline infusion 
within 6 hours of infarction onset. Infarct size was reduced by 33%, relative to the area at risk, 
(p<0.085).  However, the percentage reduction in infarct size appeared to depend upon which 
area of the heart was infarcted. In addition, adenosine showed no significant effects on 
secondary endpoints and clinical outcomes such as death, stroke, congestive heart failure, re-
infarction and cardiogenic shock (Mahaffey et al., 1999).  
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A second, larger AMISTAD trial (AMISTAD-II) sought to assess two doses of adenosine 
infusion, 50 and 70 µg/kg/min given for 3 hours, with treatment starting 15 min before the start 
of fibrinolysis or PCI, but still within 6 hours after infarction onset. Both doses reduced infarct 
size with the higher dose achieving a 59% reduction compared to 15% reduction with the lower 
dose. Despite the reduction in infarct size, no difference was observed in the survival rate 
between placebo-treated or adenosine-treated patients (Ross et al., 2005). The inconsistencies in 
the results of the two AMISTAD trials lead to major reservations about the reliability of infarct 
size quantification in clinical studies and also cast doubt about the protective effect of adenosine 
and selective adenosine receptor agonists at reperfusion in experimental studies (see review 
(Burley and Baxter, 2009)). 
 
3.3.7 Bradykinin  
Bradykinin is a nonapeptide kinin formed from a plasma protein, high-molecular-weight (HMW) 
kininogen, by the action of kallikrein; it is a very powerful endothelium-dependent vasodilator 
that helps to enlarge or open blood vessels. This lowers blood pressure, allowing the blood to 
flow more smoothly throughout the body. In addition, bradykinin constricts smooth muscle and 
stimulates pain receptors. 
Similar to adenosine, bradykinin is elevated during and after an ischaemic insult (Baumgarten et 
al., 1993; Pan et al., 2000; Schulz et al., 1998). 
 
3.3.8  Bradykinin receptors  
Cardiomyocytes have two bradykinin receptors, a constitutive B2 receptor and an inducible B1 
receptor (Bhoola et al., 1992; Marceau et al., 1998). Induction of the B1 receptor in the left 
ventricle of rats occurs 6 hours after reperfusion, and increases up to 4 fold after 24 hours 
(Tschope et al., 2000; Tschope et al., 1999). Bradykinin was first associated with IPostC when 
two different pharmacological antagonists of the bradykinin 2 receptor abolished the protective 
effect of IPostC in the isolated rat heart (Penna et al., 2007).  
 
3.3.9 Preconditioning with bradykinin 
The cardioprotective effect of bradykinin has been demonstrated in various animal models such 
as mouse, rat, rabbit and pig hearts (Bell and Yellon, 2002; Penna et al., 2007; Penna et al., 
2008; Tobe et al., 1991; Yang et al., 2004a). 
Using B2 receptor knockout mice, or a rat model deficient in high-molecular-weight (HMW) 
kininogen, Yang et al, demonstrated that IPC fails to protect against ischaemia-reperfusion, 
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therefore suggesting an important role for the B2 receptor in IPC (Yang et al., 1997). The exact 
role of the B1 receptor in cardioprotection is unknown although knockout of this receptor in 
female mice had no effect on remodelling after a myocardial infarction (Xu et al., 2005). 
Bradykinin can also mimic IPC in the rabbit heart. Exogenous bradykinin protected to a similar 
extent compared with IPC and the B2 receptor blocker completely abrogated the protection 
(Goto et al., 1995). In addition, bradykinin can mimic the effects of IPC in humans undergoing 
percutaneous transluminal coronary angioplasty (Leesar et al., 1999). However, it is unknown 
whether bradykinin receptor inhibitors can abrogate the effect of IPC (Gross and Gross, 2006). 
  
3.3.10 Postconditioning with bradykinin  
Using an isolated rat heart model of postconditioning, Penna et al, demonstrated that intermittent 
infusion of bradykinin at the beginning of reperfusion stimulates a postconditioning-like 
cardioprotection (Penna et al., 2007). The bradykinin-induced protection was abrogated in the 
presence of a B2 receptor antagonist, implicating this receptor in the protective effect. Similarly, 
isolated hearts from mice in which the bradykinin B2 receptor, the bradykinin B1 receptor or the 
adenosine A1 receptor had been knocked out, showed that the protective effect of IPostC was 
partially attenuated in the B1 receptor knockout but was abrogated in the absence of the B2 
receptor and the adenosine A1 receptor (Liu et al., 2008). Using three distinctive strains
 
of gene 
knockout mice, this study provided the first
 
conclusive evidence showing IPostC-induced 
cardioprotection
 
could be triggered by activation of multiple types of cell membrane
 
receptors, 
which include adenosine A1 and bradykinin B1 and B2 receptors. 
 
3.3.11 Proposed mechanisms in bradykinin-induced cardioprotection 
Bradykinin, given at reperfusion protects via PI3-kinase/Akt and Erk1/2 pathway and by 
opening the mitochondrial ATP-sensitive potassium channels with the generation of reactive 
oxygen species that act as second messengers to activate PKC (see review (Critz et al., 2005)). 
Studies in rat hearts with intermittent application of bradykinin at reperfusion, have 
demonstrated a sizeable reduction in infarct size with activation of NO, cGMP, PKG, mKATP 
opening, and ROS production being implicated in the protective pathway (Oldenburg et al., 
2004).   
An interesting study by Penna and colleagues in the isolated rat heart, reported the novel finding 
that postconditioning required endogenous activation of cyclooxygenase (COX) and release of 
prostacyclin GI2 (PGI2) and that bradykinin, given as a postconditioning mimetic, also triggered 
the COX activation and induced PGI2 formation during the late phase of reperfusion (Penna et 
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al., 2008). This data suggested that ischaemic postconditioning and intermittent bradykinin 
postconditioning were not solely dependent on the activation of the RISK pathway but that it 
also depended on the late release of PGI2 via activation of COX (Penna et al., 2008).  
Quinlan and co-workers proposed another mechanism in which bradykinin interacted with its B2 
receptor, inducing the formation of a signalosome (a vesicular caveolar signalling platform). 
This would then phosphorylate an unknown receptor on the outer mitochondrial membrane. As 
the terminal kinase of bradykinin is protein kinase G (PKG), this would phosphorylate the 
unknown receptor at a serine/threonine residue. The signal would then be transmitted to activate 
protein kinase epsilon1 (PKCε1) on the inner mitochondrial membrane. PKCε1 is situated close to 
the mitochondrial KATP channel and causes this to open with a subsequent increase in hydrogen 
peroxide (H2O2) production. H2O2 then activates a second PKCε - PKCε2, which would then 
inhibit the opening of the mitochondrial permeability transition pore (mPTP) thereby leading to 
cardioprotection (Quinlan et al., 2008). However, the “signalosome” hypothesis remains a 
working hypothesis and requires further validation. 
3.3.12 Clinical application of bradykinin 
In a small clinical trial, thirty patients were randomised to receive an intracoronary infusion of 
bradykinin or normal saline for 10 minutes prior to percutaneous transluminal coronary 
angioplasty (PTCA). The purpose of this study was to see if bradykinin could reproduce the 
protective effect of IPC. Electrocardiogram (ECG), chest pain score and regional wall motion 
during inflation of the balloon were used to evaluate the effect of bradykinin infusion. 
Bradykinin-treated patients fared significantly better than the control subjects suggesting that 
intracoronary infusion of bradykinin before PTCA renders the myocardium relatively resistant to 
subsequent ischaemia. The extent of this bradykinin-induced protection was comparable to that 
afforded by IPC in control subjects. In addition, no adverse effects of the bradykinin infusion 
were reported, suggesting that bradykinin could be used in selected patients undergoing PTCA to 
reduce ischaemia-reperfusion injury (Leesar et al., 1999). 
3.3.13 Opioids 
Opioids are endogenous autacoids, released by ischaemic tissues. They are pain-attenuating 
peptides that occur naturally in the brain.  
Endogenous opioid peptides are synthesised and released into the circulatory system after 
myocardial infarction. In the rat, the ventricular tissue was shown to have much higher levels of 
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preproenkephalin (an opioid) compared to the other organs, indicating that the heart may have a 
very significant endogenous opioid system (Romano et al., 2004). 
 
3.3.14 Opioid receptors 
Opioids exert their numerous pharmacological functions after fixation to their opioid receptors. 
Three opioid receptor subtypes have been cloned.  In adult ventricular cardiomyocytes only two 
receptor subtypes have been reported, the kappa (κ) and the delta (δ) (Krumins et al., 1985; 
Ventura et al., 1989; Wittert et al., 1996; Zhang et al., 1996). However, the presence of the mu 
(µ) receptor is also suggested in human atrial trabeculae (Bell et al., 2000). There appears to be a 
converse relationship between the opioid receptors and the β-adregenic pathway, in that when 
opioid receptors are inhibited, cardiac responsiveness to β-adregenic stimulation is increased 
(Pepe et al., 1997). Conversely, when agonists of β-adregenic receptors are used, the number and 
affinity of opioid receptors is increased (Pepe et al., 1997) which indicates a feedback 
mechanisms between these two systems. The protective effect of IPostC has recently been linked 
to the endogenous activation of the opioid receptors in a series of experiments by Zatta and 
colleagues (Zatta et al., 2008).  
3.3.15  Preconditioning with opioids 
Opioid release from ischaemic tissues appears to be involved in ischaemic preconditioning as 
well as in remote ischaemic preconditioning (Sadat, 2009). In a rat model, morphine, given as a 
preconditioning stimulus, decreased the infarct size in a similar manner to that of IPC and 
glibenclamide blocked the cardioprotection, implicating the involvement of the mKATP channel 
in this protective effect (Schultz et al., 1996). Other studies in the isolated rat heart model have 
demonstrated the ability of morphine to deliver the same degree of cardioprotection when 
administered just prior to reperfusion as it does when given prior to ischaemia (Gross et al., 
2004).  The protective effect of IPC in the canine heart and rat hearts can be mimicked by non-
selective opioid agonists, selective κ-receptor agonists, or selective agonists for the δ-receptor, 
while µ specific agonists failed to induce protection (Headrick et al., 2003; Schultz et al., 1997; 
Schultz et al., 1996; Wang, 2001). Alternatively, opioid antagonists have been demonstrated to 
abrogate or partially abrogate the infarct-sparing effect of IPC (Chien and Van Winkle, 1996; 
Schultz et al., 1996; Wang, 2001). 
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3.3.16 Possible mechanisms in opioid-induced preconditioning  
Preliminary evidence suggests that opioid preconditioning is mediated via endogenous opioid 
receptors, since the protective effects are inhibited by both naloxone, an opioid receptor 
antagonist, and methiodide, a peripheral acting naloxone derivative (Gross and Gross, 2006). 
Isolated rat and mouse models of ischaemia-reperfusion were unable to be protected with a 
selective κ-opioid agonist in the presence of wortmannin, a PI3-kinase/Akt inhibitor and 5-HD, a 
blocker of the mKATP channel (given prior to reperfusion) thus implicating the activation of PI3-
kinase/Akt and the mKATP channel in opioid preconditioning (Peart et al., 2008). Downey et al, 
have reported that opioid-induced protection occurs through a complex pathway which includes 
PI3-kinase/Akt, NOS, guanyl cyclase, PKG, opening of the mKATP and activation of PKC by 
redox signalling (see review (Downey et al., 2007)).  
 
3.3.17 Postconditioning with opioids 
Morphine can also protect the heart during reperfusion as shown in a study by Chen et al, in 
which morphine was given for the first 10 minutes of reperfusion in isolated rat hearts (Chen et 
al., 2008). This group demonstrated that morphine can mimic ischaemic postconditioning via 
activation of the κ-opioid receptor and the mKATP channel and they suggest that the δ-opioid 
receptor is not involved (Chen et al., 2008).  
 
3.3.18 Possible mechanisms in opioid-induced cardioprotection 
Morphine, one of the major opioids, appears to only exert a beneficial effect when administered 
during the ischaemic index or during early reperfusion (Gross, 2003). In contrast, the selective δ-
opioid agonist, DADLE, mimicked the effects of ischaemic preconditioning in human atrial 
trabeculae (Tomai et al., 1999). A recent study in isolated rat hearts has provided evidence that 
opioids signal via the JAK/STAT pathway, with JAK2 mediating Akt activation, GSK-3β and 
the inhibition of the mPTP (Gross et al., 2006). Another study in which morphine was 
administered just prior to reperfusion in the isolated rat heart, demonstrated a protective effect of 
morphine via inhibition of GSK-3β (Gross et al., 2004). In 2009, Jinkun et al, reported that 
morphine prevented opening of the mPTP through a signalling pathway involving 
NO/cGMP/PKG/Zn
2+
/GSK-3β in cardiomyocytes (Jinkun et al., 2009). In addition, an elegant 
experiment using human atrial trabeculae obtained from patients undergoing coronary artery 
bypass surgery revealed that the δ opioid receptor agonist, DADLE, appeared to protect human 




3.3.19 Clinical applications of the opioids  
A very recent study in humans has reported a combined protective effect of morphine and 
remote IPostC when treatment was initiated directly following PCI in patients with acute 
myocardial infarction (Rentoukas et al., 2010). 
 
4.0 Tumour necrosis factor alpha (TNFα)  
The principle of an antihumoral response of the innate immune system in vivo was already 
recognised in 1893 by the physician, William B Coley. His inspiration came from the 
observation that when his cancer patients had an infection, they were more likely to recover from 
the cancer. Injecting his patients with a concoction containing the bacteria, Streptococcus 
pyrogenes, reduced the tumours to a better extent when the patient developed a full-blown 
infection accompanied by a raging fever (Coley, 1893). This work was, however, not well 
documented and when Coley died in 1936, his treatment method died with him, having been 
replaced by radiation therapy. It is only in 1975 that Carswell and colleagues identified an 
endotoxin-induced serum factor that caused necrosis of tumours and they named this endotoxin 
“tumour necrosis factor alpha (TNFα)” (Carswell, 1975). Subsequently, a protein, named 
cachectin, was isolated from endotoxin-treated cells and was so named because it was presumed 
to play a role in the molecular basis of cachexia. Later on, cloning of TNFα and the protein, 
cachectin, confirmed that they were identical (Beutler et al., 1985). This soluble, multifaceted 
cytokine is produced upon activation of the innate immune system, mainly in macrophages but 
subsequent studies have shown that many other cells including cardiomyocytes, also express 
TNFα (Benigni et al., 1996; Frangogiannis et al., 1998). Two isoforms of TNF exist, TNFα and 
TNFβ. TNFα is first expressed as a transmembrane protein and subsequent studies have 
provided evidence that membrane TNFα is converted to a soluble homotrimeric form by 
proteolytic cleavage, a process known as ectodomain shedding, allowing this cytokine to have 
more widespread effects (Beutler et al., 1985).  
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Studies in various culture systems have reported ADAM17 (a disintegrin and metalloproteinase 
17) as a sheddase of TNFα and its receptors (Black et al., 1997; Moss et al., 1997; Peschon et al., 
1998; Reddy et al., 2000). In 2007, Bell et al demonstrated that ADAM17 plays a primary role in 
TNFα, tumour necrosis factor receptor 1 (TNFR1) and tumour necrosis factor receptor 2 
(TNFR2) shedding. However, deficiency of ADAM17 did not abrogate the shedding, suggesting 
that ADAM17 facilitates the shedding but is not a crucial element for shedding to occur (Bell et 
al., 2007). ADAM17 is also known as TACE (TNF alpha converting enzyme). An important 
determinant of shedding activity is thought to be the localisation of ADAM17 to a perinuclear 
compartment which raises the possibility that the intracellular environment may also be 
implicated in ADAM17-mediated ectodomain shedding (Peiretti, 2003). 
 
4.1 TNFα receptors 
Once released from the cell, TNFα docks with one of two TNFα receptors – a 55 kDa high 
affinity receptor, known as TNFR1 and a 75 kDa low affinity receptor, TNFR2 (Beutler, 1994; 
Vassilli, 1992). TNF ligand is believed to achieve all its different cellular and pathophysiological 
Fig 17: Production and release of TNFα: TNFα is first synthesised as a transmembrane 
proTNFα, allowing TNFα to exist in its membrane bound form. TACE then cleaves ProTNFα, 
releasing the soluble form of TNFα. TACE=TNFα converting enzyme; mRNA=messenger 
ribonucleic acid, (adapted from Meldrum, 1998). 
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effects by its binding to either the TNFR1 or TNFR2 receptor subtype. Like the ligand, the two 




TNFR1 contains a death domain (DD) motif which is critical in the death-inducing activity of 
this receptor (Tartaglia et al., 1993). A number of associating proteins and related molecules also 
contain a DD and signalling for cell death appears to be the function of these proteins and 
molecules. The silencer of death domain (SODD) is one such molecule and it binds to the DD in 
TNFR1 preventing the binding of other DD proteins (Jiang et al., 1999). When TNFR1 is 
stimulated by TNFα, the SODD dissociates from the DD and this allows access to the DD for 
Fig 18: Simplified diagram of some of the signalling pathways modulated by TNFR1 and TNFR2 
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other activator proteins. An important element in the activation of neutral sphingomyelinase is 
an adaptor protein called factor associated with neutral sphingomyelinase activation (FAN) 
(Adam et al., 1996; Adamklages, 1998). This adaptor protein is responsible for the generation of 
smaller sphingolipid molecules containing ceramide which play a key role in signalling 
(Kolesnick and Kronke, 1998). Both TNFR1 and TNFR-associated death domain (TRADD) are 
found at the perinuclear-Golgi complex but TRADD only associates with TNFR1 once at the 
plasma membrane (Jones et al., 1999; Ledgerwood et al., 1999). It then recruits tumour necrosis 
factor receptor-associated factor (TRAF2) to TNFR1 (Hsu et al., 1995). TRAF2, in turn, recruits 
nuclear factor kappa B (NFκB) (Vince et al., 2009). However, in addition to promoting NFκB 
signalling, TRAF2 also has anti-apoptotic signalling roles, with the ring domain of TRAF2 being 
required for protection against TNF-induced apoptosis (Vince et al., 2009).  
In addition, TRADD recruits the downstream signalling adaptor molecules, Fas-associated death 
domain (FADD) and RIP (receptor interacting protein). The role of RIP remains uncertain at this 
point. FADD contains a death effector domain (DED) that interacts with caspase 8 and a number 
of other molecules that regulate cell death mechanisms (Muzio et al., 1996) (Figure 18). 
TNFR2 does not have a DD motif but still recruits adaptor proteins including TRAF2. The 
structural and functional characterization of TNFR2 has not, to date, been studied in depth. 
However, the membrane-bound form of TNFα is suggested to be a potent activator of TNFR2, in 
contrast to the soluble form, which has a greater affinity for TNFR1 (Grell et al., 1995). In the 
immune system, TNFα would activate its receptors by cell – cell interactions. How the binding 
characteristics of membrane-bound TNFα at TNFR1 and TNFR2 compare to soluble TNFα still 
remains to be elucidated. Minor changes in the structure of the TNFα sequence can lead to major 
changes in its binding characteristics and therefore determine to which receptor it will bind 
(Lewis et al., 1991). Lewis et al, demonstrated that TNFR1 and TNFR2 are equally activated by 
murine TNFα, whereas human TNFα only stimulates TNFR1 and has no effect on TNFR2 in the 
mouse (Lewis et al., 1991). It has been suggested that most of the in vivo effects of TNFα may 
be mediated by membrane-bound TNFα with both receptors being activated, rather than the 
soluble form  which would activate TNFR1 more robustly than it does TNFR2 (MacEwan, 
2002). If this is so, than the physiological role of TNFR2 may be more important than first 
thought. TRAF2 has a direct affinity for TNFR2. Under certain conditions, FADD and RIP are 
also thought to be able to bind indirectly to TNFR2 via TRAF2. TRAF2 can also interact with 
NFκB which controls the transcription of a gene called cellular inhibitor of apoptosis protein 2 
(c-IAP2). cIAP2 binds to TRAF2 thereby inhibiting the activation of caspases 8 and 10 and 
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subsequent apoptosis (MacEwan, 2002). This could provide a platform for the beneficial effects 
of TNFα (Figure 18). 
 
4.2 TNFα and the heart  
In physiological conditions, the primary role of TNF is the regulation of immune cells. As TNFα 
is involved in cellular differentiation, growth and apoptosis (Sack et al., 2000), it is relevant to 
consider whether this pluripotent cytokine is involved in normal cardiac development. The 
cardiac phenotype of the TNFα–deficient mice has only minor differences in cardiac mass 
compared with wildtype littermate controls (Smith et al., 2001) and cardiac studies in mice 
deficient in either of the TNF receptors showed no discernable congenital cardiac defects 
(Kurrelmeyer et al., 2000). These data, taken together, imply that normal cardiac morphogenesis 
does not require TNFα signalling, or that alternate signalling pathways compensate for lack of 
TNFα.  
TNFα concentration is low in healthy hearts, where it is located mainly in endothelium and 
resident mast cells (Schulz, 2008). The discovery in the 1990s that TNFα is expressed in all 
nucleated cell types of the myocardium, including the cardiomyocyte itself, renewed interest in 
TNFα and its role in cardiac pathophysiological states such as myocardial infarction and heart 
failure (Levine, 1990; Herskowitz, 1995; Dorge, 2002). 
Myocardial TNFα is expressed in direct response to many different forms of cardiac injury, 
including acute myocardial infarction (Mann, 2003; Yokoyama, 1997; Maury and Teppo, 1989). 
Elevated plasma levels of TNFα have also been reported in several studies conducted in heart 
failure patients (see review (Batista et al., 2009)). Transgenic mice, designed to overexpress 
cardiac TNFα have highlighted the maladaptive effects of TNFα in the heart. While wildtype 
counterparts remained healthy, the mice overexpressing TNFα developed myocarditis (Kubota et 
al., 1997).  
Both human and rat cardiomyocytes possess the two TNFα cell surface receptors, TNFR1 and 
TNFR2. (Krown, 1995; Torre-Amione et al., 1995). Recently, the existence of a mitochondrial 
binding protein for TNFα has been proposed, therefore suggesting that TNFα may be delivered 
directly from the cell surface to the mitochondria independently of TNFR1 and TNFR2 
(Busquets, 2003; Ledgerwood, 1998). 
 
4.3 TNFα and ischaemia reperfusion 
Many studies have documented myocardial TNFα production during acute myocardial ischaemia 
with or without reperfusion (Irwin et al., 1999; Meldrum et al., 1998a; Meldrum et al., 1998b). 
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Preformed TNFα is released within minutes from the resident mast cells and macrophages 
during myocardial ischaemia, but with persistent ischaemia, TNFα also originates from the 
cardiomyocytes (Dorge et al., 2002) and is also one of the multi-potent cytokines known to be 
released by ischaemia-reperfusion (Sharma and Das, 1997). TNFα levels have also been 
demonstrated to be increased at the onset of reperfusion in an ischaemia-reperfusion model 
(Cain et al., 1998) and other studies revealed that in adenosine mediated cardioprotection this 
upregulation of TNFα was prevented (Cain et al., 1998; Meldrum et al., 1997). 
Initially, this cytokine was regarded as only having deleterious effects, contributing to 
myocardial dysfunction and cardiomyocyte death in ischaemia-reperfusion injury (Giroir, 1994; 
Latini, 1994; Levine, 1990). In a study conducted in mice, Maekawa et al, demonstrated that 
once reperfusion was instituted, a deficiency in TNFα signalling resulted in smaller infarct sizes 
(Maekawa et al., 2000). Confirmation of this putative detrimental effect of TNFα was 
forthcoming in a study conducted in wildtype mice using an identical ischaemia-reperfusion 
protocol in the presence of anti-TNF antibodies (Belosjorow et al., 2003; Gurevitch et al., 1997; 
Maekawa et al., 2002). 
In contrast to the detrimental effects of TNFα, it was reported that cultured cardiomyocytes are 
protected against hypoxic injury when exogenous TNFα is added (Nakano et al, 1998) while 
larger myocardial infarct sizes were observed in mice deficient in both TNF receptors compared 
to their wildtype littermate counterparts following an acute myocardial infarction (Kurrelmeyer 
et al., 2000). Both these studies implicated TNFα in cardioprotection. A plausible explanation 
for these opposing roles of TNFα may be the existence of an intrinsic cell survival programme in 
response to ischaemia which is abrogated by the inflammatory response at reperfusion. 
The concept, therefore, that selective, rather than total, inhibition of TNFα may be more feasible 
(Abraham et al., 1995)  was further explored in 2002 by Sack, who proposed that a low acute 
concentration of TNFα would be protective whereas a high and sustained concentration would 
be maladaptive (Sack, 2002).  
In humans, TNFR1 has been implicated in the initiation of the negative inotropic effects of 
TNFα in adult cardiomyocytes (Torre-Amione et al., 1995). In addition, Monden et al, 
demonstrated that TNFα was toxic via TNFR1 but was protective via TNFR2 in a murine model 
of myocardial infarction (Monden et al., 2007). Although administration of either a soluble TNF 
receptor or an anti-TNFα antibody abrogates the development of heart failure in experimental 
animals, paradoxically, the use of anti-cytokines in attempts to neutralize TNFα has not proved 
successful in patients with chronic heart failure (Anker and Coats, 2002; Mann, 2002). 
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 mice with cardiac-specific overexpression of TNFα 
and found that the absence of TNFR2 exacerbates heart failure and reduces survival whereas the 
removal of TNFR1 blunted heart failure and improved survival, therefore suggesting that 
TNFR2 signalling played a protective role in the pathogenesis of heart failure (Higuchi et al., 
2004). Additionally, deletion of TNFR1 and TNFR2 in mice subjected to myocardial infarction 
demonstrated that inhibition of TNFR1-mediated pathways attenuated ventricular dysfunction 
and improved survival with a downregulation of other proinflammatory cytokines, whereas 
inhibition of TNFR2 was deleterious, exacerbating ventricular dysfunction accompanied by 
upregulation of TNFα and other proinflammatory cytokines (Monden et al., 2007).  
Thus, it is appropriate to suggest that the role played by TNFα in ischaemia-reperfusion may be 
dependent on which TNF receptor is activated and the concentration of TNFα as well as the time 
it is present in the system (Deuchar et al., 2007; Flaherty et al., 2008; Lecour et al., 2002; 
Monden et al., 2007; Schulz, 2008). The function of TNFα in ischaemia-reperfusion remains 
controversial, with this pleiotropic cytokine‟s ability to act in both maladaptive and adaptive 
roles (Figure 19). 
 
4.4 TNFα and ischaemic preconditioning 
Persuasive evidence exists for a role of TNFα in ischaemic preconditioning. In 2002, Smith et al, 
used mice in which endogenous TNFα production was knocked out to demonstrate that the lack 
of TNFα precluded the protective effect of IPC. However, pharmacological preconditioning with 
adenosine or diazoxide was still able to reduce infarct size (Smith et al., 2002). Subsequent 
studies also demonstrated a lack of protection in mice in which TNFα had been knocked out 
(Ichikawa et al., 2004; Labruto et al., 2005). Pre-administration of TNFα, 24 hours prior to 
TNFα preconditioning, rescued the cardioprotective effect in TNF knockout mice, suggesting 
that the signalling effector system downstream of TNFα may be downregulated in TNFα 
Fig 19: TNFα in myocardial ischaemia-reperfusion: protective versus damaging effects, (Lecour, 2009). 
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deficient mice (Smith et al., 2002). Transient low concentrations of TNFα given as a 
preconditioning mimetic prior to the ischaemic insult protected the heart against ischaemia-
reperfusion in the isolated rat heart model (Lecour et al., 2005a; Lecour et al., 2002).  In rats, 
mice or rabbits, classic ischaemic preconditioning was associated with increased levels of pre-
ischaemic TNFα (Belosjorow et al., 1999; Smith et al., 2002) but a decreased level of 
endogenous TNFα was released during the ischaemia-reperfusion injury phase (Belosjorow et 
al., 1999; Kimura et al., 2006). Interestingly, preconditioning-induced cardioprotection with 
exogenous TNFα can only be achieved with a washout period prior to the sustained ischaemia, 
therefore suggesting that the time of TNFα production is another factor to be considered (Lecour 
et al., 2002). 
 
4.5  TNFα and ischaemic postconditioning 
Anaesthetized rats subjected to coronary artery ligation demonstrated that IPostC reduced levels 
of plasma TNFα during the reperfusion phase in a manner similar to that of IPC (Kin, 2008). 
However, it is presently unknown whether TNFα is involved in the protective effect of 
ischaemic postconditioning and the main focus of this thesis was to delineate the role of TNFα 
as a postconditioning mimetic. 
 
4.6 Proposed mechanisms in TNFα-induced cardioprotection 
In a manner similar to IPC, TNFα-induced preconditioning activated the sphingolipid pathway, 
PKC and the mKATP channel (Lecour et al., 2002). The inhibitors of these various pathways have 
been demonstrated to abolish the protection afforded with TNFα when given during the 
preconditioning stimulus (Lecour et al., 2002). In addition, the free radical scavenger, 
mercaptopropionyl glycine (MPG) also blocked the infarct-sparing effect of TNFα, implicating 
ROS in the prosurvival signalling cascade (Lacerda et al., 2006; Lecour et al., 2005a). One of the 
triggers for IPC is myocardial p38 MAPK which can be activated by TNFα. However, Tanno et 
al, demonstrated that TNFα-induced protection in the murine heart is independent to p38 MAPK 
activation (Tanno et al., 2003). Critical targets for downstream protection are activation of the 
mPTP (Gao et al., 2005), the Ca
2+
 activated potassium channel (Gao et al., 2005) and the 
phosphorylation of NFκB (Somers et al., 2005). 
 
4.7 TNFα-induced cardioprotection is independent of the RISK pathway  
Phosphorylation and activation of PI3-kinase and Erk1/2 at the time of reperfusion in both 
ischaemic pre-and postconditioning has been shown to protect against reperfusion injury as part 
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of the RISK pathway (see review (Hausenloy et al., 2005)). However, strong evidence is 
emerging in the literature in support of the hypothesis that protection against reperfusion injury 
does not always require activation of the RISK pathway. The protective effect of TNFα in 
isolated rat hearts could not be abolished by the Erk1/2 inhibitor, PD98059, given during the 
preconditioning stimulus (Lecour, 2005b;). Similarly, administration of wortmannin, an inhibitor 
of PI3-kinase/Akt during the preconditioning stimulus did not abrogate the protective effect of 
TNFα in a study conducted in isolated cardiomyocytes and the isolated rat heart (Suleman, 
2008).  
 
4.8 TNFα initiates the SAFE pathway via JAK/STAT-3 signalling 
Cardiac-specific STAT-3 knockout mice could not be protected by the preconditioning 
mimetics, adenosine, diazoxide and TNFα administered before the index ischaemia (Smith, 
2004). A study by Lecour et al, provided evidence that both TNFα and early IPC phosphorylated 
STAT-3 in the early phase of reperfusion in the isolated rat heart model and that AG490 
administered at the time of reperfusion, abrogated both IPC and TNFα-induced protection, thus 
linking TNFα and STAT-3 in a prosurvival signalling pathway (Lecour et al., 2005b). In 
addition, AG490, the JAK/STAT antagonist, administered to isolated hearts from STAT-3
-/-
 
mice before the preconditioning stimulus, was shown to prevent phosphorylation of Akt 
(Suleman, 2008). 
The activation of STAT-3 was demonstrated to co-incide with the activation of the RISK 
pathway during ischaemic preconditioning (Lecour et al., 2005b) but interestingly, TNFα- 
induced protection failed to activate the RISK pathway. This, therefore, implied that the 
JAK/STAT pathway may be activated independently of the RISK pathway.  
The role of TNFα and its cognate receptors has not been extensively studied in the 
postconditioning setting although there is now a growing body of evidence implicating the 
signalling of the innate immune response to the events underlying myocardial adaptation to 
ischaemia (Valeur and Valen, 2009). However, it should be emphasized that there is very little 
known regarding TNFα and its effects during the first few critical minutes of reperfusion. Many 
studies have examined the effect of TNFα when given just before the ischaemic insult 
(preconditioning), but to date, no studies could be found in the literature which investigated the 
protective role of exogenous TNFα at reperfusion or the possible protective role of the 
TNFα/JAK/STAT signalling cascade in postconditioning. Only one study, to date, has reported 
that serum and myocardium levels of TNFα were demonstrated to be decreased at reperfusion in 




Fig 20: Activation of the RISK and SAFE pathways following ischaemia-reperfusion. Ischaemic 
preconditioning increases TNFα levels resulting in TNFα binding to its cell surface receptors activating 
the JAK/STAT pathway as part of the SAFE pathway. Similarly, activation of PI3-kinase and MEK 
activate Akt and Erk1/2 respectively, as part of the RISK pathway. Both pathways enhance 
cardioprotection against ischaemia-reperfusion. Abbreviations as defined in text, (adapted from Lecour, 2009). 
ROS production (Kin, 2008), thus implicating a low concentration of TNFα in the protective 
effect of postconditioning. A schematic depicting the activation of the RISK and SAFE 
pathways following ischaemia-reperfusion is shown in figure 20. 
 
 
4.9 TNFα, obesity and diabetes 
TNFα is a multifaceted cytokine that exerts potent pro-inflammatory effects in metabolic and 
inflammatory disorders such as obesity and insulin resistance. An important fact is that obesity 
does not occur in isolation from other metabolic disorders. Chronic activation of the innate 
immune system is a feature of obesity which is associated with a low grade inflammation of 
white adipose tissue (WAT). Subsequently, this can lead to insulin resistance, impaired glucose 
tolerance and even diabetes (Bastard et al., 2006). The first detectable defect in type 2 diabetes is 
insulin resistance when insulin levels are greatly increased while glucose levels remain normal 
(Hotamisligil et al., 1995).  
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TNFα down-regulates insulin-stimulated glucose uptake by its effect on glucose transporter 4, 
insulin receptor autophosphorylation and insulin receptor substrate-1. TNFα is a powerful 
autocrine and paracrine regulator of adipose tissue. It can inhibit insulin action and insulin 
receptor signalling and this is thought to be mainly mediated by TNFR1 (Kanety et al., 1996; Liu 
et al., 1998a; Peraldi and Spiegelman, 1997). Investigators have also examined whether the TNF 
receptors play a role in the development of glucose homeostasis. These studies concluded that 
the receptors did not play a role in the induction of insulin resistance associated with obesity, but 
that the presence of both receptors may be required for normal glucose homeostasis (Schreyer et 
al., 1998). However, TNFα appears to have no significant effect on the development of dietary 
obesity, as the development of marked obesity was noted in mice which lack endogenous TNFα 
(TNF
-/-
) and were fed a high fat, high caloric diet (Uysal et al., 1997). These mice remained 
highly insulin sensitive compared to their wild type counterparts. Furthermore, the insulin 
concentrations in obese TNF
-/-
 mice were significantly lower than those of the obese TNF-WT 
and they remained at the same level as that of lean mice on a normal diet (Uysal et al., 1997). 
These results demonstrated that insulin resistance associated with dietary obesity is reduced in 
the absence of TNFα. Interestingly, genetic depletion of TNFα from macrophages in wild type 
mice does not protect these mice from developing obesity-related insulin resistance (De Taeye et 
al., 2007). 
TNFα has also been linked to the development of type 1 diabetes (Yang et al., 1994). Treatment 
with non-toxic doses of TNFα in neonatal non-obese diabetic mice for 21 – 24 days resulted in 
the onset of type 1 diabetes being accelerated, whereas inhibition of TNFα for the same time 
period resulted in a complete absence of diabetes (Yang et al., 1994). 
Interestingly, the cardioprotective effect of ischaemic preconditioning has been shown to be 
abolished in human diabetic patients (Ishihara et al., 2001). Experimental animal models have 
also indicated that diabetes abolishes the ability of IPC and pharmacological agents to reduce 
infarct size, but the mechanisms involved in this failure are unclear (Kersten et al., 2001; Kersten 
et al., 2000; Nawata et al., 2002; Paulson, 1997; Tosaki et al., 1996). 
Cachexia, the wasting disorder of muscle and fat tissues, has previously been associated with 
TNFα expression, (Beutler and Cerami, 1989; Oliff et al., 1987; Torti et al., 1985) which is in 
contradiction to the possible link between TNFα and obesity. One explanation is the circulating 
levels of TNFα. These exceed 200 ng/ml in cases of cachexia whereas, in models of obesity-
diabetes the circulating levels are very low, in the range of 10-200 pg/ml when detectable 
(Hotamisligil, 1993). Another explanation is that obesity is often associated with other hormonal 
abnormalities which may alter the body‟s response to TNFα. It has even been suggested that the 
54 
 
site of expression could determine the metabolic response to TNFα (Tracey, 1992). More 
investigative studies will be needed to elucidate how one molecule can have such diverse effects 
on a vast array of different pathophysiological states.  
Obesity, diabetes and metabolic syndrome all alter the production of adipokines, such as leptin 
and TNFα. Hotamisligil and colleagues demonstrated that in human obesity, the expression of 
TNFα in adipose tissue was significantly elevated and that this increase in TNFα was strongly 
correlated with the level of hyperinsulinaemia (Hotamisligil et al., 1995).  
 
4.10 TNFα and leptin 
Leptin is an adipocyte secreted hormone involved in energy regulation and endocrine and 
immune function. It plays a role in innate and acquired immunity. 
Both the structure of leptin and of its receptor suggests that leptin can be classified as a cytokine 
Known as the “appetite suppressing hormone”, there is a strong correlation between serum leptin 
and TNFα levels (Margalet, 2003). Additionally, there is a strong association between 
circulating leptin levels and body mass index (BMI) as well as fat mass in obesity with TNFα 
upregulating leptin production and leptin also modulating the production of TNFα (Bastard et 
al., 2006). As a function of its cytokine-like structure, therefore, leptin could exert peripheral 
biological effects (Almanza-Perez et al., 2008). 
It has been demonstrated that leptin expression is increased with administration of TNFα in 
rodents (Grunfeld, 1996; Sarraf, 1997). In a study conducted in humans, a positive and 
independent correlation between circulating levels of soluble TNFR1 and leptin was 
demonstrated, therefore suggesting an association between TNFα and leptin in humans similar to 
that seen in rodents where TNFα increases leptin expression and circulating leptin levels 
(Mantzoros, 1997). This possible effect of an activated TNFα system on blood leptin levels in 
humans could have a considerable impact on human physiology. 
It has been previously reported that leptin protects the isolated mouse myocardium against 
ischaemia-reperfusion injury via direct action on the heart (Smith, 2006) and it is known that the 
JAK/STAT pathway mediates many of the metabolic actions of leptin (Frubeck, 2006). Recent 
evidence from isolated rat hearts demonstrated a reduction in infarct size when leptin was given 
at reperfusion. This cardioprotective effect was abrogated by co-administration of the 
JAK/STAT inhibitor, AG490, therefore implicating the JAK/STAT pathway in leptin-induced 
























Ischaemic postconditioning, whereby alternating cycles of reperfusion and ischaemia are applied 
at the onset of reperfusion, is a powerful tool to reduce infarct size and preserve cardiac function. 
Delineating the exact mechanism involved in this phenomenon may lead to the development of 
novel therapies against the burden of ischaemic heart disease. A number of different signal 
transduction pathways have been reported to underlie the cardioprotective effect of IPostC. One 
of first signalling cascades to be linked to IPostC was the Reperfusion Injury Salvage Kinase 
(RISK) pathway which implicated the prosurvival kinases, phosphotidylinositol 3-kinase (PI3-
kinase)-Akt and p44/p42 extracellular signal-regulated kinases (Erk1/2) in the cardioprotective 
effect of IPostC. The activation of these prosurvival kinases at the immediate onset of 
reperfusion by a diverse variety of agents such as adenosine, bradykinin and the opioids has been 
shown to reduce myocardial infarct size in the region of 40-50%. However, the mechanism by 
which these survival pathways confer cardioprotection is poorly understood. 
TNFα is a cytokine implicated in inflammation, growth and apoptosis but previous work in our 
laboratory has demonstrated that TNFα can also protect against ischaemia-reperfusion in a dose 
and time dependent manner. 
Therefore, the aim of the present study was to explore the role of TNFα in ischaemic and 
pharmacological postconditioning-induced cardioprotection.  
 
1.1 Hypothesis and Objectives 
We hypothesized that activation of TNFα is required in both IPostC and pharmacological 
postconditioning to confer cardioprotection and that this protective effect is mediated via the 
activation of TNFR2 and the transcription factor STAT-3 (Signal Transducer and Activator of 
Transcription). Furthermore, we investigated ischaemic postconditioning in obese and diabetic 
animals, two major risk factors for ischaemic heart disease that are associated with elevated 










Fig 21: Schematic representation of hypothesis and objectives in ischaemic and 
pharmacological postconditioning. Ischaemic postconditioning activates TNFα which then binds 
to its TNFR2 with subsequent activation of the JAKs. This results in the dimerization of STAT-3 
and its translocation to the nucleus, with the mPTP of the mitochondria being a putative end 




















Objective 3: investigate the 
influence of obesity and 
diabetes in IPostC  
Objectives 1&2: explore the role 
of TNFα, TNFR2 and STAT-3 in 
















To fulfil this aim, the following objectives will be pursued: 
1) To investigate the role of TNFα and its receptors in IPostC-induced cardioprotection.  
To achieve this objective we will use TNF deficient (TNF
-/-





), cardiac-specific STAT-3 deficient (STAT-3
-/-
) mice and their 
respective wild types. Isolated hearts will be postconditioned following an ischaemia-
reperfusion insult. Should TNFα prove to be necessary in IPostC-induced cardioprotection, 
we would then use inhibitors of various pathways and the western blot technique to 
explore possible downstream targets of TNFα such as GSK-3β, RAGE, PAR-2, Akt, Erk 
and STAT-3.  
2) To investigate the role of TNFα in pharmacological postconditioning.  
To achieve this objective we will use TNF deficient (TNF
-/-
), TNFR1 deficient  
(TNFR1
-/-
), TNFR2 deficient (TNFR2
-/-
) and cardiac-specific STAT-3 deficient mice 
(STAT-3
-/-
) and their respective wild types. Isolated hearts will be subjected to an 
ischaemia-reperfusion insult and the well-known cardioprotective agents, adenosine, 
bradykinin and opioids will be used as pharmacological postconditioning mimetics. 
Should TNFα prove to be necessary in pharmacologically-induced cardioprotection, the 
western blot technique will be used to explore possible downstream targets such as STAT-
3. 
3) To investigate the effect of obesity and diabetes in IPostC–induced cardioprotection. 
For the obesity study, the mice will be fed a high carbohydrate diet from weaning for a 
total of 11 weeks. Thereafter, the isolated hearts of TNF-WT or TNF
-/-
 mice will be 
subjected to IPostC and infarct size will be used as the endpoint. To explore the role of 
diabetes in IPostC, streptozotocin will be administered to the mice to initiate onset of 
diabetes. At day 5 and at day 10 post streptozotocin, the isolated hearts will be subjected to 
IPostC and infarct size used as the endpoint. Various parameters such as body weight, 
heart to body weight ratio, blood glucose, plasma leptin and plasma insulin will be 

























1.0 Genetically modified animals 
The best animal models to achieve our objectives were whole body TNF-deficient mice which 
produce no endogenous TNFα and TNF receptor1 and 2-deficient mice. A third mouse model, 
cardiac-specific STAT-3 deficient mice were used to determine whether the JAK/STAT pathway 
was involved in the protective signalling.  
In this thesis all animal studies performed were approved by the Animal Research Ethics 
Committee of the University of Cape Town, and followed the recommendations laid down in the 
Guide for the Care and Use of Laboratory Animals published by the US National Institute of 
Health (NIH Publication No. 85 {23}, revised 1996). 
1.1  Mouse Models to investigate the role of TNFα in ischaemic postconditioning 
Homozygous TNF-deficient (TNF
-/-
) mice, TNF receptor 1-deficient mice (TNFR1
-/-
)  and TNF 
receptor 2-deficient mice (TNFR2
-/-
)  and their respective wildtype, Black 6 x 129S (TNF-WT) 
were a generous gift from Dr Muazzam Jacobs and Professor Bernhard Ryffel, Department of 
Immunology, University of Cape Town.  
Cardiomyocyte-specific STAT-3-deficient (STAT-3
-/-
) mice from C57 Black 6 background were 
created in our facilities by crossing homozygous floxed STAT-3 mice with heterozygous 
MLC2V-driven Cre recombinase mice, as previously described (Smith et al., 2004). All mice 
were 12-14 weeks of age. 
1.1.2  Genotyping of Mouse Models 








 mice, tail cuts were 
performed at weaning (3 weeks of age) and genomic DNA extracted from the respective tails. 
Genotyping was performed by means of the polymerase chain reaction (PCR). 
i) DNA Extraction 
Approximately 1 cm of a candidate mouse tail was removed from the mouse and digested by 
incubating at 55˚C overnight in 400 µl tail digestion buffer (0.5M Tris  {pH 8}, 0.1M EDTA, 
1% SDS) with 1 mg/ml proteinase K (Roche, Mannheim) added to the buffer immediately prior 
to use. The following day, 400 µl of Phenol:Chloroform:Alcohol (25:24:1)(Sigma, USA) 
mixture was added to each digested tail and the samples were gently inverted to mix. Cellular 
debris was removed by centrifugation at 13,500 rpm (Heraeus MK202, Germany) for 10 minutes 
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at room temperature. The bottom layer containing cellular debris was carefully removed with 
sterile barrier tips taking care not to disturb the interface containing contaminating proteins. 200 
µl of chloroform (Sigma, USA) was added to the remaining upper layer containing the required 
DNA to remove traces of phenol and the tube was again gently inverted to mix. The digests were 
centrifuged again at 13,500 rpm for 5 minutes. Two separate phases again occurred and the 
bottom phase was removed and discarded while the upper phase is once more centrifuged at 
13,000 rpm for 10 minutes, forcing the remaining debris into a pellet at the bottom of the tube. 
The liquid phase was then transferred to a new sterile 1.5 ml eppendorff tube and 50 µl of 7.5 M 
ammonium acetate (Merck) and 1 ml 100% ethanol added to each tube. The tubes were gently 
inverted to mix and the DNA, which appears as a white, stringy precipitate, was transferred to a 
clean eppendorff tube containing 500 µl of 70% ethanol to hydrate the DNA. The samples were 
then centrifuged at 13,000 rpm for 10 minutes and the ethanol carefully decanted to prevent loss 
of the DNA pellet. DNA pellets were air dried until ethanol had completely evaporated, then 50 
– 75 µl of ultra pure RNAse free water was added to dissolve the DNA. Thereafter samples were 
stored at -20˚C until PCR analysis. 
ii)  Polymerase Chain Reaction (PCR)  
Targeted deletion of the TNFα gene has been previously described (Marino et al., 1997). 
Genotyping was carried out, at random intervals of breeding, to confirm the genetic background 







involved testing as to whether the respective mouse‟s TNFα, TNFR1 or TNFR2 gene was intact 
or had been disrupted by the insertion of a phosphoglycerate kinase-neomycin expression 
cassette within the gene. Genotyping of the STAT-3 mice had to be performed at each stage of 
the breeding process as breeding of STAT-3
-/- 
mice gave rise to both the wild type and the 
STAT-3 deficient mice. Therefore, these mice had to be tested to see whether or not they were 
harbouring the Cre recombinase insertion as well as whether or not they were floxed. 






 mouse models 
a)  TNF
-/-
:    Sense primer:        5’-CTA AAT GAA CTG CAG GAC GA-3’ 
          Antisense primer:  5’-ATA CTT TCT CGG CAG GAG CA-3 
     
Neomycin:  Sense primer:        5’ CTG AAT GAA CTG CAG GAC GA 3’ 
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                    Antisense primer:  5’ ATA CTT TCT CGG CAG GAG CA 3’                    
The polymerase chain reactions were performed in 50 µl volumes made up as follows: 
10xMagnesium free buffer:                           10 µl 
 4mM MgCl2:                                                   8 µl 
100µM dNTP‟s:                                            1.6 µl 
Primer (TNF or Neo):                                   0.5 µl 
β actin 3‟:                                                      0.5 µl 
β actin 5‟:                                                0.5 µl                                                
H2O:             26.9 µl 
Taq:                                                              0.5 µl 
DNA sample:                                               1.5 µl 


















































1 2 3 4 8 7 6 5 10 9 
Fig 23: UV gel analysis of extracted mouse genomic DNA for the targeted disruption of the 
TNFα gene 
Lane 1 = water control 
Lanes 3 and 5 = TNF
-/-
 
Lanes 2, 4, 6-10 = TNF-WT 
m = marker 
m 
94° C 











35  cycles 

















35  cycles 





: TNFR1 - 4938:  5’ AGA AAT CTC AG ACA ATT CTC TGC 
            TNFR1 – 2883: 5’ CTC TCT TGT GAT CAG CAC TG 
            TNFR1 – Neo:  5’ TCC CGC TTC AGT GAC AAC GTC 
The polymerase chain reactions were performed in 50 µl volumes made up as follows: 
10xMagnesium free buffer:                             5 µl 
25 mM MgCl2:                                                 3 µl 
10 mM dNTP‟s:                                               1 µl 
Primers: TNFR1 2883                                      1 µl 
              TNFR1 4938                                      1 µl 
              TNFR1 Neo 34                                  1 µl 
H2O:        35.875 µl 
Taq:                                                          0.125 µl 
DNA sample:                                                  2 µl 
                                                                      50 µl 

















35  cycles 





: IMR0338:  5’-CCT CTC ATG CTG TCC CGG AAT 
                       IMR0339: 5’-AGC TCC AGG CAC AAG GGC GGG 
            IMR0340: 5’ CGG TTC TTT TTG TCG AGA C 
            IMR0341: 5’ ATC CTC GCC GTC GGG CAT GC 
The polymerase chain reactions were performed in 50 µl volumes made up as follows: 
10xMagnesium free buffer:                              5 µl 
25 mM MgCl2:                                                  3 µl 
10 mM dNTP‟s:                                                1 µl 
Primers: IMR338                                                1 µl 
              IMR339                                                1 µl 
              IMR340                                                1 µl 
              IMR341                                                1 µl 
H2O:          35.875 µl 
Taq:                                                            0.125 µl 
DNA sample:                                                    2 µl 








iv) Sequences and PCR for STAT-3
-/-
 mouse model 
To determine whether the mice were Cre positive the following sequences were used: 
Cre Sense primer:                  5’ GTT CGC AAG AAC CTG ATG GAC A 3’ 
Cre Antisense primer:           5’ CTA GAG CCT GTT TTG CAC GTT C 3’ 
The mice were also genotyped for the MLC 2V gene as a positive control for the presence of 
DNA. For this, the following sequences were used:  
MLC 2V Sense primer:        5’ GGC AAC CCT CAG ACA CCA T 3’ 
MLC 2V Antisense primer: 5’ TGT GGA GGC TCT GGA TCA GGA C 3’ 
The polymerase chain reactions were performed in 50 µl volumes made up as follows: 
10xMagnesium free buffer:                           10 µl 
4mM MgCl2:                                                   8 µl 
100µM dNTP‟s:                                           1.6 µl 
Primer:                                                          0.5 µl 
β actin 3‟:                                                      0.5 µl 
200bp 
500bp 
m 1 2 3 4 5 6 7 8 9 10 11 12 13 
Fig 26: UV gel analysis of extracted mouse genomic DNA for the targeted disruption of the 
TNFR gene 
m = marker 
lanes 1-3, 5,6,10, 11, 13 =TNFR2
-/-
 
lanes 4,7-9 = TNFR1
-/-
 















35  cycles 
Fig 27: PCR conditions for STAT-3
-/-
 mice. 
β actin 5‟:   0.5 µl                                                
H2O:            26.9 µl 
Taq:                                                              0.5 µl 
DNA sample:                                               1.5 µl 
                                                                      50 µl 
PCR Conditions: 
 
To establish whether STAT-3 was floxed, one set of primers, yielding PCR fragments of 
differing lengths, were used. A 250 bp fragment is seen on the gel if the STAT-3 is floxed 
whereas a 200 bp fragment is visualized on the gel if the STAT-3 is not floxed. If the mouse 
being tested is heterozygous, then a double band is seen.  STAT-3 floxed or non-floxed DNA 
was amplified with the following primers: 
STAT-3 primer (a) 5’CCT GAA CAA GTT CAT CTG TGT GAC 3’ 
STAT-3 primer (b) 5’ CAC ACA AGC CAT ACT CTG GTC TCC 3’ 
The polymerase chain reactions were performed in 50 µl volumes made up as follows: 
10xMagnesium free buffer:                              5 µl 
4mM MgCl2:                                                     4 µl 
100µM dNTP‟s:                                              0,8 µl 
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7 min  
∞ 
Primer:                                                           0.25 µl 
β actin 3‟:                                                       0.25 µl 
β actin 5‟:    0.25 µl                                                
H2O:               13.2 µl 
Taq:                                                               0.25 µl 
DNA sample:                                                  1.0 µl 
                                                                         25 µl 
PCR Conditions: 
1.1.3 Agarose Gel Electrophoresis 
Fig 29: UV gel analysis of genomic mouse DNA showing Cre positive band (350bp) as well as 






1 2 3 4 5 6 7 8 9 
lanes 1,3,5 = STAT-3
-/-
 
lanes 2,4,6-8 = STAT-3 WT 
lane 9 = water control 
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A 2% agarose gel was used to ensure optimal separation between bands. Two grams of agarose 
(Whitehead Scientific, RSA) was made up in 100 ml of 1 x Tris Acetate electrophoresis buffer 
(TAE) (0.04 M Tris-Acetate, 0.001 M EDTA) and heated in a microwave oven at 70% power 
until completely dissolved. Once dissolved, 1 µl ethidium bromide was added per 100 ml gel in 
order to visualize the amplified DNA fragment under ultra violet light. 1 x TAE buffer was 
added to the gel tank once the gel had set and before removal of the combs in order to prevent 
the wells being damaged. Subsequently, 10 µl of each PCR reaction was mixed with 2 µl gel 
loading buffer (0.25% Bromophenol Blue-Xylene Cyanole Dye Solution, Sigma) and carefully 
loaded into the wells. Simultaneously, 4 μl of a 100 bp DNA ladder (Roche, Germany) was run 
as a marker to verify the size of the PCR products. The gel was run at 90 V for 30 – 40 minutes 
and the bands were then visualized on a transilluminator (UviTec, USA). PCR results were 
recorded using the UviTec Geldoc apparatus with UVIband software v.97 (Cambridge, UK). 









 mice and their 
respective WTs were anaesthetized (pentabarbitone, 60 mg/kg ip) and heparinized (25 IU ip) to 
prevent the blood clotting. Once an adequate level of anaesthesia had been achieved (tested by 
lack of pedal reflex) the chest was opened and the sternum and attached costal cartilage excised 
to give adequate access to the mediastinum. Hearts were rapidly excised (Smith et al., 2002) and 
arrested in ice cold modified Krebs-Henseleit buffer (118 mM NaCl; 24 mM NaHCO3; 4 mM 
KCl; 1 mM NaH2PO4; 2.5 mM CaCl2; 1.2 mM MgCl2; 0.5 mM di-sodium EDTA; 10 mM 
glucose; gassed with 95% O2/5% CO2 at 37˚C).  The aorta was cannulated and the heart then 
mounted on the Langendorff system. The heart was fastened by means of a 4-0 silk suture (on a 
13mm curved atraumatic needle) through the apex onto a rigid lightweight lexan coupling rod to 
a force displacement transducer (Grass Technologies, FT02C, Mass. USA). Diastolic resting 
tension was adjusted to 2 g and hearts were paced at 560 beats per minute while being 
retrogradely perfused with modified Krebs-Henseleit buffer at a constant pressure of 110 cm 
H2O (Smith et al., 2002) (see Figure 30). The developed force was recorded on a Powerlab 
Labchart (ADI Instruments, Australia) and coronary flow rate was measured by timed collection. 
These parameters were utilized as measures of cardiac function for all groups of hearts used in 
the protocols. Temperature was measured by placement of a fine thermocouple wire (Physitemp, 
NJ, USA) into the right atrium and monitored on a Digitron 2600T temperature sensor (Torquay, 
UK), (figure 30). Isolated hearts were subjected to a 25 minute stabilization period followed by 
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35 minutes global ischaemia (obtained by shutting off the flow of buffer to the heart from the 
aortic cannula by means of a stopcock) and a 45 minute reperfusion period (Smith et al., 2002). 
Coronary flow, heart rate and developed force are used to determine the viability of an isolated 
heart. A minimum flow of 1.5 ml/min and maximum flow of 5.0 ml/min are acceptable for 
coronary flow, the acceptable heart rate is between 460bpm-600bpm and the developed force is 




2.1 Ischaemic and TNFα postconditioning protocol 
The Langendorff retrograde perfusion technique was used to assess infarct size and to collect 









 and their respective wildtypes. The isolated hearts were subjected to IPostC at the onset of 
reperfusion by initiating six alternating cycles of 10 seconds reperfusion, 10 seconds ischaemia. 
In a separate group, pharmacological postconditioning with TNFα was initiated by six 
alternating cycles of 10 seconds reperfusion without TNFα, 10 seconds reperfusion with 0.5 
ng/ml TNFα (TNF-PostC), figure 31. To assess whether the mounting of hearts itself had an 
effect, a time-matched control group was subjected to the full length of the protocol on the 
Langendorff apparatus with no ischaemic period or IPostC.  
Temperature probe Pacer electrodes 
Force transducer arm 
Isolated mouse heart 
Fig 30:  Mouse heart mounted on Langendorff apparatus. A cannula is inserted into aorta for 
retrograde perfusion. The pacer electrodes are used to pace the heart to 560 bpm and the heart pulls 









2.2 Infarct size assessment 
At the end of each experimental protocol, hearts were removed from the perfusion rig and infarct 
size assessed by triphenyltetrazolium chloride (TTC) staining as described previously (Sumeray 
et al., 2000). Briefly, the heart was placed in TTC stain (1% in phosphate buffer, pH7.4) for 1 
minute at 37˚C after which it was frozen for 24 hours to allow for easy slicing. 1mm slices, 
perpendicular to the apex, were then cut. Each slice includes both right and left ventricle plus 
septum. These slices were then compressed between thin glass plates 0.5mm apart and the 
sections scanned, and infarct size assessed using computerized planimetry (Planimetry+, Boreal 




Figure 31:  Protocol of pharmacological postconditioning with TNFα. Reperfusion is allowed for 
10 sec, after which the stopcock is opened for 10 sec to allow the flow of 5 ng/ml TNFα to mix with 
the reperfusion flow, giving a final concentration of 0.5 ng/ml entering the heart. The stopcock is then 
closed and reperfusion with Krebs-Henseleit buffer alone takes place for 10 sec, after which the cycle 




3.0   Nuclear and cytosolic protein extraction (adapted from Williams and Ford, 2001) 
Nuclear and cytosolic proteins were extracted from the hearts by homogenization of the tissue in 
lysis buffer as follows: 
Solution A (30ml)   µl   Final Concentration 
1M Hepes, pH7.9            600               20 mM 
2M MgCl2           37.5              2.5 mM 
500mM EDTA   6             100  µM 
100mM β-glycerophosphate       6000               20 mM 
Triton X-100 (100%)            15              0.5% 
100mM DTT         1500             500 µM 
100mM NaVO4            30             100 µM 
EDTA-free protease inhibitor       1200                  - 
Fig 32: TTC staining for infarct size evaluation. TTC reacts with the NADPH in live tissue to give a 
brick red colour. There is no reaction in the infarct tissue, which remains pale and allows infarct size 
determination by planimetric analysis. 
Postconditioned heart No postconditioning 
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100mM PMSF          300                1 mM 
5M NaCl           450              75 mM 
dH2O        19862        - 
 
Solution B (10ml)   µl   Final Concentration 
1M Hepes           200            20 mM 
2M MgCl2          12.5           2.5 mM 
500mM EDTA           2            100 µM 
100mM β-glycerophosphate       2000            20 mM 
Triton X-100 (100%)          100                1% 
100mM DTT         1500           500 µM 
100mM NaVO4            10           100 µM 
EDTA-free protease inhibitor         400                - 
100mM PMSF          100              1 mM 
5M NaCl           150            75 mM 
dH2O          6526      - 
 
Frozen hearts were wrapped in aluminium foil, pulverized under liquid nitrogen then transferred 
into 900 µl of lysis buffer (Solution A). After homogenizing twice by Polytron, at setting 4, for 5 
sec each time, the suspension was centrifuged at 10000 g (12000 rpm) for 5 min at 4˚C. The 
supernatant, corresponding to the cytosolic fraction, was carefully removed and placed in a fresh 
tube. The remaining pellet was resuspended in 300 – 500 µl of Solution B, transferred into a 
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clean Eppendorf tube and centrifuged for a further 30 min at 10000 g (12000 rpm) at 4˚C. The 
supernatant, corresponding to the nuclear fraction was removed into a clean tube.  
3.1 Mitochondrial and cytosolic protein extraction (adapted from Tal M Lewin, 2008.) 
Mitochondrial and cytosolic proteins were extracted from the hearts by homogenization of the 
tissue in lysis buffer as follows: 
Lysis buffer A                                                              Incubation Buffer 
100 mM Tris-HCl – pH 7.4                                         250 mM Sucrose 
250 mM Sucrose                                                           25 mM Tris  
1 mM DTT                                                                   8.5 mM KH2PO4 
1 mM EDTA 
Low ionic strength sample buffer (2X) 
400 μl 10% SDS 
400 μl glycerol 
40 μl mercaptoethanol 
1.16 ml 5 mM Tris (pH 6.8) 
Bromophenol blue 
Frozen hearts were minced finely with a pair of scissors in 1ml of lysis buffer. After 
homogenisation in a Dounce homogeniser, the suspension was centrifuged at 600 g for 5 min at 
4°C. The supernatant was placed in a fresh tube and further centrifuged at 10 300 g (11,500 rpm) 
for 10 min. The resulting supernatant corresponds to the cytosolic fraction. The pellet was 
resuspended in 40 µl mitochondrial incubation buffer. After protein determination, an equal 





3.2 Lowry Protein determination 
Duplicate 5 µl aliquots of nuclear, cytosolic or mitochondrial sample were added to 995 µl of 
sterile distilled water (1:200 dilution) followed by addition of 1ml of the following CTC reagent. 
i) CTC reagent: Soln A – Na2CO3 – 20g/100ml dd H2O 
                               Soln B -   CuSO4.5H2O - 0.2 g     
                                                K2 tartrate     -  0.4 g   100 ml dd H20 
                                    
Add Soln A to Soln B with constant stirring to prevent precipitation. 
ii) SDS 
10% SDS made by diluting a 20% solution 
iii) NaOH 
0.4 g/200ml dd H2O 
Equal volumes of all 3 reagents were mixed immediately prior to use. 
The samples were immediately mixed with the CTC reagent and incubated for 10 minutes at 
room temperature. 500 µl of Folin‟s Reagent, diluted 1:5 with double distilled water (Merck, 
Germany) was then added with continuous mixing, as the colour complex to be assayed forms 
immediately. The samples were incubated at room temperature for a further 30 minutes and 
optical density was read at 750 nm on a Varian 130 dual beam spectrophotometer (Peterson, 
1977). 
A standard curve was prepared using bovine serum albumin (Sigma, Germany) diluted to 
provide a concentration range from 10 – 200 μg/ml and the range was assayed in the same 
manner as the samples. 
3.3  Polyacrylamide Gel Electrophoresis (PAGE) 
100 µg of nuclear, mitochondrial or cytosolic protein was loaded per lane and run on a 10% 
(w/v) acrylamide/bisacrylamide gel at 120V for approximately 90 - 120 minutes. 7 µl of 
peqGold  Protein Marker IV (PEQLAB Ltd, UK) was run simultaneously to identify the size of 
the candidate peptides. The gel was transferred overnight (0.02 amps at 4˚C) onto an Amersham 
PVDF membrane (Hybond, Amersham, UK). Thereafter, the membrane was fixed in methanol 
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for 5 minutes, air-dried and stained with Ponceau reagent (Sigma P7170, St Louis, MO) to 
quantitate and evaluate appropriate transfer of proteins from gel to membrane. The membrane 
was placed between two acetate sheets and scanned for densiometric analysis, using the 
UVIBand software package. 
Subsequently, the Ponceau stain was rinsed off with three 5 minute washes in Tris buffered 
saline with 0.1% Tween (TBS-T). The membrane was then blocked at room temperature in 5% 
fat-free milk powder made up in TBS-T. After 2 hours the membrane was vigorously hand 
washed in TBS-T with 3 cycles of 5 minutes. The membrane was then probed overnight at 4˚C 
with one of the primary antibodies followed by 2 hours incubation with the appropriate 
secondary antibody. 
3.4 Western blot analysis 
Control or postconditioned mouse hearts were subjected to a 20 min stabilization period 
followed by 35 min of global ischemia and 15 min of reperfusion. The hearts were then snap-
frozen in liquid nitrogen before being stored at -80ºC until protein extraction was performed. 
Nuclear and cytosolic proteins were extracted from the hearts by homogenization of the tissue in 
a lysis buffer, as previously described (Lecour et al., 2005b; Sack et al., 1997). Phosphorylated 
states of Akt, Erk1/2, STAT-3 (Phospho-STAT-3, tyr705), glycogen synthase kinase-3 beta 
(phospho-GSK-3 , ser 9) as well as total levels of Akt, Erk1/2, STAT-3, GSK-3 , RAGE, PAR-
2 and glyceraldehyde-3 phosphate dehydrogenase (GAPDH) were analysed by sodium dodecyl 
sulphate-polyacrylamide gel immunoelectrophoresis (SDS-PAGE) using antibodies from Cell 
Signaling Technologies. Equal loading was verified with GAPDH. Levels of phosphorylated 
proteins were normalized, where appropriate, to their total protein levels done in the same 
samples and in the same conditions but on a separate membrane. Normalization is merely the 
ratio of phosphorylated protein to total protein, multiplied by 100. Relative densitometry was 
determined with the use of computerized software package (UVI Soft, UVI Band, UVI Tech, 
Cambridge, UK). A minimum of 6 hearts was used per group. 
3.4.1 Primary and Secondary Antibodies 
i: Total STAT 
Primary antibody: STAT-3 Antibody rabbit polyclonal IgG 1:4000 in 5% (w/v) fat-free milk 
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Secondary antibody (2 hours at room temperature): Anti-rabbit 1:3000 in 5% (weight/volume 
{w/v}) fat free milk 
ii: Phosphorylated STAT 
Primary antibody: PhosphoPlus 
R
 STAT-3 (Tyr705) rabbit polyclonal IgG 1:1000 in TBS-T 
Secondary antibody (2 hours at room temperature): Anti-rabbit 1:3000 in 5% (w/v) fat free milk 
iii): Akt 
Primary antibody: Akt Antibody rabbit polyclonal IgG 1:1000 in TBS-T 
Secondary antibody: Anti-rabbit (2 hours at room temperature):  1:4000 in 2.5% (w/v) fat free 
milk 
iv: Phosphorylated Akt  
Primary antibody: Phospho-Akt (Ser473) Mouse mAB - 1:1000 in TBS-T. 
Secondary antibody (2 hours at room temperature): Anti-mouse 1:4000 in 2.5% (w/v) fat free 
milk 
v: Glycogen Synthase Kinase-3 Beta (GSK-3β) 
Primary antibody: GSK-3β Rabbit mAb 1:1000 in TBS-T 
Secondary antibody (2 hours at room temperature): Anti-rabbit 1:4000 in TBS-T 
vi: Phosphorylated Glycogen Synthase Kinase-3 Beta (pGSK-3β) 
Primary antibody: Phospho- GSK-3β (Ser9) 1:3000 in TBS-T 
Secondary antibody (2 hours at room temperature): Anti-rabbit 1:3000 in TBS-T 
vii: p44/42 MAPK (Erk1/2)  
Primary antibody: p44/42 (Erk1/2) 1:1000 in TBS-T 
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Secondary antibody (2 hours at room temperature): Anti-rabbit 1:4000 in 2.5% (w/v) fat free 
milk 
viii: Phospho-p44/42 MAPK (Erk1/2)  
Primary antibody: Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) 1:1000 in TBS-T 
Secondary antibody (2 hours at room temperature): Anti-rabbit 1:4000 in 2.5% (w/v) fat free 
milk 
ix: Receptor for Advanced Glycation End Products (RAGE) 
Primary antibody: Anti-mouse RAGE Antibody 1:1000 in TBS-T 
Secondary antibody (2 hours at room temperature): Anti-goat 1:4000 in 2.5% (w/v) fat free milk 
x: Protease-Activated Receptor -2 (PAR-2) 
Primary antibody: PAR-2 (SAM11): sc-13504 1:1000 in TBS-T 
Secondary antibody (2 hours at room temperature): Anti-mouse 1:4000 in 2.5% (w/v) fat free 
milk 
xi: Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
Primary antibody: GAPDH (FL-335) 1:1000 in TBS-T 
Secondary antibody (2 hours at room temperature):  Goat Anti-rabbit 1:3000 in TBS-T 
For mitochondrial and cytosolic fractions, the following antibodies were used: 
i: Total STAT 
Primary antibody: STAT-3 Antibody rabbit polyclonal IgG 1:4000 in 5% (w/v) fat-free milk 
Secondary antibody (2 hours at room temperature): Anti-rabbit 1:3000 in 5% (weight/volume 
{w/v}) fat free milk 
ii:  Phosphorylated STAT 
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Primary antibody: phospho STAT-3 (Ser 727) rabbit polyclonal IgG 1:1000 in TBS-T 
Secondary antibody (2 hours at room temperature): Anti-rabbit 1:4000 in 2.5% (w/v) fat free 
milk 
iii: VDAC 
Primary antibody: VDAC goat polyclonal IgG 1:3000 in TBS-T (1 hour at room temperature). 
Secondary antibody: Anti-goat 1:4000 in 2.5% (w/v) fat free milk (30 minutes at room 
temperature). 
All antibodies were from Cell Signaling Technology, USA with the exception of RAGE (RD 
Systems,USA), PAR-2 and GAPDH (both from Santa Cruz Biotechnology, USA). Relative 
densitometry was determined with the use of computerized software package (UVI Soft, UVI 




























Part of the work in this section has been published in Cardiovasc Res, (2009) 84, 201-208 
“Ischaemic postconditioning protects against reperfusion injury via the SAFE pathway” 
Part of the experiments in this section have been performed in conjunction with Sarin Somers, registered as a PhD 





Following acute coronary occlusion, early reperfusion is the current optimal way to rescue the 
heart. Although essential, reperfusion is associated with cellular damage by activation of 
deleterious signalling cascades, as early as in the first seconds of reperfusion (Braunwald and 
Kloner, 1985).  Attempts in the management of reperfusion injury have recently entered the 
clinical arena (Piot et al., 2008; Staat et al., 2005; Yellon and Hausenloy, 2007). IPostC is still 
often thought to protect only via activation of the RISK pathway (Reperfusion Injury Salvage 
Kinases) which includes activation of the prosurvival kinases Akt and Erk1/2 at the time of 
reperfusion (Hausenloy et al., 2005; Kin, 2008; Tsang et al., 2004). However, recent studies 
demonstrated that protection with ischaemic postconditioning can occur independently of the 
activation of the RISK pathway, therefore confirming the existence of multiple protective 
pathways (Heusch et al., 2008; Montecucco et al., 2009 Schwartz, 2006; Przyklenk et al., 2008; 
Skyschally et al., 2009).  
The activation of the SAFE pathway, which includes the cytokine TNFα, activates the 
transcription factor STAT-3 and is now recognized as a “RISK-free” pathway that can confer 
protection in ischaemic preconditioning (Lecour, 2009a; Lecour, 2009b; Lecour et al., 2002; 
Lecour et al., 2005b; Suleman et al., 2008). However, the role of TNFα in the SAFE pathway 
during ischaemic postconditioning has not yet been elucidated. 
It is known that TNF  is activated during the course of reperfusion, contributing to cardiac 
dysfunction and apoptosis (Belosjorow et al., 1999; Maekawa et al., 2002; Mann, 2002). 
Although ischaemic preconditioning is associated with an increase in TNFα during the 
preconditioning stimulus, its protective effect is partly attributed to a reduction in myocardial 
TNFα levels at the time of reperfusion (Kin, 2008). However, TNF  can have adaptive effects in 
relation to its concentration (with low concentrations being cardioprotective and high 
concentrations being harmful (Kurrelmeyer et al., 2000; Lecour et al 2005a; Lecour et al., 
2005b; Lecour et al., 2002) and to which of its two receptors it binds (binding to TNF receptor 1 
is suggested to have an adverse effect while binding to its receptor 2 is suggested to be 
cardioprotective) (Monden et al., 2007; Schulz, 2008; Schulz and Heusch, 2009).  
Therefore, our aim was to explore whether TNF -signalling, through the activation of its 
receptor 2 (TNFR2), was involved in the protective effect of IPostC and whether this signalling 
mechanism activated the SAFE pathway rather than the RISK pathway, to confer protection. We 
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also wished to explore whether GSK-3β, RAGE and PAR-2 were part of the signalling cascade 
in ischaemic postconditioning. We used an isolated heart model from wild type mice (TNF-WT) 
and 3 different transgenic mice from the same background, TNF knockout (TNF
-/-
), TNF 
receptor 1 knockout (TNFR1
-/-
) and TNF receptor 2 knockout (TNFR2
-/-
) to demonstrate that 
binding of TNF  to its receptor 2 during ischemic postconditioning is indeed required for the 
protection. Pharmacological protein kinase inhibitors and mice which are deficient in the 
transcription factor, STAT-3 in their cardiomyocytes were used to demonstrate that, in the 
context of ischemic postconditioning, TNFα confers its cardioprotective effect via the activation 
of the transcription factor STAT-3 rather than the protein kinases Akt and Erk1/2. 
Furthermore, using western blot analysis, we explored whether phosphorylation of GSK-3β, 
RAGE or PAR-2 may act as downstream targets of the SAFE (TNF/JAK/STAT) pathway. A 





















RAGE PAR - 2 GSK-3β 
CARDIOPROTECTION 
? ? ? 
? ? 
Fig 33: Schematic of proposed hypothesis. Does TNFα initiate cardioprotection during ischaemic 
postconditioning via the SAFE pathway? Which receptor is involved? Are RAGE, GSK-3β and 
PAR-2 involved in TNFα-induced protection? Abbreviations as described in text. 
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2.0        Methods 
All experiments were performed in accordance with the Guide for the Care and Use of 
Laboratory Animals published by the US National Institutes of Health {NIH Publication No. 85 
(23), revised1996}. All procedures were approved by the Faculty of Health Sciences Animal 
Ethics Committee, University of Cape Town. 
Homozygous TNF deficient mice (TNF
-/-
), TNF receptor 1 deficient mice (TNFR1
-/-
) or TNF 
receptor 2 deficient mice (TNFR2
-/-
) and their respective wildtype, Black6x129S (TNF-WT) 
were used. All these mice were a generous gift from Dr Muazzam Jacobs and Prof Bernhard 
Ryffel, Department of Immunology, Faculty of Health Sciences, University of Cape Town. 
Cardiomyocyte-specific STAT-3 deficient mice (STAT-3
-/-
) from C57Black6 background were 
created in our facilities by crossing homozygous floxed STAT-3 mice with heterozygous 
MLC2V-driven Cre recombinase mice, as previously described (Smith et al., 2004). All mice 
were 12-14 weeks of age (weighing 25-30g). 
2.1  Perfusion of isolated mouse hearts 








 mice and 
their respective wild types were excised rapidly and perfused retrogradely using the Langendorff 
apparatus. Isolated hearts were subjected to a 20 minute (min) stabilization period followed by 
35 min global ischemia and a 45 min reperfusion period as previously described  (Smith et al., 
2002)] (see Section C for protocol). At the onset of reperfusion, IPostC was initiated with 6 
alternating cycles of 10 seconds reperfusion, 10 seconds ischaemia. In a separate group, 
pharmacological postconditioning with TNFα was initiated with 6 alternating cycles of 10 
seconds reperfusion without TNF , 10 seconds reperfusion with 0.5 ng/ml TNFα (TNF-PostC), 
(see Figure 31 in Section C). A time-matched control was used to assess infarct size to determine 
whether the technique itself had damaged the heart. Infarct size by TTC staining demonstrated 
that the technique had no adverse effect. 
To determine whether STAT-3, Akt or Erk1/2 were involved, AG490, an inhibitor of the 
JAK/STAT pathway (100 nmol/L), wortmannin (wort), an inhibitor of the phosphotidylinositol-
3 kinase (PI-3 Kinase)/Akt pathway (100 nmol/L) or PD98059 (PD), an inhibitor of the 
Mek/Erk1/2 pathway (100 nmol/L) were given during the first 15 min of reperfusion. To 
confirm the role of the TNF receptors, specific antibodies to TNFR1 or TNFR2 (3 mg/L) were 
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given to TNF-WT mice during the ischemic postconditioning protocol, (Figure 34). The 
concentration of the antibodies corresponded to the ND50 of the antibodies, as given by the 
manufacturer.  A minimum of 6 hearts were used in all groups. Infarct size was evaluated by 
triphenyltetrazolium chloride (TTC) staining and assessed using computerized planimetry as 




2.2 Ischaemic postconditioning 24 hours after administration of TNFα to TNF
-/-
 mice 
In a separate set of experiments, 24 hours prior to performing the ischaemic postconditioning 
protocol, each TNF
-/-
 mouse was given a single ip injection of 0.5 ng TNFα. Thereafter, the 
isolated hearts underwent the identical ischaemic postconditioning protocol as described in the 
previous section. 
2.3 TNFα release from heart tissue 
Two minutes after the onset of postconditioning the hearts were removed from the cannula by 
cutting off the atria. They were then placed into an eppendorff tube and immediately immersed 
in liquid N2, to snap freeze. Once frozen, the tubes were stored at -80°C until analysis. The 
Fig 34: Schematic of experimental protocol. Hearts were removed for Western blot analysis at the 
timepoint indicated, in a separate experiment. TNF receptors antibodies were added throughout the 
reperfusion protocol. Inhibitors of PI-3 kinase, JAK/STAT and Erk1/2 were added during the 
postconditioning protocol as indicated. PD= PD98059; wort = wortmannin; AB = antibody; All other 




frozen hearts were wrapped in aluminium foil and pulverized under liquid nitrogen. The 
pulverized tissue was placed in 1.5 ml ice-cold phosphate buffered saline (PBS) and the 
suspension was then ultrasonically homogenised (Virtis, Virsonic; USA) at 50W for 10-20 
seconds. Homogenates were centrifuged at 14000 rpm for 20 min at 4°C and the supernatant was 
collected for TNFα measurement by Elisa (kit) as per manufacturer‟s instructions. 
2.4 Chemicals and Pharmacological Agents 
Unless otherwise stated, all chemicals were obtained from Sigma-Aldrich Chemicals, Germany. 
Murine TNFα was obtained from PeproTech Inc., Israel; TNF Receptor monoclonal antibodies 
were obtained from R&D Systems, U.S.A.  
2.5 Statistical Analysis 
Data are presented as mean ± SEM. Comparisons between multiple groups were performed by 
One-way ANOVA followed by Tukey post hoc test or Bonferroni multiple comparison test. The 
unpaired t test was used for TNFα release from heart tissue (Graph Pad Instat).  p<0.05 was 














3.1 Postconditioning with TNFα 
  
 TNFα is required in IPostC 
To determine whether TNF  is required in IPostC mediated cardioprotection, we compared 
infarct size (calculated as a percentage of total ventricular volume) in TNF-WT versus TNF
-/-
 
mice following the IPostC protocol of 6 x 10 sec cycles of alternating reperfusion and ischaemia, 
(see Figure 34). IPostC in TNF-WT mice reduced infarct size from 52 ± 3% in the ischaemic 
control group (I/R) to 18 ± 2% for IPostC (p<0.05; Figure 35).  IPostC with 6 x 10 sec cycles in 
the TNF
-/-
 hearts failed to reduce the infarct size (37 ± 3%, p=ns versus TNF
-/-
 I/R group. Similar 
data was obtained with TNF-PostC, (Figure 35). 





Fig 35: TNF   is required in, and can also mimic, IPostC.  6 x 10 sec cycles of IPostC reduced the 
infarct size in TNF-WT but not TNF-/- mice, n ≥ 6 per group, *p<0.05 vs respective I/R. Similarly, the 
infarct size in WT was reduced by 6 x 10 sec cycles of TNF-PostC but this failed to reduce the infarct 
























 TNFR1-/- but not TNFR2-/- mice can be postconditioned  










 mice had an infarct size of 42 ± 3 % and 42 ± 2%, 
respectively, which was similar to data obtained in TNF-WT mice.  IPostC protocol significantly 
reduced the infarct size in TNFR1
-/-
 mice (15 ± 1%, n=6; p<0.05 versus TNFR1
-/-
 ischaemia-
reperfusion control) but failed to protect the heart in TNFR2
-/-
 mice (38 ± 3%, p=ns, versus 
TNFR2
-/-
 I/R control group). Similarly, TNF-PostC decreased the infarct size to 22 ± 2% in 
TNFR1
-/-
 hearts, (p<0.05 vs its TNFR1
-/-
 I/R control group) but failed to protect the TNFR2
-/-
 
hearts (p=ns, versus TNFR2
-/-
 I/R control group), (Figure 36A). 
We confirmed these results by using specific neutralizing antibodies to each receptor during the 
ischaemic postconditioning protocol in TNF-WT mice. Ischaemic-reperfusion control hearts had 
an infarct size of 49 ± 2%. Perfusion of the TNFR1 antibody during the IPostC protocol did not 
affect the protective effect of postconditioning (19 ± 2%, p<0.05 versus ischaemic-reperfusion 
control group). In contrast, the protective effect of IPostC was lost in the presence of TNFR2 
antibody (53 ± 1%, p=ns, versus ischaemic-reperfusion control group), (Figure 36B). 

















 but not TNFR2
-/-
 mice can be postconditioned. (A) 6 x 10 sec cycles of IPostC 
reduced infarct size in TNFR1
-/-
 mice but not in TNFR2
-/-
 mice, n = 6 per group. (B) Addition of TNFR2 
antibody (Ab) but not TNFR1 Ab, abolished the infarct sparing effect of IPostC in TNF-WT hearts, 
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A single ip injection of TNFα (0.5 ng/ml) 24 hours prior to I/R did not alter the infarct size in 
TNF
-/-
 hearts compared to TNF-WT controls. However, the protective effect of IPostC was 
restored, significantly decreasing infarct size in TNF
-/-
 hearts from 45 ± 2% to 16 ± 2%, 
p<0.001, (Figure 37). 
 
 









Fig 37: Restoration of protective effect in TNF
-/-
 hearts. 24 hours after administration of a single ip 
injection of 0.5 ng TNFα, protection is restored in the isolated TNF
-/-



























Fig 38:  AG 490 abrogates TNF-PostC protection in TNF-WT mice.  Inhibiting the activation of 
STAT-3 (by AG 490) during early reperfusion abrogates the protective effect of TNF-PostC in wild 
type mice. However, administration of wortmannin (a PI-3K inhibitor) or PD98059 (an inhibitor of 
Erk1/2) during early reperfusion did not abolish the postconditioning effect of TNF ; n = 6 per group 
*p<0.05 vs I/R alone; ≠p<0.05 vs IPostC alone and $p<0.001 vs TNF-PostC alone. Abbreviations as 

















 Inhibition of STAT-3 but not Akt or Erk abrogates the protective effect of 
pharmacological postconditioning with TNF  
To further investigate the mechanism responsible for the cardioprotective effect of TNF , we 
measured infarct size in hearts perfused with an inhibitor of the JAK/STAT pathway (AG490), 
an inhibitor of the PI-3 kinase/Akt pathway (wortmannin) or an inhibitor of Mek/Erk1/2 (PD 
98059),  given during the first 15 min of reperfusion in IPostC or TNF-PostC hearts. The 
inhibitors did not affect the infarct size in the ischaemic control group. Addition of wortmannin 
(wort) or PD98059 did not alter the protective effect of TNF-PostC (19 ± 2% and 20 ± 1% 
respectively, p<0.05, versus 49 ± 2% in the ischaemia-reperfusion control group). Similarly, 
PD98059 did not affect the protective effect of IPostC (29±2%, p<0.05 versus I/R+PD;) but 
wortmannin completely abrogated the effect of IPostC (43±1%, p=ns versus 44±0.5% for I/R+ 
wort).  Inhibition of the JAK/STAT pathway with AG490 during the IPostC or TNF-PostC 
protocols, abolished the infarct sparing effect of both postconditioning protocols (47±2% for 
IPostC; p=ns versus 47±3% for I/R and 51 ± 2% for TPostC, p=ns, versus 47±3% for ischaemia-





































 TNF   failed to mimic ischemic postconditioning in STAT-3-/- mice 
The infarct size in STAT-3-WT mice compared to the ischaemic control group was significantly 
decreased by pharmacological postconditioning with 6 x alternating cycles of 10 sec reperfusion 
without TNF  and 10 sec reperfusion with 0.5 ng/L TNF  initiated at the onset of reperfusion 
(20 ± 1% for TNF-PostC versus 52 ± 2% in I/R, p<0.05; Figure 39). In contrast, the STAT-3
-/-
 
mice could not be postconditioned with TNF  (44 ± 3% in I/R versus 47 ± 1% in TNF-PostC, p 
= ns), (Figure 39). 
         










Fig 39: TNF  can mimic IPostC in STAT-3-WT but not STAT-3
-/-
 mice. 6 x 10 sec cycles of IPostC 
reduced the infarct size in STAT-3-WT but not STAT-3
-/-
 mice, n ≥ 6 per group. Similarly, the infarct 
size in STAT-3-WT was reduced by 6 x 10 sec cycles of TNF-PostC but this failed to reduce the infarct 
size in STAT-3
-/-




 TNFα release from heart tissue after IPostC 
I/R reduced TNFα levels from 33.2 ± 4.4 pg/100mg tissue to 21.7 ± 1.9 pg/100mg tissue, p<0.05 




3.2       Western blot results 
 Levels of STAT-3, Akt, Erk1/2 and GSK-3β in wild type and TNF-/- mice in nuclear 
and cytosolic fractions 
 
a) Nuclear fraction  
We examined the levels of STAT-3, Akt, Erk1/2 and GSK-3  during the first 15 min of 
reperfusion with no ischaemic episode (time-matched control) and after either IPostC or TNF-
PostC. An increase in phosphorylated STAT-3 (in arbitrary units [AU] from 18 ± 2 for I/R to 54 
± 6, p<0.05), GSK-3  (from 5 ± 0.4 for I/R to 15 ± 1, p<0.05) and Erk1/2 (from 9 ± 1 for I/R to 
26 ± 2) occurred in the nuclear fraction after TNF-PostC in TNF-WT hearts. In contrast, Akt 











































Fig 40: TNFα release by IPostC. The TNFα released from untreated hearts was 33.2 ± 4.4 pg/100mg 
tissue. IPostC restored TNFα release to 36.7 ± 3.2 pg/100 mg tissue whereas I/R significantly 




WT hearts subjected to IPostC, an increase in phosphorylation of STAT-3 (from 18 ± 2 for I/R 
to 46 ± 5, p<0.05) and GSK-3  (from 5 ± 0.4 for I/R to 32 ± 2, p<0.05) was observed but the 
Akt level was unchanged. In TNF
-/-
 mice subjected to IPostC, a modest increase in 
phosphorylated STAT-3 occurred compared to the I/R group, but no increase in GSK-3β was 
observed in the nuclear fraction after the postconditioning stimulus compared with the I/R group. 
Of note, phosphorylation of both Akt and Erk1/2 was significantly increased in the nuclear 
fraction by IPostC compared with I/R in TNF
-/-
 mice, (Figures 41a & 41b). 
                   







Fig 41a: Phosphorylation of STAT-3, Akt, Erk1/2 and GSK-3β in nuclear fraction. Bar graphs of data 
derived from western blots of the nuclear fraction demonstrating phosphorylation of STAT-3, Akt and Erk1/2 
after 15 minutes of reperfusion in isolated TNF-WT and TNF
-/-
 hearts; *p<0.05 versus I/R; ≠p<0.05 vs 
TPostC. Specific bands were quantified by densitometry and expressed in AU. Equal loading was confirmed 
with GAPDH Abbreviations as described in the text. 
 
 




































































































































































































































































                                       
TPostC 
Fig 41b: Representative western blots of STAT-3, Akt, Erk1/2 and GSK-3β in nuclear fraction. 
Representative western blots of the nuclear fraction demonstrating phosphorylation of STAT-3, Akt 
GSK-3β and Erk1/2 after 15 minutes of reperfusion in isolated TNF-WT and TNF
-/- 
hearts; p<0.05 
versus I/R. Specific bands were quantified by densitometry  and expressed in AU. Equal loading was 
confirmed with GAPDH Abbreviations as described in the text. 
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b) Cytosolic fraction 
In the cytosolic fraction, I/R increased phosphorylation of STAT-3 and decreased 
phosphorylation of Erk1/2 and Akt in wild type animals. IPostC reduced phosphorylated STAT-
3 but increased the phosphorylation of both Akt and Erk1/2 in the cytosol compared to the I/R 
group. Pharmacological postconditioning with TNF  increased phosphorylation of Erk1/2 while 
phosphorylation levels of STAT-3 remained unchanged in the cytosol. 
In the TNF
-/-
 mice, we were surprised to observe an increase of phosphorylation in both STAT-3 
and Akt in the cytosol associated with a decrease in phosphorylated Erk1/2 following an IPostC 
stimulus, (Figure 42a & 42b). 
























Fig 42a: Phosphorylation of STAT-3, Akt, Erk1/2 and GSK-3β in cytosolic fraction. Bar 
graphs of data derived from western blots of the cytosolic fraction demonstrating 
phosphorylation of STAT-3, Akt and Erk1/2 after 15 minutes of reperfusion in isolated TNF-
WT and TNF
-/-
 hearts; *p<0.05 versus I/R; ≠p<0.05 vs TPostC; n=6. Specific bands were 
quantified by densitometry and expressed in AU. Equal loading was confirmed with GAPDH. 
Abbreviations as described in the text. 
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Fig 42b: Representative western blots of STAT-3, Akt, Erk1/2 and GSK-3β in cytosolic fraction. 
Representative western blots of the cytosolic fraction demonstrating phosphorylation of STAT-3, Akt 
and Erk1/2 after 15 minutes of reperfusion in isolated TNF-WT and TNF
-/- 
hearts; p<0.05 versus I/R. 
Specific bands were quantified by densitometry and and expressed in AU. Equal loading was confirmed 
with GAPDH Abbreviations as described in the text. 
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 RAGE in TNF-WT and TNF-/- mice 
a) Nuclear fraction 
We examined the expression of total RAGE in nuclear fractions extracted from TNF-WT and 
TNF
-/-
 hearts, during the first 15 min of reperfusion after either IPostC or TNF-PostC. In TNF-
WT hearts, IPostC decreased the expression of RAGE significantly in the nuclear fraction from 
142.8 ± 9.6 AU in control hearts to 41.0 ± 4.5 AU in IPostC; p<0.05. TPostC, however, restored 
the level of RAGE to a similar level seen in the controls, (p=ns). TNF
-/- 
hearts showed no 





Fig 43: Expression of Total RAGE in nuclear fraction. Bar graphs of data derived from western blots 
and representative western blots demonstrating total RAGE expression after 15 minutes of reperfusion in 
isolated TNF-WT and TNF-/- hearts; *p<0.05 versus respective CTL; n =6. Specific bands were 
quantified by densiometry and expressed in AU. Equal loading was confirmed with GAPDH. 

















































































































b) Cytosolic fraction 
In the cytosolic fraction of TNF-WT hearts, RAGE expression after IPostC and TNF-PostC was 
significantly decreased versus the control group, from 530 ± 10 AU to 267 ± 100 AU, p<0.05 
and 116 ± 20 AU, p<0.01, respectively. No significant differences were observed amongst the 
groups in TNF
-/-
 mice, p=ns. However, the I/R group of TNF
-/-
 hearts expressed significantly less 
RAGE compared with the I/R group of TNF-WT, (p<0.01), (Figure 44).  
 
Fig 44: Expression of Total RAGE in cytosolic fraction. Bar graphs and representative western 
blots demonstrating total RAGE expression after 15 minutes of reperfusion in isolated TNF-WT and 
TNF-/- hearts; *p<0.05 versus TNF-WT I/R, **p<0.01 versus TNF-WT I/R. Specific bands were 
quantified by densitometry and expressed in AU. Abbreviations as described in text 
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 Expression of Total PAR-2 in TNF-WT and TNF-/- mice 
We examined the expression of PAR-2 in total protein extracted from TNF-WT and TNF
-/-
 
hearts, during the first 15 min of reperfusion after either IPostC or TNF-PostC. In TNF-WT 
hearts, both I/R and IPostC decreased the expression of PAR-2 significantly to 76 ± 7 AU and 70 
± 12AU respectively, when compared to control hearts (172 ± 21 AU) which underwent no 
interference, (p<0.05). TPostC, however, restored the level of PAR-2 to a similar level as that of 
the controls, (p=ns). TNF
-/-
 control hearts had a significant decrease in PAR-2 expression (63 ± 5 
AU) compared to hearts from TNF-WT control group (172 ± 21AU), (p<0.01). TNF
-/-
 I/R group 
significantly increased the PAR-2 expression to 160 ± 8 AU versus their control group, (p<0.05), 
figures 45 & figure 46. 
                     
 
 
Fig 45: Expression of Total PAR-2. Bar graphs of data derived from western blots demonstrating 
total PAR-2 expression after 15 minutes of reperfusion in isolated TNF-WT and TNF
-/-
 hearts; 
*p<0.05 versus respective CTL. CTL hearts from TNF
-/- 
had significantly decreased PAR-2 
expression versus CTL hearts from TNF-WT, ≠≠p<0.01. Specific bands were quantified by 
densitometry and all groups were corrected to GAPDH densities and expressed in AU. Abbreviations 

























































































































Fig 46: Representative western blots of Total PAR-2 expression. Representative western blots, 
demonstrating Total PAR-2 expression after 15 minutes of reperfusion in isolated TNF-WT and TNF-/- 
hearts; p<0.05 versus CTL. Specific bands were quantified by densitometry and all groups were 





Using the different animal models, our data show, for the first time and possibly counter 
intuitively, that endogenous or exogenous TNF , at the time of reperfusion, initiates a novel and 
RISK-free protective pathway in ischaemic postconditioning. In brief, six episodes of IPostC, 
performed by alternating cycles of reperfusion and ischaemia in TNF deficient mice, failed to 
protect against ischaemia-reperfusion damage. The activation of TNFR2 is implicated in the 
postconditioning protective effect as TNFR1
-/-
, but not TNFR2
-/-
 mice, could be postconditioned. 
The protection of IPostC was reduced in the presence of wortmannin, PD98059 and AG490, 
while postconditioning with TNF  could only be abrogated by AG490. Furthermore, the STAT-
3
-/-
 hearts could not be postconditioned. Our data demonstrate that protection with ischaemic 
postconditioning can be achieved via the activation of TNF , its binding to TNFR2 and 
subsequent activation of STAT-3, key components of the prosurvival SAFE pathway.  
4.1 Cardioprotective role of TNF  
Previously, we have consistently demonstrated, in both in vitro and in vivo experiments, that 
exogenous TNF  could confer a cardioprotective effect against reperfusion injury in a time and 
concentration dependent manner (see review (Lecour, 2009b)). Our group has shown that tissue 
levels of TNF  in the in vivo rat heart were significantly increased in the area at risk and that 
various doses of exogenous TNF  administered prior to the ischaemic protocol could be used as 
a preconditioning stimulus (Deuchar et al., 2007). Furthermore, a recent in vivo rat study 
demonstrated that the protection with IPostC is concomitant with decreased plasma levels of 
TNF  at reperfusion (Kin, 2008). Our present data demonstrate that TNF , given immediately 
at the onset of reperfusion, confers protection in the isolated heart. This is in apparent 
contradiction to previous reports from isolated rat hearts, suggesting that the release of TNF , as 
part of the inflammatory response during the reperfusion phase, contributes to the development 
of myocardial infarction, contractile dysfunction and apoptosis (Belosjorow et al., 1999; Kupatt 
et al., 1999). However, the recent demonstration of a biphasic kinetic pattern of TNFα release in 
a murine reperfusion model suggests that protection is conferred by the limited release of TNFα 
during the first few minutes of reperfusion (2-10min) (Reil et al., 2007). This limited amount of 
TNFα is then washed out and replaced with a more robust release of TNFα in the later stages of 
reperfusion. This subsequent increase in TNFα levels is thought to be responsible for its 
detrimental effects (Reil et al., 2007). In our present study we show, for the first time, in an 
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isolated murine heart model, that during either IPostC or TNF-PostC, the binding of TNFα to 
TNFR2 at the early stage of reperfusion is crucial for protection. Therefore, a possible 
explanation of our potentially controversial findings is that the synergetic limited early 
release/addition of TNFα, together with its binding to TNFR2, at the onset of reperfusion, may 
limit further harmful production of TNFα during the later stages of reperfusion. 
Using TNF
-/-
 mice in our experiments, we were surprised to observe that TNF  postconditioning 
in these mice failed to protect the heart. In a previous study, our research group demonstrated 
that the administration of TNF  to TNF knockout mice, 24 hours prior to experimentation 
rescued the protective effect of ischaemic preconditioning in these mice (Smith et al., 2002). 
These data suggest that in TNF knockout mice, the signalling pathways downstream of TNF  
may be downregulated. Similar data were obtained in our postconditioning setting in the TNF
-/-
 
mice. In these mice the protective effect of TNF-PostC could be restored following 
administration of 0.5 ng TNF , ip 24 hours prior to the experiments. Further functional studies 
are necessary to evaluate the TNF receptor densities and receptor-ligand interaction to fully 
explain this ability to rescue the protective effect in TNF
-/- 
hearts. 
4.2 TNF   initiates the activation of a prosurvival pathway independent of the RISK 
pathway 
An established protective pathway, known as the RISK pathway and involving the activation of 
protein kinases Akt and Erk1/2 in early reperfusion, has been described in both pre- and 
postconditioning (Hausenloy et al., 2005; Tsang et al., 2004).  
A recent study done in pig hearts reported an activation of the kinases involved in the RISK 
pathway following an ischemic postconditioning stimulus (Skyschally et al., 2009). However, 
the inhibition of these kinases did not alter the protective effect, therefore questioning the 
essential role of the RISK kinases in their model (Skyschally et al., 2009).  Similarly, our present 
study, performed on a mouse model, demonstrates that pharmacological postconditioning with 
TNF  is independent of the RISK pathway, as neither PD98059 nor wortmannin abolished the 
protective effect of TNF-PostC. In contrast, the protective effect of both IPostC and 
pharmacological postconditioning with TNF  was abolished in the presence of AG490, the 
JAK/STAT pathway inhibitor. In addition, neither ischaemic nor pharmacological 
postconditioning with TNF  could protect in STAT-3 deficient mice.  
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Our new data show the existence of an alternative protective pathway during the reperfusion 
period of IPostC. This pathway, previously described in ischaemic preconditioning, and 
involving the activation of both TNF  and STAT-3, is now recognized as the SAFE pathway 
(Lecour, 2009a; Lecour, 2009b). Our present data strongly support the hypothesis that the recent 
studies describing a RISK-independent protective effect of ischaemic postconditioning may in 
fact activate the SAFE pathway (Przyklenk et al., 2008; Schwartz and Lagranha, 2006; 
Skyschally et al., 2009).  
Current and past studies, done in our laboratory, suggest that inhibiting either the SAFE or RISK 
pathway is enough to abolish the infarct sparing effect of ischaemic pre or postconditioning 
(Fuglesteg et al., 2008; Lecour et al., 2002; Suleman et al., 2008). Attempts to delineate a 
possible crosstalk between the two pathways reveal a complex interaction. Hence, in the 
presence of wortmannin during the ischaemic preconditioning stimulus, phosphorylation of 
STAT-3 was inhibited (Suleman et al., 2008). Similarly, Akt failed to be phosphorylated in 
STAT-3 knockout mice subjected to ischaemic preconditioning (Suleman et al., 2008). In 
contrast, a substantial increase of phosphorylated Akt is observed in TNF
-/-
 mice subjected to 
ischaemic postconditioning (data from this study). Further studies are needed to characterize the 
crosstalk between the SAFE and RISK pathways in both ischaemic pre and postconditioning. 
4.3 Possible downstream targets of SAFE pathway  
Inactivation of GSK-3β is a well established downstream target of the protective pathway (Gross 
et al., 2006; Hausenloy and Yellon, 2007a; Juhaszova et al., 2004; Juhaszova et al., 2009). Our 
present work aimed to delineate whether GSK-3β could be a common target for the SAFE and 
RISK pathways. In our model, both ischaemic postconditioning and pharmacological 
postconditioning with TNF  increased the phosphorylation of GSK-3  in WT mice. In contrast, 
we were surprised to observe that the absence of an infarct sparing effect in TNF
-/-
 mice was 
associated with a similar level of Phospho/Total GSK-3β as that of wild type mice subjected to 
the TNF-PostC protocol. Although the data from this study support the proposal suggesting that 
inactivation of GSK-3β is not an essential link in the cardioprotective effect of ischaemic 
postconditioning, this still remains controversial (Juhaszova et al., 2009; Nishino et al., 2008). 
Further studies using GSK-3  genetically modified mice will be required to confirm whether 
GSK-3  is, or is not, an effective downstream target of the TNF /JAK/STAT-3 pathway.  
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In contrast to previous studies (Napoli et al., 2000; Napoli, 2002) the expression of RAGE was 
not increased by I/R in our TNF-WT model, although it showed a slight increase in TNF
-/-
 mice. 
In addition, we observed that IPostC gave a significant reduction in RAGE expression whereas 
with TNF-PostC the expression returned to baseline levels. TNF
-/-
 mice also exhibited this 
significant decrease in RAGE during IPostC, suggesting that RAGE is not a downstream target 
of the SAFE pathway. 
PAR-2 levels were decreased significantly by I/R and IPostC but were restored by TNF-PostC. 
In TNF
-/-
 mice I/R increased PAR-2 expression significantly. Although there was also an 
increase in PAR-2 expression after IPostC this was not considered significant. Our data suggest 
that PAR-2 is not a downstream target of the SAFE pathway.   
Additional possible downstream targets of the SAFE pathway include phosphorylation of the 
pro-apoptotic target Bad (Deuchar et al., 2007; Lecour et al., 2005b) and the inactivation of 
NF B (Kin, 2008; Nishinakamura et al., 2007). TRAF2 has also been recently implicated in the 
action of TNFα on NFκB by promoting the binding of TNFα to TNFR2 and discouraging the 
binding to TNFR1, thereby preventing TNFα-induced apoptosis (Vince et al., 2009).  The 
inhibition of the mitochondrial permeability transition pore opening (Gao et al., 2004) is likely to 
be the common point at which the SAFE and RISK pathways converge. 
4.4 Other alternative pathways operative in postconditioning 
The presence of multiple protective pathways has already been suggested in ischaemic 
preconditioning (Jin et al., 2004; Lecour et al., 2005b) and it is likely that the SAFE and RISK 
pathways are activated in parallel with other paths in ischaemic postconditioning. Hence, 
sphingolipids have been proposed as members of a downstream activated path in ischaemic 
postconditioning (Jin et al., 2008; Vessey et al., 2008). Sphingosine-1-phosphate can activate 
Akt, Erk1/2 and STAT-3 in the heart (Frias et al., 2009; Radeff-Huang et al., 2004; Vessey et al., 
2008). While TNF  protects via the activation of the sphingolipids, (Heusch et al., 2008) and 
preliminary data in our laboratory suggest that sphingosine-1-phosphate mimics ischaemic 
preconditioning via the activation of STAT-3 (Kelly, 2008), the existence of sphingosine-1-
phosphate as an alternative path to the SAFE or RISK pathway still needs to be confirmed.  
In summary, our studies have consistently shown that activation of the SAFE pathway, as 
represented by the activity of TNFα and STAT-3 is required in both ischaemic pre- and 
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postconditioning (Deuchar et al., 2007, Baxter, 2003#242 ; Lecour et al., 2002; Lecour et al., 
2005b; Smith et al., 2002; Suleman et al., 2008). The specific involvement of TNFR2 in our 
studies suggests that this protective pathway is linked to this receptor. Overall, these results 
further emphasize the importance of RISK-independent pathways in cardiac protection at the 
time of reperfusion, which may have potential therapeutic application in the mitigation of 
ischaemic-reperfusion injury. A schematic of the SAFE pathway in postconditioning, based on 
















































PAR-2  GSK-3β  RAGE  
GSK-3β 
Akt ERK1/2   
 
Fig 47: Schematic of SAFE pathway. TNFα activates JAK/STAT-3 via TNFR2 to confer 
cardioprotection. RAGE, GSK-3β and PAR-2 are not downstream signalling targets of 






















Part of the experiments in this section have been performed in conjunction with Sarin Somers, 




Ischaemic postconditioning with intermittent episodes of ischaemia and reperfusion at the onset 
of reperfusion requires precise and timed applications that are impractical to apply in a clinical 
setting. Pharmacological agents such as bradykinin, opioids and adenosine can be substituted as 
preconditioning mimetics to reduce infarct size following an ischaemia-reperfusion insult but 
their role as postconditioning mimetics has been poorly studied (Cohen, 2001; Gross, 2006; 
Downey, 2007). These three mediators are known to protect via the activation of the RISK 
pathway (Bell, 2003; Riksen, 2004; Fryer, 2002) and several studies conducted in a 
preconditioning setting suggest that divergent pro-survival signalling pathways may be activated 
by these components. Hence, bradykinin and opioids, but not adenosine, require the activation of 
the mKATP channel and free radicals to confer cardioprotection in IPC (Cohen, 2001). 
In the previous section, our data demonstrate that activation of the prosurvival SAFE pathway, 
with TNFα and STAT-3, acts as an alternative signalling pathway to confer cardioprotection in 
IPostC. The role of TNFα as a downstream signalling target of bradykinin, opioids and 
adenosine has never been investigated. 
Therefore, the purpose of our study is to explore whether adenosine, bradykinin and opioids can 







 and cardiomyocyte specific STAT-3 deficient mice (STAT-3
-/-
) to demonstrate that 
this pharmacological postconditioning effect can be attributed, at least in part, to the activation 
of the prosurvival SAFE pathway initiated by TNFα and STAT-3. A recent study suggested the 
possibility that STAT-3 can translocate to the mitochondria after its phosphorylation in the 
cytosol (at the serine site) (Wegrzyn, 2009). As mitochondria are considered as the end target for 
the protection afforded with postconditioning (Heusch, 2010), we will use western blot 
techniques to investigate the possible activation and translocation of STAT-3 to the 
mitochondria following a pharmacological postconditioning stimulus.   
Our aim, therefore, was to firstly delineate whether adenosine, bradykinin and opioids could 
mimic IPostC in an isolated mouse heart model and secondly, to explore whether this 
postconditioning effect could be attributed, at least in part, to the activation of the SAFE 






Fig 48: Schematic of proposed hypothesis. Pharmacological agents activate TNFα via TNFR2 and 

































2.0  Methods 
2.1  Perfusion of mouse hearts 
All animal studies performed were approved by the Animal Research Ethics Committee of the 
University of Cape Town, and followed the recommendations laid down in the Guide for the 
Care and Use of Laboratory Animals published by the US National Institute of Health (NIH 
Publication No. 85 {23}, revised 1996). Six mice were used per experimental group for each 
genotype of mouse. 








 mice and their respective 
WTs were subjected to the identical retrograde perfusion technique as described in Section C. 
Postconditioning with each of the well known cardioprotective agents as postconditioning 
mimetics was performed in the same manner as we have described in Section D, with 6 x 10 
second alternating cycles of reperfusion and reperfusion together with each of the drugs in turn 




Fig 49: Schematic of Langendorff experimental model. Isolated hearts were subjected to a 
stabilization period of 20 min followed by 35 min global ischaemia and a 45 min reperfusion period. At 
onset of reperfusion, ischaemic postconditioning (IPostC) was initiated with 6 alternating cycles of 10 
sec reperfusion, 10 seconds ischaemia. In a separate group, postconditioning with 100 µM adenosine 
(Adeno-PostC), 100 nM Bradykinin (Bk-PostC) or 100 nM DADLE (D-PostC) was initiated with 6 
alternating cycles of 10 sec reperfusion with no drug, 10 seconds reperfusion with the drug of choice.  
 
I/R = ischaemia/reperfusion 




35’ 2’ 13’ 
4) Adeno, Bk or Dadle-PostC 
3) IPostC  
Infarct size 
1) Time-matched control 
45 min reperfusion 
35 min Global ischaemia 
6 x 10 sec cycles I/R 
6 x 10 sec cycles R or R + drug 
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2.1.2 Infarct size assessment 
At the end of each experimental protocol, hearts were removed from the perfusion apparatus and 
infarct size assessed by triphenyltetrazolium chloride (TTC) staining and planimetry as 
described previously in Section C.  
2.2 Postconditioning with classic cardioprotective agents 
Adenosine (100 µM), bradykinin (100 nM), and 100 nM of the delta opioid agonist, D-Ala 2‟, 









mice and their respective wild types. Six 
alternating cycles of 10 seconds reperfusion, 10 seconds reperfusion with pharmacological agent 
was initiated at onset of reperfusion (Figure 49). A minimum of 6 hearts was used in all groups.  
2.3 Western blot analysis 
Control or murine hearts postconditioned with bradykinin, adenosine or DADLE were subjected 
to a 20 min stabilization period followed by 35 min of global ischemia and 15 min of 
reperfusion. The hearts were then snap-frozen in liquid nitrogen before being stored at -80ºC 
until protein extraction was performed. To determine whether the activation of the prosurvival 
signalling cascade initiated the translocation of activated STAT-3 from the cytosol to the 
mitochondria we extracted mitochondrial and cytosolic proteins from the hearts by 
homogenization of the tissue in a lysis buffer, as previously described in Section C. Total and 
phosphorylated states of STAT-3 (Phospho-STAT-3, ser 737), were analysed by sodium dodecyl 
sulphate-polyacrylamide gel immunoelectrophoresis (SDS-PAGE) using antibodies from Cell 
Signaling Technologies and Santa Cruz Biotechnology, Inc. USA.. Equal loading for the 
mitochondrial fraction was verified with an antibody for the voltage dependent anion channel 
(VDAC). GAPDH was used as a loading control for the cytosolic fraction. The ratio of 
phosphorylated STAT-3 translocated from the cytosolic fraction to the mitochondrial fraction 
was calculated. Relative densitometry was determined with the use of computerized software 
package (ImageJ analysis and processing in Java). A minimum of 6 hearts was used per group. 
2.4 Chemicals and Pharmacological Agents 




2.5 Statistical Analysis 
Data are presented as mean ± SEM. Comparisons between multiple groups were performed by 
1-way ANOVA followed by Student-Newman-Keuls Multiple Comparison Test (Graph Pad 













































Fig 50: Adenosine protects TNF
-/-
 mice. IPostC decreased infarct size in TNF-WT from 48 ± 1% to 
16 ±1% versus I/R. Similarly, Bk-PostC, D-PostC and Adeno-PostC reduced infarct size in TNF-WT 
hearts to 19 ± 1%, 24 ± 1% and 15 ± 1%, respectively. Postconditioning with adenosine protected 
TNF
-/-
 hearts against ischaemia-reperfusion injury, reducing infarct size from 45 ± 1% to 19 ± 1%, 
***p<0.001 vs  respective I/R control. In contrast, IPostC, Bk-PostC and D-PostC failed to protect 
hearts from TNF
-/-
 mice, p=ns. n=6 per group. IPostC=ischaemic postconditioning; Bk-













3.1 Postconditioning with classic cardioprotective agents  
In TNF-WT mice, ischaemic postconditioning (IPostC) reduced infarct size from 48 ± 1% in the 
ischaemic control group (I/R) to 16 ± 1% in IPostC, (p<0.001). Bradykinin postconditioning 
(Bk-PostC), DADLE postconditioning (D-PostC) and Adenosine postconditioning (Adeno-
PostC) reduced the infarct size in a similar manner to TNF-WT hearts, (p<0.001versus I/R). In 
contrast, (IPostC), Bk-PostC and D-PostC failed to protect hearts from TNF
-/-
 mice, (p=ns), 
whereas adenosine protected the TNF-deficient hearts against ischaemia-reperfusion injury, 


















 were similar to WT mice. IPostC 
reduced infarct size in TNF-WT and TNFR1
-/-
 hearts to 19 ± 1% and 20 ± 1%, respectively 
versus their respective I/R controls, (***p<0.001). In contrast, TNFR2
-/-
 hearts failed to be 
protected, (p=ns versus I/R). Postconditioning with 100 nM bradykinin (Bk-PostC) and 100 nM 
DADLE (D-PostC) significantly decreased infarct size in TNFR1
-/-
 hearts from 50 ± 1% in I/R to 
21 ± 1% and 20 ± 1%, respectively, (***p<0.001). However, TNFR2
-/-
 hearts could not be 






Fig 51: Bradykinin and DADLE postconditioning protect TNFR1
-/-
 but not TNFR2
-/-
: IPostC 
significantly decreased infarct size in TNF-WT and TNFR1
-/-
 hearts vs their respective I/R controls. 
Similarly, Bk-PostC and D-PostC decreased infarct size in TNFR1
-/-
, (***p<0.001 versus respective I/R 
controls). In contrast, hearts from TNFR2
-/-
 mice failed to be protected, (p=ns); n=6 per group. 



































Fig 52: Pharmacological postconditioning in STAT-3-WT and STAT-3
-/-
 mice. IPostC 
protected STAT-3-WT from I/R, ***p<0.001. Similarly, Bk-PostC, D-PostC and Adeno-PostC 
reduced infarct size in STAT-3-WT hearts (***p<0.001 versus I/R). In contrast, none of the 
postconditioning protocols protected the STAT-3
-/-
 hearts against ischaemia-reperfusion injury, 
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3.3 Bradykinin, DADLE and Adenosine fail to protect STAT-3
-/-
 hearts 
IPostC in STAT-3-WT mice reduced infarct size from 48 ± 2% in the ischaemic control group 
(I/R) to 23 ± 5% for IPostC, (p<0.001). Bk-PostC, D-PostC and Adeno-PostC reduced the 
infarct size in a similar manner to STAT-3-WT hearts, from 48 ± 2% in I/R to  18 ± 3%, 18 ± 
2% and 17 ± 2%, respectively,  (p<0.001versus I/R). In contrast, STAT-3
-/-
 mice failed to be 









3.4 Western blot analysis 
 Levels of pSTAT-3 in mitochondrial and cytosolic fractions of TNF-WT and TNF-/- 
We examined the translocation of phosphorylated STAT-3 from the cytosolic fraction to the 
mitochondrial fraction after pharmacological postconditioning. An increase in the ratio of 
mitochondrial pSTAT-3 to cytosolic pSTAT-3 (expressed in arbitrary units) was observed with 
Bk-PostC and D-PostC from 156  ± 4 in I/R to 220 ± 2 and 280 ± 4, respectively, (p<0.05). 
There was no significant translocation of pSTAT-3 observed when adenosine was used as a 
postconditioning mimetic, (p=ns), figure 53. A similar trend was observed in TNF
-/-
 mice. 


















































VDAC blot  
Fig 53: Phosphorylation and translocation to mitochondria of STAT-3. Bar graphs and 
representative western blots of mitochondrial and cytosolic fractions demonstrating the translocation of 
pSTAT-3, *p<0.05 vs I/R; **p<0.01 vs I/R. The VDAC blot is evidence of the mitochondrial fraction. 
n=4. IPostC=ischaemic postconditioning; Bk-PostC=bradykinin postconditioning; D-PostC=DADLE 




4.0  Discussion 
The novel data in this section show that bradykinin and opioids, given as true postconditioning 
mimetics, can mimic the cardioprotective effects of IPostC via the activation TNFα binding to 
TNFR2, and leading to subsequent activation of JAK/STAT-3, major components of the recently 
discovered SAFE pathway. Adenosine, however does not require TNFα to mimic IPostC, but 
activates JAK/STAT-3 to confer protection. In brief, six alternating episodes of reperfusion and 
reperfusion with bradykinin or DADLE in the TNF
-/-
 mice failed to reduce the infarct size, 
whereas the protective effect was still evident when adenosine was used as a postconditioning 
mimetic. Postconditioning with bradykinin or DADLE protected against reperfusion injury in the 
TNFR1 deficient, but not in TNFR2 deficient mice. In addition, STAT-3
-/-
 mice failed to be 
protected against ischaemia-reperfusion by bradykinin, DADLE or adenosine. Surprisingly, 
TNF
-/-
 hearts were still protected with Adeno-PostC, therefore suggesting adenosine-induced 
cardioprotection may occur through partial but not total activation of the SAFE pathway.  
4.1 Cardioprotective role of adenosine 
Endogenous adenosine is released during ischaemia and reperfusion with blood and interstitial 
concentrations being elevated after ischaemic insults. In emergency situations adenosine plays 
an important role in the cardiovascular system. For several decades, adenosine has been widely 
used for treatment of supraventricular arrythmias. The potential of adenosine therapy for 
myocardial infarction has been shown in clinical trials and it has also exhibited cardioprotective 
effects in preclinical models of myocardial stunning and infarction (Claeys et al., 2004; Kloner 
et al., 2006; Marzilli et al., 2000; Quintana et al., 2003; Ross et al., 2005). However, adenosine 
has a short half life in the plasma and has the unwanted side effect of lowering the blood 
pressure. Great progress is being made in the development of agonists and antagonists which can 
mimic the beneficial effect of the drug without the deleterious side effects. One such agonist is 
GP531, a potent second generation adenosine-regulating agent, which has a better half life than 
adenosine with none of the harmful side effects, such as the lowering of blood pressure (Hale 
and Kloner, 2010). 
In contrast with our data, Penna et al failed to protect the isolated rat heart when adenosine 
(10 M or 30 M) was given as a postconditioning stimulus (5 cycles of 10seconds) at the onset 
of reperfusion (Penna et al, 2009). These data suggest that adenosine may protect as a 




Delineating the mechanisms involved in adenosine-induced cardioprotection would certainly 
contribute to the development of agents which would encompass the beneficial effects of 
adenosine without presenting its deleterious side-effects. In the present study, we found that 
TNF
-/-
 mice but not cardiomyocyte specific STAT-3
-/-
 mice could still be protected with an 
adenosine postconditioning stimulus. Our data suggest that STAT-3 was not activated as a 
downstream target of TNFα. This is in accordance with previous work conducted in our 
laboratory whereby adenosine, given as a preconditioning stimulus, was able to protect against 
ischaemia-reperfusion in TNF
-/-
 mice but failed to protect STAT-3
-/-
 mice (Smith, 2002; Smith 
2005). In fact, STAT-3 activation with adenosine may occur via Erk1/2 activation (Frias, 2009) 
or PKC activation. Hence, in a late preconditioning setting, Bolli‟s group demonstrated that 
activation of PKC contributed, at least in part, to the phosphorylation of STAT-3 (Xuan, 2005; 
Xuan, 2007) (figure 54). 
 Adenosine is one of the most widely studied endogenous signalling molecules in 
cardioprotection, but results found in the literature have not always proved to be consistent. 
Further investigation into the exact signalling mechanisms involved in ischaemia-reperfusion 
injury is required. 
  
4.2 Bradykinin and opioids mimic IPostC via the SAFE pathway 
Bradykinin is released in significant amounts from the ischaemic myocardium to activate 
protective effects and plays a role in assuaging reperfusion injury.  
There is almost complete agreement that B2 receptor activation is required for bradykinin-
induced protection since icatibant, a selective and specific B2 receptor antagonist, abolishes 
bradykinin-induced protection in most models (see review, (Baxter and Ebrahim, 2002)). 
IPostC-induced cardioprotection in isolated rat hearts was abrogated in the presence of selective 
inhibitors of the bradykinin B2 receptor during intermittent bradykinin administration, therefore 
confirming targeting of the B2 receptors during early reperfusion is responsible for the protective 
effects of bradykinin (Penna et al., 2007).  The signalling mechanisms downstream of bradykinin 
receptors involved in the acute protective actions of bradykinin are, however, poorly understood. 
Similarly, an ischaemic insult to the heart results in the synthesis and release of endogenous 
opioid peptides which have also been documented in postconditioning-induced cardioprotection 
(Kin et al., 2005b). IPostC-mediated protection in rat hearts has been reported to be abrogated by 
a selective antagonist of the opioid δ-receptor as well as a selective antagonist of the κ-receptor 
(Wang et al., 2007) suggesting that the protective effect of IPostC may be mediated by the δ and 
κ opioid receptors.  
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In our present study, intermittent bradykinin or opioid (DADLE) postconditioning at reperfusion 
required TNFα activation via TNFR2 to confer cardioprotection. Our novel data confirm the 
protective effect of bradykinin and DADLE as ischaemic postconditioning mimetics and we 
show for the first time that bradykinin and opioids activate TNFα via TNFR2. To our 
knowledge, opioids have not been given intermittently as postconditioning mimetics, but only 
towards the end of ischaemia and/or during reperfusion. Both bradykinin and opioids are known 
to activate the RISK pathway when given at reperfusion (Gross and Gross, 2006; Penna et al., 
2007). Our present data show that both agents can activate the SAFE pathway as a RISK-free 
signalling mechanism, therefore confirming the existence of multiple prosurvival pathways. 
4.3  STAT-3 in mitochondria 
STAT-3 is a transcription factor but it is unlikely to act as one as the effects seen in our 
experimental conditions occur too rapidly. A new role for serine STAT-3 by its translocation to 
the mitochondria was suggested by Wegrzyn et al, (Wegrzyn et al., 2009). This group provided 
evidence that STAT-3 is required for optimal function of the mitochondrial electron transport 
chain, which may permit STAT-3 to facilitate responses to cellular homeostasis. Our western 
blot analysis demonstrates that postconditioning with bradykinin or DADLE increases the ratio 
of phosphorylated STAT-3 in the mitochondrial fraction to that of the STAT-3 in the cytosolic 
fraction, therefore suggesting the involvement of mitochondrial STAT-3 in the signalling 
pathway of these cardioprotective agents. However, although adenosine protection required 
STAT-3 signalling, it did not stimulate its translocation to the mitochondria, therefore suggesting 
an additional mechanism of action for STAT-3 which may be linked to its activation in the 
cytosol (phosphorylation at the serine site) or translocation to the nucleus.  
In conclusion, our data provide new evidence that bradykinin and opioids as postconditioning 
mimetics activate STAT-3 via TNFα and TNFR2 to confer cardioprotection (SAFE pathway). 
Considering the low levels of STAT-3 found in the mitochondria (Wegrzyn et al, 2009), it is 
appropriate to suggest that the role of STAT-3 in the signalling cascade may be attributed to a 
“kinase-like” activity. Overall, the existence of multiple alternate pathways in ischaemic and 
pharmacological postconditioning at the time of reperfusion may have potential therapeutic 
application against ischaemia-reperfusion injury. However, further studies will be required to 




















Fig 54: Schematic of our recent data. Activation of TNFα via TNFR2 by bradykinin and DADLE 
initiates the phosphorylation of JAK/STAT and subsequent cardioprotection. Adenosine makes 
partial use of the SAFE pathway via STAT-3 signalling but does not require TNFα. 
 
IPostC 






















Fig 55: The evolution of man to obesity and diabetes. Fast food and lack of exercise can lead to obesity 
and diabetes, (adapted from www.evolutionminute.com). 
1.0 Introduction 
There is an increasing awareness that both obesity and diabetes are not only growing epidemics 
but also pose a serious risk factor for cardiovascular disease, in particular myocardial infarction. 
Prolonged exposure to environmental factors such as high fat or high carbohydrate diets and 
physical inactivity leads to the development of overweight and resultant obesity and diabetes 
(MacDonald, 1998). 
Interestingly, obesity can also be considered as an inflammatory disorder, with TNFα 
overexpressed in adipose and muscle tissue of obese humans (Hotamisligil et al., 1995; Kern et 
al., 1995; Krogh-Madsen et al., 2006; Saghizadeh et al., 1996).  Nearly all animal models of 
obesity and insulin resistance seem to produce higher levels of TNFα mRNA and protein 
compared to their lean counterparts (Hamann et al., 1995; Hofmann et al., 1994; Hotamisligil et 
al., 1994a; Hotamisligil et al., 1996).  A model of obesity in TNFα-deficient mice suggested that 
the absence of TNFα limits the development of dietary obesity and these mice had significantly 
improved insulin sensitivity in both diet-induced obesity and in the ob/ob mouse model 
compared to their wildtype counterparts (Uysal et al., 1997). These data suggested that TNFα 
facilitates the development of insulin resistance associated with obesity and diabetes and it is 
further suggested that this effect is mediated via TNFR1 (Uysal et al., 1998).  
Animal studies suggest that the ischaemic tolerance is attenuated with obesity, cholesterol and 
elevated glucose levels (Aasum et al., 2008; Ferdinandy., 2007). In Zucker diabetic fatty and 
lean Goto-Kakizaki type 2 diabetic rats, ischaemic preconditioning failed to protect the isolated 
hearts from ischaemia-reperfusion injury (Kristiansen et al., 2004). Similarly, Zucker obese rats 
subjected to ischaemia-reperfusion failed to be protected with pharmacological preconditioning 
(Katakam et al., 2007). The outcome of postconditioning in obese and diabetic patients is 
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uncertain as the recent application of ischaemic postconditioning in clinical studies has excluded 
patients who were diabetic. Therefore, the aim of our study was to evaluate: 
1) whether obesity or diabetes would alter the protective outcome of ischaemic 
postconditioning and 
2) whether TNFα may alter the cardiovascular risk of obese or diabetic mice subjected to 
ischaemia-reperfusion and postconditioning, (Figure 56). 
 
To investigate our aims we will use TNF-WT and TNF
-/-
 mice.  
1) A high carbohydrate diet will be fed to the mice for a total of 11 weeks, commencing 
upon weaning (at 3 weeks of age) to create an obese murine model. 
2) Diabetes will be induced with a single streptozotocin injection administered 
intraperitoneally. 
3) Isolated mouse hearts from the obese and diabetic animals will be subjected to 
ischaemia-reperfusion and an ischaemic postconditioning protocol as outlined in Section 
C. 
Fig 56: Influence of obesity and diabetes on the outcome of ischaemic postconditioning: does  
TNFα contribute to this effect? 
 









4) Physiological parameters, such as glucose tolerance test, blood glucose, plasma insulin 














































2.1 All animal studies performed were approved by the Animal Research Ethics Committee 
of the University of Cape Town, and followed the recommendations laid down in the Guide for 
the Care and Use of Laboratory Animals published by the US National Institute of Health (NIH 
Publication No. 85 {23}, revised 1996). The total number of animals used in this study was 24. 
2.2 High carbohydrate diet (HCD) mouse model  
For an obese murine model, male mice were removed from the animal unit at weaning (3 weeks 
of age) and placed in our facility. TNF-WT and TNF
-/-
 were separated into 2 groups each. One 
group of mice received a normal diet (ND) of mouse chow and the other group received a diet 
containing elevated carbohydrates and fats that resembles a Western-type diet (HCD),  for 11 
weeks, (figure 57). The high carbohydrate diet compared to normal chow, provided energy in the 
form of carbohydrate, protein and fats, as illustrated in the table below (Aasum et al., 2008; du 
Toit et al., 2008). 
   
 Carbohydrates (%) Protein (%) Fats (%) 
Normal diet (ND) 60 30 10 













HCD ND HCD 
11 weeks 
Langendorff – infarct size 
Elisa – plasma leptin, insulin, TNFα 






2.3 Streptozotocin diabetic mouse model (STZ) 
Experimental diabetes type 1 was induced in a total of 10 mice per group by a single ip injection 
of 180 mg streptozotocin (STZ)/kg body weight, dissolved in 0.1 M citrate buffer (Daniel et al., 
2007). Non-diabetic control animals were treated with solvent (citrate buffer) alone. Standard 
mouse chow and tap water were provided ad libitum for all groups. At the end of each time 
period, only STZ-treated mice with a blood glucose level greater than 16 mmol/l were 
considered as diabetic (normal blood glucose levels in mice range from 3.4 to 9.7 mmol/l). Of 
the 10 STZ-treated TNF-WT mice, 7 met the criteria, 2 did not achieve sufficiently high glucose 
levels, and 1 died shortly after receiving the STZ.  No death occurred in the 10 non-diabetic 
control animals in each group. 
 
  
Fig 57: Creation of obese mouse model in TNF-WT and TNF
-/- 
mice.  




2.4 Blood glucose and glucose tolerance test 
Blood glucose and the glucose tolerance test (GTT) were done at 14 weeks. Mice were fed 
normal chow or HCD as described in Table 1. Prior to performing the blood glucose tolerance 
test, the mice were fasted for 7 hours, but had free access to drinking water. A 20% solution 
(w/v) of glucose was made up in sterile distilled water. Each mouse was then sedated with a 
mixture of ketamine (75mg/kg) and medetomidine (0,5mg/kg) given intraperitoneally. Sufficient 
depth of anaesthesia was determined by pedal reflex. Body weight was recorded for each mouse, 
a tail cut was done and blood glucose determined in mmol/L by means of a blood glucose 
monitor (Accu-Chek Active; Roche Diagnostics, Mannheim, Germany) as per the 
manufacturer‟s instructions. The Accu-Chek Active allows very small volumes of blood (1-2 μl) 
to be accurately assessed. A bolus of glucose was given ip (15 mg/kg) and the time of the 
injection noted. Thereafter, a blood glucose measurement was performed every 30 min post 
injection, until a decrease in the glucose level was observed (120 to 150 min). 
2.5 Perfusion of mouse hearts 
The HCD fed mice (14 weeks of age), the STZ-treated mice (5 and 10 days post STZ treatment) 
and their respective controls were anaesthetized (pentabarbitone, 60 mg/kg ip) and heparinized 
(25 IU ip) to prevent the blood clotting. Once an adequate level of anaesthesia had been 
achieved (tested by lack of pedal reflex), body weight was recorded and the hearts were isolated 
and perfused retrogradely as described in Section C. At the same time, blood was taken from the 
thoracic cavity of each mouse and placed in a chilled heparinized tube for plasma collection. 
2.6 Ischaemic postconditioning  
HCD fed mice and STZ-treated mice were subjected to the ischaemic postconditioning (IPostC) 
protocol which consisted of six alternating cycles of 10 seconds reperfusion, 10 seconds 
ischaemia, commencing at the onset of reperfusion as described in detail in Section C.   
2.7 Ratio of heart weight to body weight 
At the end of the perfusion protocol, each heart was carefully dried and weighed after staining 




2.8  Insulin levels 
The blood samples were centrifuged at 5000 rpm for 5 min at 4°C and the plasma was removed 
and frozen until required. Quantitative determination of baseline insulin levels were evaluated 
using the Ultra Sensitive Mouse Insulin Elisa Kit (Crystal Chem Inc; USA) as per the 
manufacturer‟s instructions. 
2.9  Leptin levels 
For analysis of leptin levels, blood samples were centrifuged at 5000 rpm for 5 min at 4°C and 
the plasma was removed and frozen until required. Quantitative determination of baseline leptin 
levels were evaluated using the Ultra Sensitive Mouse Leptin Elisa Kit (Crystal Chem Inc; USA) 
as per the manufacturer‟s instructions. 
2.10 Chemicals and Pharmacological Agents 
Unless otherwise stated, all chemicals were obtained from Sigma-Aldrich Chemicals, Germany.  
2.11 Statistical Analysis 
Data are presented as mean ± SEM. Comparisons between multiple groups were performed by 
1-way ANOVA followed by Tukey post hoc test or Bonferroni multiple comparison test 
(GraphPad Instat). Two-way ANOVA followed by Bonferroni multiple comparison test 
(GraphPad Prism) was performed where species or diet differed. p<0.05 was considered to be 









3.1 Effect of high carbohydrate diet on physiological parameters in TNF-WT mice  
HCD increased the body weight significantly in the TNF-WT mice from 29.0 ± 1.0 grams to 32 
± 0.7 grams, (p<0.05 vs ND; figure 58A), but the heart weight to body weight ratio remained 
unchanged between ND and HCD fed mice, (p=ns, figure  58B). Although HCD did not affect 
baseline blood glucose levels, (p=ns, figure 58C), it improved glucose tolerance in the WT 
animals , (p<0.05 vs ND, figure 58D), and increased plasma insulin and leptin levels to 0.64 ± 
0.06 ng/ml from 0.46 ± 0.03 ng/ml in ND, (p<0.05), and to 10.6 ± 0.9 ng/ml from 4.5 ± 0.4 












































Fig 58: Effects of HCD on physiological parameters in TNF-WT mice. Body weight, plasma insulin 
and plasma leptin levels were significantly increased by HCD, but no significant difference was observed 

















































































































































3.2 Effect of high carbohydrate diet on IPostC-induced cardioprotection in TNF-WT 
hearts 
To determine whether obesity can affect the outcome of IPostC, the isolated hearts of mice fed 
with either a normal diet or a HCD were subjected to the IPostC protocol with 6 x 10 second 
cycles of alternating reperfusion and ischaemia. HCD mice subjected to I/R presented a similar 
infarct size compared to mice fed with ND (p=ns). Furthermore, IPostC conferred protection to a 
similar extent in HCD mice compared with ND mice versus their respective ischaemia 


























Fig 59: Effect of HCD on IPostC-induced cardioprotection in isolated TNF-WT hearts. 
IPostC in TNF-WT (ND) reduced infarct size from 50 ± 2% in the ischaemic control 
group (I/R) to 18 ± 0.5% for IPostC. The infarct size in TNF-WT (HCD) was 




3.3 Effect of high carbohydrate diet on physiological parameters in TNF
-/-
 mice  
Mice in which endogenous TNFα is not produced were used to investigate the role of TNFα in 
obesity. TNF
-/-
 mice were fed either the normal diet or the HCD and physiological parameters 
were assessed 11 weeks later. Similar to TNF-WT mice, body weight was increased with HCD 
from 26 ± 0.4 grams to 31.5 ± 0.5 grams, (p<0.05 versus ND, figure 60A).  However, TNF
-/-
 
mice on the HCD had a significantly lower heart weight to body weight ratio than their ND 
counterparts, (p<0.05 versus ND, figure 60B). Baseline blood glucose and tolerance of HCD-fed 
TNF-deficient mice to glucose remained unchanged by HCD, (p=ns; figure 60C and 60D). 
Plasma insulin levels were increased significantly by HCD from 0.41 ± 0.02 ng/ml to 0.57 ± 
0.01 ng/ml, (p<0.05 versus ND, figure 60E). Similarly, the plasma leptin levels were 
significantly increased by the HCD from1.3 ± 0.08 ng/ml to 11.2 ± 0.8 ng/ml, (p<0.05 versus 


























Fig 60: Effects of HCD on physiological parameters of TNF
-/-
 mice. Body weight, plasma 
insulin and plasma leptin levels were significantly increased by HCD, but blood glucose levels 
remained unchanged, p=ns. However, heart weight to body weight ratio was partially decreased 







































































































































































Fig 61: HCD restores cardioprotection in TNF
-/-
 mice. IPostC reduced infarct size in the HCD 
fed mice from 56 ± 1.8% to 45 ± 4.2% whereas mice fed the normal diet could not be protected, 
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To determine whether absence of TNFα in obesity can affect the outcome of IPostC , the isolated 
hearts of TNF
-/-
 mice fed with either a normal diet or a HCD were subjected to the IPostC 
protocol as described in Section C. HCD mice subjected to I/R presented a similar infarct size 
compared to mice fed with ND (p=ns). Surprisingly, the hearts from TNF
-/-
 mice fed with HCD 
















3.5 Effects of diabetes on physiological parameters in TNF-WT mice 
To create a type 1 diabetic model, TNF-WT mice were given a single intraperitoneal injection of 
streptozotocin (180 mg/kg body weight). Physiological parameters and experiments were 
performed either 5 days or 10 days post STZ administration. TNF-WT had a significant decrease 
in body weight 5 days post treatment, from 29.7 ± 1.3 grams to 21.0 ± 2.6 grams (p<0.001 
versus no STZ). However, the weight was restored by day 10, (p=ns versus no STZ; figure 62A). 
There was no change in the heart weight to body weight ratio (p=ns; figure 62B). Streptozotocin 
injection increased baseline blood glucose at day 5 and 10, (p<0.01 vs no STZ; figure 62C), but 
decreased plasma insulin  from 1.02 ± 0.2 ng/ml to 0.53 ± 0.14 ng/ml (5 days post STZ) and to 
0.36 ± 0.02 ng/ml (10 days post STZ), (p<0.05 vs no STZ-treatment; figure 62D). Similar results 
for glucose and insulin after streptozotocin treatment have been reported (Nakamura et al., 
2006).  Leptin levels were also reduced by STZ at day 5 and 10 after injection from 4.5 ± 0.7 
ng/ml to 0.6 ± 0.2 ng/ml and 0.23 ± 0.04 ng/ml, respectively, (p<0.001 vs no STZ treatment;  
figure 62E) 
 





































Fig 62: Effects of diabetes on physiological parameters in STZ-treated TNF-WT mice. Body 
weight was decreased 5 days post STZ treatment, ***p<0.001 vs untreated controls and returned 
to normal at day 10, p=ns. Heart weight to body weight ratio remained unchanged at both time 
points, p=ns. Insulin and leptin levels were both decreased, respectively. STZ increased baseline 
blood glucose at days 5 and 10, *p<0.05 and ***p<0.01, vs no STZ, 
 

















































































































































Fig 63: IPostC protects diabetic TNF-WT hearts. Infarct size was significantly decreased  by 
IPostC in untreated animals, ***p<0.001 vs I/R. Similarly, IPostC reduced infarct size from 40 ± 3% 
to 25.3 ± 0.5% at 5 days and from 44 ± 1% to 23.6 ± 1.8% at 10 days in the STZ-treated mice, 


































3.6 Effect of diabetes on IPostC-induced cardioprotection in TNF-WT hearts                                                                                                             
Isolated hearts from TNF-WT were subjected to the IPostC protocol. STZ-treated TNF-WT mice 
subjected to I/R showed a similar infarct size to the untreated I/R control, at both time points, 
(p<0.001 vs I/R). STZ-treatment did not affect the cardioprotective effect of IPostC after 5 or 10 














3.7 Effect of diabetes on physiological parameters in TNF
-/-
 mice  
To investigate whether TNFα plays a role in type 1 diabetes, TNFα-deficient mice were injected 
intraperitoneally with a single dose of streptozotocin (180 mg/kg body weight). Similar to TNF-
WT mice, STZ administration had no effect on body weight, 5 or 10 days after STZ treatment 
(p=ns, figure 64A). However, the heart weight to body weight ratio was significantly increased 
by the STZ after 10days, (p<0.01 vs untreated, figure 64B). As expected, STZ increased baseline 
blood glucose at both time points (p<0.001 vs untreated, figure 64C). Although no significant 
difference was seen in plasma insulin levels at 5 days post STZ treatment, there was a significant 
increase 10 days after treatment, from 0.32 ± 0.1 ng/ml to 1.06 ±0.3 ng/ml, (p<0.01 versus 
untreated control, figure 64D). The diabetic TNF
-/-
 animals also demonstrated significantly 
elevated levels of plasma leptin at 5 days post STZ administration, from  2.3 ± 0.1 ng/ml to 3.0 ± 
0.4 (p<0.001 versus untreated control), but the levels were drastically reduced in the 10 day post 
























Fig 64: Effects of diabetes on physiological parameters in STZ- treated TNF
-/-
 mice. Body weight 
remained unchanged by STZ-treatment. STZ significantly increased the heart to body weight ratio and 
plasma insulin levels after 10 days. Blood glucose was increased at both timepoints. Plasma leptin was 
significantly increased at day 5 but decreased below baseline at day 10, *p<0.05, **p<0.01, 



























































































































































3.8 Effect of diabetes on IPostC-induced cardioprotection in TNF
-/-
 hearts  
Hearts were isolated from the two groups of STZ-treated mice at the appropriate time point. The 
hearts were subjected to the IPostC protocol of 6 x 10 sec cycles of alternating reperfusion and 














Fig 65:  STZ-induced diabetes in TNF
-/-
 mice abrogates the cardioprotective effect of IPostC. 
Ischaemic postconditioning failed to protect hearts from TNF
-/-
 mice after both 5 and 10 day STZ-






























As most of the patients hospitalized with myocardial infarction are obese or diabetic, it is critical 
to investigate whether IPostC can be considered as a successful therapy for these patients. 
Ischaemic heart disease accounts for more than 50% of deaths in diabetic patients (Kannel and 
McGee, 1979), therefore it is important to explore  the cardioprotective signalling mechanisms 
involved in diabetes associated with ischaemia-reperfusion injury.  
Our data revealed that 11 weeks of a high carbohydrate diet or the administration of a single 
intraperitoneal injection of streptozotocin resulted in a modest model of obesity or diabetes as 
demonstrated by changes in body weight, blood glucose levels, plasma insulin and plasma leptin 
levels. IPostC-induced cardioprotection was evident in the TNF-WT with either obesity or 
streptozotocin-induced diabetes, whereas in the absence of TNFα no protection occurred with 
the IPostC stimulus in the diabetic mice. Suprisingly, partial restoration of the cardioprotective 
effect was seen in the TNF
-/-
 mice fed with the HCD. 
 
4.1 Obesity/diabetes and susceptibility to ischaemia-reperfusion 
 
The HCD used in our study is of a similar composition to the conventional Western-type diet of 
humans and was chosen to represent a moderately obese phenotype (Aasum et al., 2008), unlike 
the more severe obese models of either ob/ob mice or the db/db mice which are either leptin 
deficient or have no leptin receptors or the rat models with severe obesity or diabetes.  Despite 
the possible benefits of a low carbohydrate diet, the possibility exists that there are potential 
adverse effects in those with ischaemic heart disease. A diet low in carbohydrates as commonly 
used to reduce weight, has been demonstrated to affect myocardial energy substrates, insulin 
signalling and increased myocardial injury following ischaemia-reperfusion injury in the isolated 
rat heart (Wang et al., 2008).  
Obesity is associated with hyperinsulinaemia which markedly modulates the extent to which 
myocardial injury occurs during ischaemia-reperfusion (Jonassen, 2000; Jonassen, 2001; Zhang, 
2004). Therefore, it is plausible to suggest that in obesity, the impact of high levels of circulating 
insulin on myocardial injury during ischaemia and reperfusion could over-shadow myocardial 
susceptibility to ischaemia-reperfusion injury. 
Diabetes is associated with an increased mortality and reduced myocardial tolerance to 
ischaemia (Aronson, 1997; Aasum, 2003) and myocardial ischaemic injury has been shown in 
vivo in animal and human studies to be aggravated by diabetes and insulin resistance (Huang, 
2009). However, a wide range of results, ranging from no change, increased or decreased 
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sensitivity to ischaemia with or without reperfusion injury has been demonstrated in several 
experimental studies conducted in diabetic animal models (Forrat, 1993; Liu, 1993; Vogel, 1988; 
Ferdinandy, 2007; Boudina, 2007). 
In our obese and diabetic models, the detrimental effect of ischaemia-reperfusion on infarct size 
was unchanged in the TNF-WT and the TNF
-/-
 mice.  
 
4.2 Obesity/diabetes susceptibility to IPC and IPostC 
 
A study demonstrating the absence of protection in the heart after an IPC stimulus was 
conducted using rat models which have severe forms of diabetes and obesity (Zucker diabetic 
fatty rats and the Goto-Kakizaki type 2 diabetic rat) (Kristiansen et al., 2004). Other scientists 
have reported attenuation of IPC-induced protection in the diabetic hearts of rats and dogs 
(Tosaki, 1996; Kersten, 2000; Ravingerova, 2000). In contrast, several experimental studies have 
reported that the streptozotocin-induced diabetic heart is protected by IPC (Liu, 1993; Tatsumi et 
al, 1998; Thirunavukkarasu, 2007). 
The majority of experimental investigations on postconditioning-induced cardioprotection have 
been done using healthy, young animals and there is a scarcity of studies exploring the role of 
IPostC in the presence of associated risk factors such as obesity and diabetes. Our data 
demonstrate that obesity, induced by a high carbohydrate diet or streptozotocin-induced diabetes 
did not affect the cardioprotective effect of IPostC in the wildtype animals.  
Failure of IPostC to limit infarct size was reported from a study conducted in ob/ob mice, which 
are leptin deficient (Bouhidel et al., 2008). However, a limitation of this study was the lack of 
leptin in this mouse strain. In contrast to Bouhidel‟s study, we found that in our model of modest 
obesity infarct size was decreased and this was accompanied by an increase in plasma insulin 
and leptin levels, suggesting a cardioprotective role for these two hormones in obesity.  
Postconditioning in the diabetic animal model has also not been thoroughly studied but data 
from experiments conducted in Goto-Kakizaki rats suggested that to protect the diabetic 
myocardium, the IPC stimulus needed to be increased in order to achieve the necessary threshold 
for cardioprotection (Hausenloy, 2006b; Tsang, 2005). A very recent study in a murine model of 
streptozotocin-induced diabetes (using a similar dose to ours) reported a loss of efficacy in 
IPostC-induced cardioprotection (Przyklenk, 2010). Possible explanations for the contradiction 
between this study‟s findings and the findings of our study are: 1) the insulin levels of the mice 
in Przyklenk‟s study were significantly lower (0.18 ± 0.08 ng/ml) than the insulin levels found in 
our diabetic mice (0.36 ± 0.02 ng/ml); 2) the difference in mouse species; and 3) the number of 
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I/R cycles performed to postcondition the heart. The disparity, therefore, in IPC and IPostC 
experimental studies conducted in obese and diabetic animals may possibly be due to a number 
of factors such as: the type of animal model, the choice of experimental protocol, the type of 
diabetes and the model to induce obesity or diabetes.  
 
4.3 Role of TNFα in obese and diabetic animals 
 
TNFα production is markedly increased in muscle and adipose tissue in obese humans and 
rodent models of obesity-diabetes, compared with tissues of lean individuals. Several studies 
have demonstrated that TNFα plays a role in mediating insulin resistance as a result of obesity 
(Hotamisligil, 1993; Hotamisligil, 1994a; Hotamisligil, 1994b; Kern, 1995; Hotamisligil, 1995; 
Saghizadeh, 1996). Weight loss or treatment with pioglitizone, an insulin-sensitizing agent, 
reduces TNFα levels (Hotamisligil, 1993; Hotamisligil, 1995; Kern, 1995a; Kern, 1995b; 
Hofman, 1994). Three factors which contribute to the control of body weight have been linked to 
TNFα: 1) the intake of food, 2) expenditure of energy and 3) storage of energy. Administration 
of TNFα in a rat model resulted in reduced food intake (Rothwell, 1993) and also inhibited 
gastric emptying, leading to a feeling of satiation, most likely due to activation of leptin (Arbós 
et al., 1992; Fargeas et al., 1993). Neutralization of TNFα by intravenous administration of a 
soluble TNF receptor-immunoglobulin G chimeric protein provided a significant improvement 
in insulin sensitivity in fatty rats (Hotamisligil, 1993; Hotamisligil, 1994a), but treatment of 
humans with non-insulin-dependent diabetes mellitus with a specific TNFα antibody had no 
effect on insulin sensitivity (Ofei, 1996). Although TNFα has been proposed as a link between 
obesity and insulin resistance (Hotamisligil, 2003), in our study the baseline blood glucose was 
unchanged by HCD in the TNF-WT and TNF
-/-
 mice but plasma insulin levels were increased, 
therefore suggesting the development of insulin resistance, even in the absence of TNFα.  
Surprisingly, in our study the HCD partially restored the protective effect of IPostC in the TNF-
deficient mice, therefore suggesting that absence of TNFα in obesity may be of benefit to the 
heart. In our modestly obese TNF
-/-
 mice, which could be partially protected by IPostC, the 
plasma leptin level was significantly elevated compared to the animals kept on the normal diet 
where IPostC-induced protection was abrogated, therefore suggesting that this adipokine may be 
implicated in a compensatory mechanism. The increased plasma leptin levels observed in our 
TNF
-/-
 mice correlate with an increase in body weight and the same correlation was found in 
mice fed a high fat diet (Ahren, 1999).  
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In contrast to our obese TNF
-/- 
mice, our STZ-induced diabetic TNF-WT model had significantly 
decreased leptin levels and the protective effect of IPostC was abolished.  
It has recently been reported that the tissue preserving actions of leptin are influenced by obesity 
(Dixon et al., 2009). Dixon‟s group showed that leptin decreased the infarct size in Wistar and 
Zucker lean rats, which have functional leptin receptors, but the cardioprotection was lost in the 
Zucker obese rats in which the leptin receptors are non-functional. This data provided evidence 
suggesting that the tissue preserving actions of leptin are influenced by the severe obesity seen in 
Zucker obese rats. Thus, the degree of obesity as well as the presence or absence of TNFα may 
be of importance in determining the protective effects of leptin.  
In experimental conditions, using a TNFα infusion to induce insulin resistance requires 
concentrations of TNFα which far exceed the physiological range usually observed in insulin 
resistant rodent models (Altomonte et al., 2003). Rodent data and human data therefore, do not 
always coincide and the role of TNFα in insulin sensitivity is far from being straightforward.  
The presence of TNFα in obesity has been reported to contribute towards the development of 
cardiac hypertrophy in cardiomyocytes (Yokoyama, 1997). In support of this hypothesis, our 
data demonstrate a decrease in the heart to body weight ratio in TNF-deficient mice fed with a 
diet high in carbohydrates. 
Interestingly, when TNF receptor deficient mice were fed a high fat diet the data suggested that 
the two TNF receptors work in concert to protect against diabetes (Schreyer et al., 1998). In this 
study TNFRI knock out mice were protected against diet-induced obesity implicating TNFα and 
TNFR2 in protection against obesity. Our data support this study as in our TNF
-/-
 mice fed with a 
HCD, the body weight increased by 21% whereas in comparison, the body weight of TNF-WT 
increased by only 11%, therefore suggesting that absence of TNFα leads to an increase in weight 
and would thus, influence the development of obesity. It would be of interest to repeat our 






 animals to further delineate the role of TNFα 
receptors in our model. 
In conclusion, our data demonstrate that the cardioprotective effect of IPostC was unaltered in a 
high carbohydrate diet model of obesity and streptozotocin-induced obesity. Whilst TNFα is 
necessary for IPostC-induced cardioprotection, maintenance of glucose homeostasis and in the 
control of appetite to prevent obesity it can also lead to cardiac hypertrophy. In our obesity 
model, absence of TNFα partially restores cardioprotection, while in our diabetic model, the 
absence of TNFα abrogated the protective effect of IPostC, illustrating the bidirectional effect of 
TNFα and the fact that the role of TNFα in obesity and diabetes related ischaemic heart disease 
remains a complex one. Further studies measuring the levels of TNFα or using TNF antibodies 
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will be required to better understand the protective/deleterious role of TNFα in these 
pathologies.  
A schematic illustrating our present data on the influence of obesity and diabetes on the outcome 














Fig 66: Schematic illustrating the effect of obesity and diabetes on the outcome of IPostC. 





















































1.0 Concluding remarks 
 
The discovery of IPostC in the last decade has opened a novel era for therapeutic targets against 
reperfusion injury. In IPostC, the alternating cycles of reperfusion and ischaemia are applied at 
the onset of reperfusion, making this a more applicable treatment for patients with myocardial 
infarction, either in the ambulance or on admission to hospital. However, delivering these 
alternating cycles requires precise and timed application which is difficult and could 
substantially differ with the pathophysiology of the individual. Therefore, pharmacological 
postconditioning, where a drug, agonist or antagonist could be administered at the onset of 
reperfusion would seem to be a better alternative in the quest to attenuate the injury caused by 
reperfusion therapy 
To further understand the signalling mechanisms of cardiac postconditioning, we aimed to 
explore the role of TNFα in ischaemic postconditioning as well as pharmacological 
postconditioning. As obesity and diabetes are now considered to be burden diseases, we also 
wished to investigate the influence of obesity and diabetes on the protective effect of ischaemic 
postconditioning and explore the role of TNFα in obesity/diabetes related ischaemic heart 
disease. 
The main and novel findings presented in this thesis are as follows: 
1. IPostC confers cardioprotection in the murine model of I/R via the SAFE pathway which 
involves the activation of TNFα, TNFR2 and the subsequent triggering of the 
JAK/STAT-3 protective signalling cascade. 
2. TNFα mimics IPostC independently of the RISK pathway. 
3.  Bradykinin and opioids mimic IPostC via the SAFE pathway and therefore require the 
activation of TNFα and STAT-3 for protection. Bradykinin and opioids possibly protect 
via translocation of STAT-3 to the mitochondria. In contrast, adenosine protects via 
STAT-3 but independently of TNFα. 
4. Our data confirm the existence of multiple parallel prosurvival signalling pathways in 
IPostC, (Figure 67). 
5. Cardioprotection can still be conferred by ischaemic postconditioning in modestly obese 
mice or in streptozotocin-induced diabetic mice.  
6. Obese TNF knockout mice could be partially protected with IPostC, therefore suggesting 





Fig 67: Proposed signalling scheme of the novel SAFE pathway and the known RISK pathway 
in ischaemic and pharmacological postconditioning-induced cardioprotection. 
 
Our data suggest that obese and type 1 diabetic individuals may still benefit from IPostC, 
relative to the severity of the disease. The existence of multiple alternate pathways in IPostC and 
pharmacological postconditioning at the time of reperfusion may provide novel therapeutic 
applications against ischaemia-reperfusion injury in the clinical setting.  
In summary, our data provide evidence for the alternative protective prosurvival SAFE pathway 
in both ischaemic and pharmacological postconditioning, involving activation of TNFα, TNFR2 





2.0 Study Limitations 
The use of an isolated heart system in this thesis does not take into account the intracoronary 
activation of leucocytes which may result in a detrimental effect of TNF  in the setting of 
myocardial ischaemia. Our data will need to be validated in vivo. Kinetic analysis of blood and 
cardiac TNFα levels following ischaemic postconditioning would facilitate the understanding of 
the exact role of TNFα as a cardioprotective agent against reperfusion injury. However, previous 
data exploring the protective effect of TNF  have demonstrated a good correlation between in 
vitro and in vivo preconditioning experiments, therefore suggesting that the circulating 
leucocytes do not play a major role (Deuchar et al., 2007; Lecour et al., 2005a). Alternatively, 
the cellular origin of the cardioprotective TNF  may reside in cardiomyocytes, and other cells 
such as resident cardiac mast cells and macrophages (Dorge et al., 2002; Frangogiannis et al., 
1998)  
Another limitation to the study lies in the use of non-specific inhibitors, such as wortmannin and 
AG490. Wortmannin inhibits the PI-3 kinase signaling cascade and not Akt directly. AG490 
blocks JAK2, which is upstream of STAT-3. Therefore, the use of such inhibitors can only 
indicate that a particular signaling cascade is blocked, but cannot pinpoint the exact downstream 
protein kinase involved. Further studies, either with siRNA techniques or genetically modified 
mice, such as Akt null mice and GSK-3β knockout mice, may give greater specificity to the 
findings of the present study. 
The high carbohydrate diet was given to our mice from 3 weeks of age (at weaning) for a period 
of 11 weeks only as we wished to keep the age of the mice consistent with the 12-14 weeks we 
had used in our previous experiments. Therefore, the increase in weight in our mice was modest 
and all the manifestations of obesity may not have yet developed. Future work should include a 
group in which the HCD is given for a total of 16 weeks to explore the role of severe obesity on 
the cardioprotective effect of IPostC, bearing in mind that an increase in age generally affects the 
outcome of postconditioning adversely.  
Our diabetic model was created with streptozotocin which induces type 1 diabetes. Future 
experiments should be done with a type 2 diabetic mouse model to confirm the data observed in 




3.0 Future directions 
The cellular origin of TNFα is mainly in the macrophages and resident mast cells (Frangogiannis 
et al., 1998), but cardiomyocytes also produce TNFα under prolonged ischaemic conditions 
(Dorge et al., 2002). Delineation of the cellular source of TNFα production in the context of 
myocardial infarction may be of clinical value. For this purpose we are in the process of 
generating a cardiomyocyte-specific TNF
-/-
 mouse, using the Cre-Lox P technology. The Cre-
Lox P system of genetic targeting requires two separate mouse lines, a homozygous TNF floxed 
mouse and an organ specific heterozygous Cre recombinase-expressing mouse. These two mice 
are crossed to produce the cellular specific TNF
-/-
 mouse. Using the same Cre-Lox P technology, 
we are also in the process of breeding macrophage-neutrophil TNFα-deficient mice. Together 
with the cardiomyocyte specific TNF
-/-
 this should provide us with a better insight into cellular 
origin of the cardioprotective TNFα. 
The mechanisms triggering the activation of TNFα in the SAFE pathway remain uncertain. Toll-
like receptors (TLR‟s) play a role in the innate immune system to activate TNFα. Recent data 
exploring the impact of the toll-like receptors 2 or 4 in ischaemia-reperfusion, have not been 
conclusive as to whether TLR2 or TLR4 are protective or deleterious (Abarbanell et al., 2010; 
Arslan et al., 2010; Dong et al., 2010). Using our TNF-WT and TNF
-/-
 mice we aim to 
investigate the possibility that TLR‟s contribute to the activation of TNFα in the initiation of the 
prosurvival SAFE pathway.  
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